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Fecal microbiota transplantation (FMT) is an emerging and effective therapy for the treatment 
of recurrent Clostridioides difficile infection. Members of the gut microbiome have been 
implicated in other diseases and FMT has been considered as a potential therapy. Two such 
conditions include non-alcoholic fatty liver disease (NAFLD) and multiple sclerosis (MS), 
both of which involve increased small intestinal permeability believed to contribute to the 
development and disease progression. One of the aims of this project was to determine if FMT 
could be safely used in patients with NAFLD and MS to improve health outcomes. Before 
starting the clinical studies, optimal ways of storing and preparing stool for FMT were 
investigated with a goal of reducing loss of viable bacteria due to sample collection, handling, 
and storage. Bacterial culture and next-generation sequencing techniques were utilized to 
assess the impact of processing and storage. With optimal procedures in place, which included 
storing samples as whole stool at -80 °C for up to 3 months, FMT donor screening was 
expanded to extend beyond transmissible diseases to include lifestyle factors, and 
personal/family history of disease. From this, only 5 of 46 healthy potential donors qualified, 
and they provided stool for patients with NAFLD (n=21) and MS (n=10). All FMT recipients 
with elevated small intestinal permeability, determined using the lactulose:mannitol 
permeability assay, improved following FMT. Microbiota engraftment was detected in some 
patients. The treatment was safe and well tolerated in all recipients. With NAFLD being the 
second leading cause of liver transplant in North America and MS having no cure, the use of 
FMT could potentially contribute to the quality of life and reduction in comorbidities. Since 
current treatment options for both diseases are not particularly effective, and the rates are 
increasing, new approaches are needed. The current findings provide a basis for larger studies 
with earlier intervention and longer follow-up. In summary, the improvement in intestinal 
barrier function with FMT shows a novel mechanism for this therapy, and one that has 
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Summary for Lay Audience 
Fecal microbiota transplantation (FMT) is the transfer of stool from a healthy donor into the 
intestine of a diseased recipient. This requires stool samples to be homogenized and filtered, 
and the end product results in the transfer of microorganisms, including bacteria, viruses, 
archaea, and fungi, plus undigested food and fibre, and host cells into the intestine of the 
recipient. FMT has effectively treated recurrent Clostridioides difficile infections that cause 
severe and prolonged diarrhea in patients, but a number of other conditions may also benefit 
from these transplants. The first goal of this thesis was to ensure that storage and handling of 
donor samples optimally retained the viability of bacteria, which are likely a necessary 
component of FMT to be effective. Selecting donors for FMT is not simple, as many healthy 
people may be carriers of infectious diseases and/or have a person/family history of disease 
that could be passed along by FMT. Surprisingly, only 1 in 10 healthy people qualified to be a 
stool donor using our criteria. Using fecal material from the selected donors, two clinical trials 
were undertaken, which was the second goal of this thesis. The purpose of these two studies 
was to treat patients with non-alcoholic fatty liver disease (NAFLD) and others with multiple 
sclerosis (MS). Both of these conditions share having a modified bacterial composition in the 
gut, compared to healthy people. In addition, both have abnormal gut barrier function or “leaky 
gut syndrome”, which means that the proteins that usually bind intestinal epithelial cells tightly 
together to stop microorganisms and small molecules from entering the bloodstream, are less 
prevalent and less effective. The administration of FMT restored gut barrier function in these 
studies. The diseases NAFLD and MS are examples of chronic illnesses that afflict people 
worldwide. While there are a number of therapies available for both diseases that seek to reduce 
the symptoms or treat disease, none are particularly efficient, and the rates of both these 
diseases are slowly increasing. As more successful FMT donors are characterized and FMT 
becomes more readily available, we may see expanded uses of this therapy for a variety of 
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Chapter 1  
1 General Introduction 
1.1 The Microbiome 
1.1.1 Definitions 
The two terms microbiome and microbiota are often used interchangeably in scientific 
research, but they have different meanings. The microbiota is defined as the 
microorganisms associated with a specific site on the host1. The microbiome was initially 
defined as “the ecological community of commensal, symbiotic, and pathogenic organisms 
that literally share our body space”2. The Burton Lab defines the microbiome as; the 
microbiota, the metagenome, and the microbial metabolites in a particular environment3. 
The metagenome is the functional potential of the microbiota4, and the concept was first 
brought about in 1998 by Handelsman et al.5 The metabolome is defined as “the complete 
complement of all small molecule (<1500 Da) metabolites found in a specific cell, organ 
or organism”6. It gives clues to the metabolic behaviours as it is typically representative of 
the end-product of metabolic actions or pathways.  
1.1.2 How do we study the microbiome? 
The microbiome and its components can be studied in a variety of ways. Depending on the 
question that needs to be addressed, a particular technique or combination of techniques 
can be used to assess the microbiome. Traditional methods of studying the microbiota 
include the use of culture-based techniques. Isolating individual bacteria from an 
environment and characterizing the bacteria in vitro can give an idea of the microbiota that 
constitute part of the microbiome of a given environment. This is limited by the media and 
conditions necessary to allow bacteria to grow. Certain bacteria have very stringent nutrient 
and atmospheric requirements that are difficult or currently impossible to replicate in an 
artificial setting and typically are provided in vivo by other microbial community members. 






culturable7,8. The recovery rate for bacteria originating from the human gut was 
approximately 20% fifteen years ago9, but it is significantly higher in some laboratories10. 
In order to have a better understanding of the species of bacteria that are present in a 
sample, genomic sequencing techniques are utilized. 
The microbiota can be studied using techniques that extract, amplify, and sequence the 16S 
ribosomal RNA (rRNA) gene from bacteria in a sample. The 16S rRNA gene is transcribed 
into the 16S rRNA subunit of the 30S ribosome in prokaryotes. Bacteria can be identified 
because the 16S rRNA gene sequence is highly conserved within a species due to the slow 
rate of evolution of the gene11. The 16S rRNA gene can be sequenced using a multitude of 
methods including Sanger sequencing and next-generation sequencing (NGS). Methods of 
NGS have evolved over time from Ion Torrent, Roche 454 system12, to Illumina13. There 
are currently a variety of Illumina sequencers including iSeq 100 system, MiniSeq System, 
MiSeq Series, and NextSeq Series14. Each varies in the maximum number of reads per run, 
the run time, and maximum read length. Illumina platforms sequence short segments of 
DNA that can range between 150 and 300 bp14. The Illumina MiSeq Series has a maximum 
of 25 million reads per run and a maximum read length of 2 x 300 bp, which is the longest 
of all Illumina platforms14. Primers are attached to a glass chip and bridge PCR, where the 
DNA is fixed to a surface, is used to synthesize the complimentary strand of DNA15. 
Fluorescently labeled nucleotide bases are sequentially added one at a time to the template 
strand of DNA; this method is more accurate than Sanger sequencing because only one 
base is added at a time16. Lasers are used to activate the fluorescent tags and a camera 
detects which base has been added to millions of strands of DNA that are being sequenced 
at one time. The fluorescent tag is then cleaved, and the next nucleotide is added in the 
sequence13. After the Illumina run, the reads are sorted using the nucleotide sequence of 
barcoded primers unique for each sample; a process called demultiplexing. These reads are 
quality filtered to identify and correct errors made during Illumina sequencing using the 
software package DADA217. Taxonomy is assigned for each read and a resulting table with 






generated. Reads that have 97% similarity are grouped into an OTU, as most strains within 
a bacterial species have 97% similarity in their 16S rRNA gene sequence18. 
One limitation of NGS compared to culture is that an actual abundance of bacteria cannot 
be determined. As stated previously, Illumina® MiSeq has a fixed number of reads per run. 
The actual number of reads for each OTU is not a direct reflection of the total number of 
cells of a particular OTU within a sample. The reads for each OTU are divided by the total 
number of reads per sample and the relative abundance of each OTU is calculated. Despite 
this limitation, the benefit of using NGS is that individual bacteria do not have to be isolated 
and cultured from complex mixtures to be identified, which allows for identification of 
organisms that would otherwise be unaccounted for. However, NGS data cannot provide 
information on the actual abundance of bacteria. 
The study of the metagenome or “the analysis of genomes contained within an 
environmental sample” is termed metagenomics19. It can be used to sequence the genes 
from all bacteria present in a sample. The method is especially important to identify 
metabolic pathways possessed by the organisms20-22. It can also differentiate between 
closely related bacteria and identify different bacterial strains within a species, as there are 
larger segments of DNA that are sequenced, and this can further differentiate between 
closely related bacteria23-24. Metagenomics gives a theoretical potential of the microbes in 
an environment, whereas metabolomic analysis provides the actual readout of what those 
microbes are doing at a particular point in time.  
The study of these metabolic products is termed metabolomics25. Metabolites can be 
formed by the host, microbes, or originate from the environment such as food or 
medications6. The analysis is commonly performed using high-performance liquid 
chromatography (HPLC) and/or liquid chromatography-mass spectrometry (LC-MS)6,26. 
These techniques can identify molecules and their concentration, in both targeted and 
untargeted ways26. It must be noted that there is functional redundancy in the gut 
microbiome, as many microorganisms possess equivalent biochemical pathways that are 






metabolome are all important components necessary to determine microbiome 
composition and function. 
 
Figure 1.1 Studying the microbiota, metagenome, metabolome and microbiome.  
 
1.1.3 The human gut microbiome 
The microbiome is an important element of the human body due to the vast and complex 
interactions between the microbes that reside in and on the host and host physiology. It was 
believed that bacterial cells outnumbered human cells in the body by 10:1 28. This estimate 
was revised recently and in fact, it is more likely that the ratio of human cells to bacteria 
cells in/on the human body is approximately 1:1 29. The densest source of bacteria can be 
found in the human gut30, with over 1 000 bacterial species known and every person is 
thought to be colonized by a minimum of 160 bacterial species31. The concentration of 
bacteria varies depending on the area of the gastrointestinal tract. In the stomach there is 
approximately 103-104 bacteria/mL, the duodenum and jejunum have 103-104 bacteria/mL, 
the ileum contains 108 bacteria/mL, and the colon has approximately 1011 bacteria/mL29. 
The increase in bacterial concentration is associated with a rise in pH, from 1.7-4.7 in the 
stomach, to 5.9-6.3 in the proximal small intestine, to 7.4-7.8 in the distal small intestine, 
to 5.0-8.0 in the colon32. 
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There are a small number of bacterial genera in high abundance in the human intestine, 
with many more in low abundance33. Most human intestines are dominated by one of the 
three genera: Bacteroides, Prevotella, or Ruminococcus34. Other genera that are found in 
high abundance include: Faecalibacterium, Eubacterium, Dorea, Alistipes, and 
Bifidobacterium35. The predominant archaea detected in the human gut are methanogens, 
with the most abundant genera being Methanobacterium, Methanobrevibacter, and 
Woesearchaeota36. Methanobrevibacter smithii has been estimated to make up 10% of the 
anaerobic microbes found in the human colon9. 
Bacteriophage, viruses that infect bacteria and archaea, are found in the ratio of 1:10 
compared to bacteria in the human gut37. The collection of bacteriophages, or phageome, 
is highly variable between individuals38. It has been reported that the median number of 
species of bacteriophage in an individual’s gut is 44, and it can range between 19 to 785 
39. The intrapersonal composition of bacteriophage remains stable over time, which 
indicates that bacteriophage colonize the gut38. The phageome may influence the gut 
microbiome by infecting and killing bacteria and archaea thereby altering the microbial 
composition40. 
The gastrointestinal tract also contains proportionally fewer fungi, collectively referred to 
as the mycobiome41. The species of fungi are quite variable between healthy individuals 
and change drastically over time within an individual. This indicates that these 
microorganisms aren’t necessarily persisting in the human gut, but instead they are 
transient and originate from food or the oral cavity42,43.   
Fermentation of dietary fibres and protein by bacteria in the gastrointestinal tract results in 
the production of various compounds including short-chain fatty acids (SCFAs)44,45. The 
production of SCFAs largely takes place in the proximal colon46. The three most abundant 
SCFAs are acetate, propionate, and butyrate found in a molar ratio of approximately 
60:20:20 throughout the colon44. Butyrate is used as a primary source of energy by 






The intestinal epithelial layer is held together by tight junctions that control paracellular 
transport47. A decrease in butyrate has been hypothesized to cause an increase in intestinal 
permeability. Although there has been contradictory evidence from cell line models using 
Caco-2 cells48,49, butyrate has been shown to increase the expression of tight junction 
proteins in vitro in Caco-2 cells50. Intestinal permeability is important in the context of the 
gut microbiome because if there is increased intestinal permeability, then microbial and 
dietary antigens from the intestinal lumen bypass the physical barrier that the intestine 
normally provides and could enter into the mucosa and circulation.  
1.1.4 What causes changes in the microbiome and how can we fix 
them? 
There are a number of factors that can influence the gut microbiome. These include method 
of delivery at birth51,52, being breastfed or formula fed as an infant51, genetics53,54, sex55, 
circadian rhythms56, diet57, medication use, such as antibiotics33, as well as other drugs 
58,59, and exercise60. Each individual has a unique gut microbiome that is like a fingerprint31. 
A healthy gut microbiome has not been defined, as there is variation in the gut microbiome 
between healthy people61,62. Microbial diversity is often used to determine if someone has 
a gut microbiota composition that is associated with health or disease. Diversity is 
calculated based on richness (the number of different species present) and evenness (how 
equal in abundance each species is) in a given environment63. The diversity of the gut 
microbiota is measured by alpha diversity, which is the mean species diversity of a 
particular community63. Shannon’s diversity index is a measurement of alpha diversity that 
is used in microbiome research to compare the gut microbiota composition of multiple 
individuals. High diversity in the gut microbiota has been shown to be associated with 
health at all ages62 and is protective against and beneficial for resolving recurrent 
Clostridioides (formerly Clostridium) difficile infection (rCDI)64-66. 
Dysbiosis is another widely used term, but its definition is a topic of debate67. If a healthy 
gut microbiome has not been defined, it is difficult to characterize its dysbiosis. Similar to 






individuals, there can also be interindividual variation in groups of people that share a 
common disease68, such as inflammatory bowel disease69. Some research groups have 
attempted to classify dysbiosis into different types. Common themes include the 
appearance of pathogens, the loss of commensal species, or the gross change of the 
microbiota composition70,71. In theory, these different types of dysbiosis should receive 
different treatment therapies67. The appearance of pathogens could be approached with 
treatment methods that are specific for the pathogen that would be able to treat dysbiosis 
without altering other aspects of the microbiome67. In the case of the loss of commensal 
species, probiotics could be used to replenish them as long as administration was 
continuous as probiotic strains do not colonize67. If there is a gross change of the microbiota 
composition, fecal microbiota transplantation (FMT) may be an appropriate treatment as it 
can extensively change the microbiome67.  
1.2 Fecal Microbiota Transplantation 
1.2.1 What is a fecal microbiota transplantation? 
An FMT is the process of transplanting fecal matter from a healthy individual into the 
intestine of a recipient. This is not a new practice and coprophagy in humans has been 
documented in ancient China 1700 years ago to treat diarrhea72,73. In World War II it was 
reported that soldiers in Africa consumed camel feces as a treatment for dysentery74. FMT 
was first reported in a medical journal in 1958 to treat patients with pseudomembranous 
enterocolitis75. Since then, the practice has been greatly refined and applied to a broad 
range of diseases.  
An FMT can be delivered in a multitude of ways including, enema, colonoscopy, 
endoscopy, nasoenteric tube, or capsules. Enema and colonoscopy are used to deliver the 
FMT to the colon. Endoscopy, nasoenteric tube or capsules are used when it would be 
advantageous to the deliver the fecal material to the small intestine, although these methods 
will also impact the colonic microbiome. The fecal sample first needs to be suspended in a 
fluid so that the FMT material can easily flow through syringes, tubing, or micropipettes. 






fecal samples. Clinics can also vary in the equipment used to suspend the stool in liquid. 
Kitchen blenders were initially used to suspend the samples in clinics as they are 
inexpensive, but paddle blenders are now preferred as they can be used multiple times and 
require minimal cleaning between uses. Going forward, standardization of FMT 
preparation should be required to avoid substandard methods that could impact the number 
of viable bacteria being delivered.  
1.2.2 What is being transferred? 
Stool is a complex material that is comprised of water, bacteria, viruses, archaea, fungi, 
colonocytes, metabolites of human and microbial origin, undigested food, and inorganic 
compounds. It is approximately 75% water by weight with the amount of water is directly 
proportional to undigested fibre81. The typical concentration of bacteria in stool has been 
reported to range from 1.5 to 5 x 1011 bacteria/g stool, however it can differ from person to 
person depending on the water content of the stool29. There are estimated to be between 
108-109 virus-like particles per gram of feces, with the majority being bacteriophages37. 
Archaea are also present in stool with the most common genera being Methanobacterium, 
Methanobrevibacter, and Woesearchaeota36. Transient fungi are predominantly from the 
genus Candida42. As mentioned, stool also contains enterocytes that have been sloughed 
off from the intestinal lining, as the average intestinal epithelial cells undergoes apoptosis 
every four to five days82. Short-chain fatty acids are also present in stool, but their 
concentrations are decreased as a proportion are absorbed by the intestinal epithelium and 
further metabolized or taken up into the blood stream44. Healthy concentrations of SCFAs 
in stool are not yet known and a variety of concentrations have been reported. Acetate is 
found in stool at concentrations of 39.9-56.1 mM, propionate at 12.8-23.6 mM, and 
butyrate at 12.2-19.0 mM83.  
1.2.3 How are FMT donors selected? 
As a healthy gut microbiome has yet to be defined, screening FMT donors based on their 
fecal microbiome is not currently practiced. Donors are selected with the assumption that 






donor is screened for an extensive list of infectious pathogens that may be transmitted 
through stool and potentially cause harm to the recipient of an FMT. Given that the practice 
of FMT is still recent, it is best to take a broad and cautious approach when screening 
donors. Therefore, there are a number of diseases that have been found to be associated 
with the gut microbiome and a personal and family history of these diseases are reasons 
for exclusion. These include but are not limited to; autoimmune diseases (multiple 
sclerosis85, type 1 diabetes86, rheumatoid arthritis87), obesity88, metabolic syndrome89, 
coronary disease90, gastrointestinal disease91-93, liver disease94, and depression95. The 
reasoning behind screening of personal history of disease is to reduce the risk of passing 
along an undesired phenotype. Family members have also been shown to have similar gut 
microbiomes96, and therefore family history of disease is sufficient for exclusion as the 
potential donor may be healthy at the time they are screened, but they could develop the 
disease later.   
1.2.4 FMT for recurrent Clostridioides difficile infection 
The first application of modern-day FMT was for rCDI. This Gram-positive, spore forming 
bacterium is the leading cause of nosocomial diarrhea. Antibiotic therapy is still the 
primary treatment for rCDI with vancomycin, metronidazole, and fidaxomicin being the 
most commonly used, even though these antibiotics may increase the risk of rCDI later on. 
Broad spectrum antibiotic therapy can cause drastic changes to the gut microbiota33 and 
this makes patients more susceptible to recurrent infections. The chance of having a 
recurrence of C. difficile infection following one course of antibiotics has been reported to 
range from 10% to up to 40% 97. If a patient has had one recurrence, the chance of having 
a second recurrence increases to approximately 45% 98. The chance of having a third goes 
to 65% 98. Use of antibiotics unrelated to CDI as well as being elderly, have been associated 
with a greater risk of recurrence97. An estimated 44 500 deaths occurred in the US in 2014 
as a result of C. difficile infection99. There is an increased risk of mortality with 
recurrence97. Therefore, it is vital to find effective therapies for rCDI that also decrease the 






The use of FMT to treat rCDI has been investigated as an alternative to antibiotics. Studies 
have shown that FMT is more effective than vancomycin and fidaxomicin at resolving 
rCDI100-102. One of these studies compared the effectiveness of FMT and vancomycin to 
vancomycin alone and found that 81% (13/16) of patients that received an FMT had 
resolution of rCDI versus 31% (4/13) that received only vancomycin100. In a clinical trial 
comparing the effectiveness of FMT delivered by colonoscopy versus vancomycin 
treatment, 90% (18/20) of FMT patients had resolution of rCDI compared to 26% (5/19) 
of patients that received vancomycin101. Likewise, another study found that FMT had the 
highest rate of resolution when compared to fidaxomicin or vancomycin therapy (71%, 
33%, 19%, respectively)102. Another issue is that metronidazole and vancomycin have been 
associated with increased abundance of vancomycin-resistant enterococci when given for 
rCDI103. On average FMT for rCDI has a resolution rate of 92%104. Despite the evidence 
that FMT is more effective than antibiotic therapy for rCDI, it is not approved to be used 
as the first course of treatment yet. 
The exact mechanism of action for how FMT resolves rCDI is unknown. Many believe 
that it is the bacteria in the suspension that are responsible for the success105-106, by 
outcompeting C. difficile for nutrients, displacing it from its niche, and produce metabolites 
or signaling molecules that inhibit its growth. One hypothesis is that FMT increases the 
concentrations of secondary bile acids107, produced by bacteria in the gut, as these inhibit 
the growth of C. difficile108. Secondary bile acids are lower in concentration in stool from 
rCDI patients before FMT and higher in concentration following successful FMT108. 
Stimulation of germination occurred when concentrations of primary and secondary bile 
acids typically found in stool from rCDI patients were incubated with clinically isolated C. 
difficile strains108. Germination was not induced, and vegetative growth of C. difficile 
spores was greatly reduced when concentrations of primary and secondary bile acids found 
in stool from rCDI patients following successful FMT were used108.  
Other studies have questioned the necessity for live bacteria being the key to resolution of 






success of FMT for rCDI as past studies have shown that engraftment of the donor 
microbiota was not necessary for resolution of rCDI, and sterile filtered FMTs, engraftment 
of bacteriophage, and treatment with bacterial spores have all been associated with 
resolution of rCDI109-112. Bacteriophages may limit the number of bacteria adhered to the 
mucosa of the intestine and therefore reduce the interactions of pathogenic bacteria with 
the host113. Due to the wide success of FMT for treating rCDI, researchers have expanded 
the use of FMT to a range of conditions in which the microbiome is believed to play a role.  
1.2.5 FMT for other gastrointestinal diseases 
Some of the most common gastrointestinal diseases that have been treated with FMT 
include inflammatory bowel disease (IBD), such as Crohn’s disease and ulcerative colitis 
(UC), and irritable bowel syndrome (IBS). So far, these studies have had small sample 
sizes and varying degrees of success.  
In one study, it was found that 0% (0/6) of patients with Crohn’s and 25% (2/8) of patients 
with UC had disease remission at eight weeks post-FMT114. A larger study found that 77% 
(23/30) of Crohn’s patients had disease remission one month after FMT115, but this short 
follow-up is insufficient to draw conclusions. Success in a slightly longer study showed 
58% (11/19) of Crohn’s disease patients had improvement in symptoms twelve weeks 
following FMT116. For UC patients, a randomized controlled trial showed that 24% (9/38) 
of patients had remission of symptoms following FMT compared to 5% (2/37) of patients 
that received the placebo117. In another randomized control trial of UC, there was no 
significant difference in the efficacy of treating UC with an FMT from a healthy donor or 
using an autologous FMT where the patient received their own stool, 30.4% (7/23) vs 
20.0% (5/25), respectively118.  
Using FMT for treatment of IBS also has a range of success reported. One meta-analysis 
stated that FMT for IBS was effective in 58% of patients (28/48)119. Halkjær et al. found 
that IBS patients had a greater improvement in symptoms when they were given a placebo 






FMT that included a placebo group found that FMT was more effective at improving 
symptoms of IBS than the placebo, 65% (36/55) versus 43% (12/28), respectively121.  
The mechanism of action of FMT for treating other gastrointestinal diseases is not fully 
understood, but there have been multiple studies that have demonstrated an increase in 
bacterial diversity in the gut as a method of resolution. Vermeire et al.114 found that patients 
who experienced remission of UC were given an FMT from donors with higher bacterial 
diversity than donors that did not result in remission. Vaughn et al.116 reported that Crohn’s 
patients that responded to FMT had an increase in fecal bacterial diversity following the 
FMT. Moayyedi et al.117 found that there was an increase in bacteria diversity of UC 
patients that responded to FMT therapy compared to patients that received a placebo. In 
the case of IBS, the complexity of the condition and high efficacy of the placebo has made 
it difficult to understand if and how FMT is effective. Patients with IBS often have lower 
fecal bacterial diversity that is restored to that of healthy donors following FMT120, but it 
is not clear if this is sufficient justification for the intervention. Unlike rCDI, which is 
caused by an infectious agent, IBS and IBD may be the result of more complex changes in 
the gut microbiome which are not yet fully understood. The role of the gut microbiome 
may be variable by patient and some may benefit from this therapy more than others.   
1.2.6 FMT for distal site diseases 
As the field of microbiome research has expanded, the number of conditions that have been 
found to have links to the microbiome has also increased. The use of FMT is now starting 
to be applied to these conditions that have distal site manifestations from the 
gastrointestinal tract. These conditions include hepatic encephalopathy122, metabolic 
syndrome123,124, multiple sclerosis (MS)125, autism126 and recurrent urinary tract 
infection127. These studies have low sample size numbers and firm conclusions on the 






1.3 Non-Alcoholic Fatty Liver Disease 
1.3.1 Characterization of NAFLD 
Non-alcoholic fatty liver disease is an obesity-related disorder characterized by having 
more than 5% hepatic fat by volume and a lack of any additional cause of hepatic fat, such 
as alcohol consumption128. It affects an estimated 20-30% of North American adults and 
80% of obese individuals129. Ten to twenty percent of NAFLD patients can progress to 
non-alcoholic steatohepatitis (NASH), where hepatocyte injury, inflammation, and 
hepatocellular ballooning are present130. This can sometimes be accompanied by 
fibrosis131, the formation of scar tissue in the liver.  
Fibrosis is not symptomatic, but it can lead to more serious complications. The stage of 
fibrosis is directly correlated with disease mortality131. Approximately 9% of NASH 
patients have progression of fibrosis, which can lead to cirrhosis of the liver132. Patients 
with cirrhosis can experience symptoms such as fatigue, unexplained weight loss, bruising, 
abdominal pain, and jaundice. Outcomes of cirrhosis can include liver failure with the 
potential need of a transplant, hepatocellular carcinoma, or death. In 2001, 1.2% of liver 
transplants were for NASH patients and that rose to 9.7% by 2009133. In 2013, NASH-
related liver disease became the second most common indication for liver transplants in 
America and it is quickly becoming the leading indication for liver transplant134. During 
the first year after enlisting for a liver transplant, NASH patients have a 40.5% chance of 
receiving a liver and a 34.1% probability of survival while waiting for the transplant134. 
The 3-year survival rate following transplantation is 78% 133. As NAFLD progresses, the 
risk of hepatocellular carcinoma increases. NASH patients are ten times more likely to 
develop hepatocellular carcinoma compared to NAFLD patients132. In North America, 12% 
of hepatocellular carcinoma cases are related to having NASH135. Hepatocellular 
carcinoma is present in approximately 21% of NASH patients waiting for a liver transplant 






1.3.2 Other comorbidities of NAFLD 
In addition to liver damage, NAFLD patients have additional comorbidities. For example, 
metabolic syndrome occurs in 67% of NAFLD patients136. Metabolic syndrome is 
characterized by meeting three of more of the following criteria137: abdominal obesity 
(waist circumference >102 cm in men, > 88 cm in women); elevated plasma triglyceride 
levels (> 1.7 mmol/L); decreased high-density lipoprotein (HDL) cholesterol (< 1.03 
mmol/L in men and < 1.30 mmol/L in women); elevated blood pressure (≥ 130/85 mmHg); 
or elevated fasting glucose levels (≥ 6.1 mmol/L).  
Type 2 diabetes mellitus (T2DM) is another concurrent comorbidity and approximately 
60% of T2DM patients have NAFLD138. The T2DM is a result of decreased insulin 
sensitivity (or insulin resistance) and increased fasting glucose levels. These patients are at 
an increased risk of developing neuropathy, blindness, and kidney disease from abnormally 
high blood glucose concentrations. The leading causes of death in NAFLD patients are 
cardiovascular disease related139 due to the presence of high blood pressure, increased 
triglycerides and decreased HDL cholesterol. A past meta-analysis review showed that 
patients with NAFLD and NASH have increased intestinal permeability compared with 
healthy controls140. Miele et al.141 discovered that NAFLD patients have significantly 
increased gut permeability compared to healthy controls, and the higher the gut 
permeability, the greater amount of fat in the liver. 
1.3.3 Current treatment options for NAFLD  
It is important to treat NAFLD before it progresses; at this stage of disease it is possible 
for fibrosis to resolve with improved lifestyle habits, such as diet and exercise. Weight loss 
is often recommended to NAFLD and NASH patients and it has been shown to prevent 
progression of fibrosis142. Other therapies for NAFLD include medications to better 
manage metabolic syndrome symptoms, which can include blood pressure medication, and 
metformin for the treatment of insulin resistance. While there are a number of options to 






amount of NAFLD worldwide, likely due to the obesity epidemic. Thus, new therapies for 
NAFLD patients are warranted.  
1.3.4 The gut microbiome and NAFLD/NASH 
Many have postulated that one of the reasons that obese individuals may develop NAFLD 
is due to differences in the composition of bacteria in the gut compared to healthy people. 
There have been numerous studies that have compared the gut microbiota of NAFLD, 
obese, and healthy individuals and no consistent differences at the phylum or genus level 
have been found. One study noted that there was an increase in the relative abundance of 
Lactobacillus, Dorea, Robinsoniella, and Roseburia in obese NAFLD patients (n=30) 
compared to healthy controls (n=30)143. Another study reported that NASH patients (n=24) 
have a higher relative abundance of Escherichia compared to healthy controls (n=16) and 
obese controls without NASH (n=25)94 , while a different study found no differences in the 
relative abundance of Bifidobacterium, Bacteroidetes, Clostridium leptum, Clostridium 
coccoides, Escherichia coli and total bacteria using qPCR when they compared the fecal 
microbiota composition of NAFLD patients (n=11) to healthy controls (n=27)144. In a study 
of NASH patients (n=16), they found lower relative abundances of Faecalibacterium and 
Anaerosporobacter and higher relative abundances of Parabacteroides and Allisonella 
compared to healthy controls (n=22)145.  
Additional studies reported that certain bacterial species were differentially abundant 
between mild/moderate NAFLD (n=72) compared to advanced fibrosis (n=14)146. Patients 
with mild/moderate NAFLD had higher relative abundances of Ruminoccocus obeum, 
Eubacterium rectale, and Faecalibacterium prausnitzii146. Patients with advanced fibrosis 
had higher relative abundances of Escherichia coli and Bacteroides vulgatus146. Boursier 
et al.147 also reported that NASH patients (n=35) had a significant increase relative 
abundance of Bacteroides and a decrease in the relative abundance of Prevotella and 
advanced fibrosis patients (n=27) had a significant increase in the relative abundance of 
Ruminococcus. In a study of pediatric NAFLD, there was an association of increased 






microbiome may play a role in developing NAFLD and progression of NAFLD to 
advanced fibrosis and NASH. The small samples sizes in these studies are likely the reason 
why the results of these microbiota studies are so variable. Future studies with larger cohort 
sizes are needed to determine what differences in bacterial composition exist in NAFLD 
and NASH patients compared to healthy controls. Then, experiments with species and 
strains of interest could be conducted to determine which bacteria may be contributing to 
or protective against the disease. 
Some researchers believe that the gut microbiome of NAFLD patients has an increased 
energy harvesting potential, leading to weight gain. This hypothesis is based upon an obese 
mouse model. In 2006, Turnbaugh et al.149 found that stool of obese mice had less energy 
compared to lean mice leading to the conclusion that the microbiota of obese mice could 
extract more energy from their diet. When fecal transplants from obese mice were given to 
lean mice it resulted in weight gain without changes in exercise or diet149. Increased energy 
harvesting potential of the gut microbiome has not yet been demonstrated in humans. The 
early work by Turnbaugh et al. has been heavily criticized in the past150. 
As opposed to certain bacteria being responsible for the pathogenesis of NAFLD, bacterial 
metabolites may be the driving force. It has been found that NASH patients (n=22) have 
significantly higher blood ethanol levels compared to healthy controls (n=16) and obese 
individuals (n=25)94. The increased ethanol could be a result of fermentation by bacteria in 
the gut which can lead to liver inflammation and the development of NAFLD and 
eventually NASH94. Volynets et al.151 also found that blood ethanol levels were higher in 
NAFLD patients (n=20) compared to healthy controls (n=10). On the contrary, another 
study showed no difference in the concentration of ethanol measured from the breath of 
NASH patients (n=21) compared to healthy controls (n=10)152. Therefore, there is 
insufficient evidence to conclude that endogenous ethanol production by the gut microbiota 
is responsible for NAFLD or NASH.  
As previously mentioned, NAFLD patients have an increased prevalence of abnormal 






general, including genetic susceptibility153, hyperglycemia154, bacterial pathogens155, and 
alterations to the gut microbiome. Some bacteria that make up the gut microbiota are able 
to ferment dietary fibre into SCFAs. As previously mentioned, butyrate increases intestinal 
barrier integrity, therefore if there is a decrease in butyrate production in the gut then this 
would lead to increased intestinal permeability. NAFLD patients may have a decrease in 
the abundance of butyrate producers, which causes the increased prevalence of elevated 
intestinal permeability.  
The increase in intestinal permeability may be a driving force in the development and 
progression of NAFLD. It has been found that NAFLD patients have higher amounts of 
Gram-negative bacteria compared to healthy controls146,156 and therefore a greater amount 
of lipopolysaccharide (LPS) can pass through the intestinal membrane and eventually into 
the portal vein due to increase intestinal permeability. LPS can cause inflammation in the 
liver and the chronic inflammation can contribute to the development of NAFLD and 
progression to NASH157. A decrease in butyrate and an increase in the amount of LPS 
passing through the intestinal membrane has been shown in mice to cause NAFLD and 
insulin resistance158. An increase in intestinal barrier integrity may reduce the amount of 
LPS from bacteria in the lumen of the intestine from passing through the intestinal 
membrane. Gao et al.159 found that administering butyrate to mice fed a high-fat diet 
increased their energy expenditure and protected them from developing insulin resistance. 
Human studies have shown that NAFLD patients have higher levels of LPS in their blood 
and higher titres of antibodies to LPS160,161.  
Insulin resistance can also be associated with the microbiome as a number of studies have 
shown that Faecalibacterium prausnitzii and Akkermansia muciniphila are protective 
against insulin resistance and their abundance is inversely related to obesity162-164. Hippe 
et al.162 found that F. prausnitzii was in the highest abundance in lean healthy controls 
(n=18) when compared to T2DM patients (n=24) and obese controls (n=26). They noted 
that there were different phylotypes of F. prausnitzii and hypothesized that some 






al.163 found that increased A. muciniphila was associated with lower fasting glucose levels 
and waist-to-hip ratio when studying patients overweight and obese patients (n=49). 
Remely et al.164 observed an increase in the abundance of Faecalibacterium prausnitzii and 
Akkermansia muciniphila in T2DM patients (n=24) following weight loss. The exact 
mechanism for how these bacteria influence human physiology is not yet known, but many 
hypothesize that since the bacteria are known butyrate producers that they are beneficial 
for gut barrier function.  
1.4 Multiple Sclerosis 
1.4.1 Characterization of multiple sclerosis 
Multiple Sclerosis is an autoimmune, inflammatory, demyelinating disease of the central 
nervous system influenced by genetic susceptibility and environmental factors165. Patients 
with MS may experience loss of motor function and vision, bladder and bowel dysfunction, 
muscle spasms, and cognitive impairment, which can significantly decrease their quality 
of life166. There are three main types of MS; relapsing-remitting MS (RRMS), secondary-
progressive MS (SPMS), and primary-progressive MS (PPMS). The most common type of 
MS is RRMS, characterized by having defined relapses where there are new symptoms of 
MS or existing symptoms get worse, followed by complete or nearly complete recovery. 
There were approximately 98 000 MS cases in Canadians in 2011 and this number is 
expected to grow to approximately 133 000 by 2031167. In Canada, MS is more prevalent 
in females than in males167,168. The disease impacts life expectancy, with an estimated loss 
of 7 years on average169. Progression of the disease can be measured using the Expanded 
Disability Status Scale (EDSS), which ranges from 0 (healthy; no MS) to 10 (death; due to 
MS). The EDSS is graded using the following functional systems: pyramidal function, 
cerebellar functions, brain stem functions, sensory functions, visual (or optic) functions, or 
cerebral (or mental) functions170.  
There are no existing therapies available to stop the progression of MS. Current 
medications are used to slow the progression, manage relapse symptoms, and speed up 






central nervous system, to improve recovery time and reduce the severity of symptoms171. 
Other medications, such as interferon-beta, are used to increase the time between 
relapses172.  
1.4.2 The gut microbiome and multiple sclerosis  
Several studies have investigated the differences in the gut microbiome of MS patients 
compared to healthy controls. These studies have reported that MS patients do not have 
lower fecal microbiota diversity compared to healthy controls173-175. Differences between 
MS patients and healthy controls may take place at a lower taxonomic level as there have 
been reported differences in the relative abundance of specific genera and species, although 
the findings have varied between studies. One study reported that MS patients (n=18) had 
increases in the relative abundances of Bilophila, Desulfovibrio, and Christensenellaceae, 
and decreases in the relative abundances of Lachnospiraceae and Ruminococcaceae 
compared to healthy controls (n=17)174. A larger study reported increases of the relative 
abundance of Methanobrevibacter and Akkermansia and a decrease in the relative 
abundance of Butyricimonas when they compared MS patients (n=60) to healthy controls 
(n=43)85. Chen et al.176 reported increases in the relative abundances of Pseudomonas, 
Mycoplana, Haemophilus, Blautia, and Dorea, and decreases in the relative abundances of 
Parabacteroides, Adlercreutzia and Prevotella when RRMS patients (n=31) were 
compared to a group of healthy controls (n=36). Cosorich et al.177 compared nineteen 
RRMS patients to seventeen healthy controls and found that RRMS patients have increased 
abundances of Streptococcus mitis and Streptococcus oralis and a decrease in Prevotella. 
Miyake et al.173 studied a group of Japanese RRMS patients (n=20) and compared their 
fecal microbiota composition to healthy controls (n=40). They found that MS patients had 
increases in the relative abundances of Bifidobacterium and Streptococcus, and decreases 
in the relative abundances of Bacteroides, Faecalibacterium, Prevotella, Anaerostipes and 
Clostridia clusters XIVa and IV173. They also noted that MS patients’ fecal microbiota 
composition had more inter-individual variability compared to the group of healthy 
controls173, which means that the gut microbiome of MS patients may be more difficult to 






to experimental and analytical inconsistencies. This makes it difficult to pinpoint the key 
organisms that may be contributing to disease progression. It does suggest that the complex 
microbial community found in an FMT could be used to overcome functional changes in 
the microbiome rather than individual species changes.  
Another potential mechanism that the gut microbiome can contribute to the development 
and progression of MS is the production of blood-brain barrier disrupting toxins by 
bacteria. Clostridium perfringens type B has been shown to produce the toxin “ETX” that 
can create holes in the blood brain barrier of MS patients178. One study found that 10% of 
RRMS patients (12/118) tested positive for ETX-specific antibodies compared to 1% of 
healthy controls (1/100)178. Molecular mimicry could also be a possible factor contributing 
to the development of MS, Pseudomonas peptides capable of activating myelin basic 
protein (MBP)-specific T-cell clones from MS patients179. A number of other bacterial 
species have also been proposed that produce peptides with molecular mimicry to myelin, 
but their prevalence in MS patients has not been studied180. 
Functionally, the most common finding is a decrease in some butyrate-producing bacteria 
including Clostridium cluster XIVa, Faecalibacterium, Lachnospiraceae, 
Ruminococcaceae, Fusobacterium and Butyricimonas173,174,181. A decrease in butyrate may 
cause an increase in intestinal permeability, allowing microbial and dietary antigens to pass 
through the intestinal epithelium and trigger autoimmune responses in the host. These 
antigens could include peptides that have molecular mimicry to myelin or bacterial toxins, 
thereby contributing to the development and progression of MS. Fecal microbiota 
transplantation could be used to deliver butyrate-producing bacteria, and these effects 
might be reduced182. More than one study noted a decrease in the relative abundance of 
Prevotella173,176,177, a known producer of propionate, which has been shown to be 
correlated to increased TH17 expansion cells and a higher prevalence of intestinal TH17 
cells177, which are involved in the development of the disease.  
The possibility that the immunomodulatory therapies used to treat MS can alter the 






studies174,176. One study reported that MS treatment caused an increase in the relative 
abundances of Prevotella and Sutterella85. This study reported that the microbiota of MS 
patients currently using immunomodulatory therapy was closer in composition to healthy 
controls than MS patients that were treatment naïve and concluded that immunomodulatory 
therapy may help combat changes in the microbiome that led to the development of MS85, 
but this has not been proven. The microbiome of MS patients may also play a role in relapse 
events. Seventeen MS patients were followed for an average of approximately twenty 
months and relative abundance of fusobacteria was found to be decreased in patients that 
had shorter lengths of time between relapses183. 
These previously mentioned studies had limited numbers of patients and their results were 
variable to the findings of other studies. Some observed large inter-variability between MS 
patients, making it difficult to define the microbiome of MS patients. Larger, multicenter 
studies need to take place to determine what differences exist in the gut microbiome of 
multiple sclerosis patients compared to healthy controls and if current therapies impact the 
gut microbiome. Studies using FMT are required to assess the potential to slow disease 
progression and improve quality of life through microbiota manipulation. 
1.5 Thesis Overview 
Both NAFLD and MS are important diseases worldwide due to the burden they place on 
the healthcare industry. While there are a number of therapies available that seek to reduce 
the symptoms or treat these diseases, none are particularly efficient, and the prevalence of 
both of these diseases are slowly increasing. As such, alternate therapies that can 
potentially treat these diseases or reduce the morbidity associated with them should be 
investigated. Given that changes to an individual’s gut microbiome can potentially elicit 
systemic changes, FMT has the potential to be a strong candidate as a treatment or adjunct 
for these complicated, multifaceted diseases. This formed the basis for the enclosed thesis 






Before this could be done however, it was deemed critical to develop a standardized 
method for processing and storing fecal material and identifying healthy donors. Having 
stool banked in the clinic allows FMTs to be performed at a moment’s notice. Given the 
difficulty of processing fecal material into a form that can be delivered and the additional 
difficulty of finding donors to readily donate material on short notice, determining the 
length of time that fecal material can be stored for was important. Little work has been 
carried out that investigates the length of time that fecal material can be stored while 
maintaining bacterial viability. This led to Objectives 1-3. 
1) Does fecal matter prepared for enema delivery stored for up to 3 months retain 
similar bacterial viability to fecal material that is fresh? 
2) Does fecal matter prepared for FMT capsules stored for up to 2 months retain 
similar bacterial viability to fecal material that is fresh? 
3) What proportion of healthy people qualify to be an FMT donor? 
The objectives were addressed by taking samples of healthy human feces and preparing 
them using existing methods for enema delivery and capsule delivery. The samples were 
then frozen, and they were evaluated at various time points (enema delivery: fresh, 1 week, 
2 weeks, 4 weeks, 8 weeks, 12 weeks; capsule delivery: fresh, encapsulated, 1 day, 3 days, 
5 days, 1 week, 2 weeks, 4 weeks, 8 weeks). A maximum of 3 and 2 months were tested 
as most FMT clinics do not store their samples prepared for enema or capsule delivery for 
longer than this time frame, respectively. Once the storage time and processing methods 
were optimized, healthy donors were screened to determine what percentage met the 
inclusion criteria to be an FMT donor.  
After donors were selected, the following objective was addressed: 
4) Does treating patients suffering from NAFLD with FMT from thin and 
healthy donors improve insulin resistance, liver proton density fat fraction, 






This objective was addressed by enrolling NAFLD patients in a clinical trial and measuring 
for a change in the primary outcome of insulin resistance, and secondary outcomes of liver 
proton density fat fraction (PDFF), and small intestinal permeability. A number of 
biochemical tests on blood were conducted to assess safety of FMT. Patients were 
randomized to receive an allogenic FMT from a thin and healthy donor or an autologous 
FMT which contained their own stool. 
The final objective of this project was to determine if FMT would be a candidate therapy 
for treating patients that had MS.  
5) Does FMT alter the gut microbiota of RRMS patients and is this therapy safe 
and tolerable in RRMS patients? 
The intention was to enroll 40 patients with MS in an FMT clinical trial and measuring for 
changes in EDSS, small intestinal permeability and the gut microbiota composition over 
twelve months. However, due to the unexpected death of the principal investigator and 
referring clinician, this resulted in us having to complete the study with a smaller patient 
number (n=10). In addition to this, safety of FMT was measured in these patients. Results 
from this project will ultimately be utilized in order to assess if FMT for treatment of 
diseases beyond rCDI are able to reduce symptoms or morbidity in addition to being safe 
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Chapter 2  
2 Commonly used methods to prepare fecal samples for 
fecal microbiota transplantation results in decreases in 
bacterial viability 
2.1 Introduction 
Fecal microbiota transplantation is typically used to treat rCDI. Clinics use a variety of 
methods to store and prepare fecal samples for transplant. Many vary in the time a sample 
is collected to when it is processed, the diluent used, the storage temperature, and the length 
of storage1-7. There has been a shift to the use of frozen stool after it was shown to be as 
effective as fresh stool in treating rCDI1. Some studies pre-dilute the stool samples with 
saline2, water1,3, or 10% glycerol4-6 before long-term storage at sub-zero temperatures. 
Frozen stool suspended in 10% glycerol and stored for two to ten months has been used to 
treat rCDI, with a disease resolution rate of 88%, similar to using stool that has been stored 
for shorter durations7. While the resolution rates of rCDI has not apparently been strongly 
affected by the preparation methods of feces, these materials are now being expanded to 
treat a wide range of conditions in which the gut microbiome has been indicated. These 
conditions include multiple sclerosis, obesity, metabolic syndrome, irritable bowel 
syndrome, inflammatory bowel diseases, and cancer immunotherapeutics8-17. Therefore, 
the extent to which bacterial viability is lost with processing the fecal material needs to be 
minimized in case the impact on efficacy is greater in non-rCDI patients and to prevent 
passing along the phenotype of the previously mentioned conditions.  
Traditional next-generation sequencing analysis targeting the 16S rRNA gene does not 
differentiate between live and dead bacteria. Propidium monoazide (PMA) is a dye that 
can bind covalently to DNA inside of bacterial cells with compromised cell membranes 
and prevent its amplification during PCR18. It can be used in conjunction with next-
generation sequencing to sequence the DNA selectively from only the live bacteria. This 
method has been optimized for stool samples19. A past study examined the effect of oxygen 






abundance of viable bacteria. They found that the biggest factor influencing the living 
profile of bacteria was the level of oxygen exposure20. Another study used a similar 
technique and found that there was a significant loss of viable bacteria and a change in 
composition after initial processing of stool samples for FMT21. A different study used 
PMA to examine the effect of storage time on the percentage of viable bacteria, but not the 
total number of viable bacteria nor the composition of viable bacteria22.  
While it has been shown that sterile fecal filtrate transfer is effective at treating rCDI23, it 
is entirely possible that a decrease in bacterial viability and change in composition could 
impact the effectiveness of FMT for other conditions beyond rCDI. The aim of this study 
was to determine what storage conditions for donated stools provided the highest bacterial 
viability and the smallest change to the composition over time. 
2.2 Methods 
2.2.1 Sample Collection 
Fecal samples were collected from a healthy 22-year-old female donor from the FMT clinic 
at St. Joseph’s Health Care in London, Ontario. The donor was screened using our 
previously published protocol25. Three 80 g fecal samples were collected from the donor 
over a period of six months (n=3). Samples were collected at the research facility and 
brought directly to the lab to be processed within one hour of collection. The Western 
University Health Science Research Ethics Board granted ethical approval for the 
experiments. The experiments were carried out in accordance with the approved guidelines 
(REB CER 106715). Informed consent was given from the donor.  
2.2.2 Sample Preparation and Storage 
Whole stool samples were suspended 1:5 stool to fluid in normal sterile saline (0.9 % NaCl 
w/v), sterile deionized water, normal saline with 10% glycerol (v/v) or remained as whole 
stool. Samples were mixed inside of BA614/STR filter bags (Seward, Islandia, NY) using 
the Stomacher® 400 Circulator (Seward, Islandia, NY) at 230 rpm for 30 seconds. Samples 






stored in the fridge for 1 week. Time points were taken before suspension, immediately 
after suspension, 4 hours, 24 hours, 3 days, 5 days, and 7 days later. Samples were stored 
at -20 °C or -80 °C for 3 months with time points at 1 week, 2 weeks, 4 weeks, 2 months, 
and 3 months. 
Figure 2.1 Methods for the preparation and storage of fecal samples used for FMT 
delivered by enema, colonoscopy, and endoscopy.   
2.2.3 Bacterial Culture 
At each time point the sample was serially diluted in PBS and plated on 5 different agar 
plates: Brain heart infusion supplemented (BHIS) agar (BD, Mississauga, ON) (selective 
for total anaerobes), MacConkey agar (BD) (selective for Enterobacteriaceae), Columbia 
Blood agar (BD) (selective for anaerobic staphylococci and streptococci), Columbia CNA 
Blood agar (BD) (selective for aerobic staphylococci, streptococci and enterococci), and 
Rogosa agar (BD) (semi-selective for lactobacilli and bifidobacteria). BHIS, Rogosa, and 
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Columbia Blood agar plates were incubated at 37 °C for 48 hours in an anaerobic chamber 
(10% hydrogen, 10% carbon dioxide, 80% nitrogen). Columbia CNA and MacConkey agar 
plates were incubated at 37 °C for 24 hours. 
2.2.4 PMA Exposure 
The fecal sample aliquots were diluted 1:100 in sterile PBS in an anaerobic chamber. At 
each time point, 2.5 µL of 20 mM PMA (Biotium, Scarborough, ON) was added to 500 µL 
of sample in 1.5 mL Eppendorf tubes for a final concentration of 100 µM PMA19. The 
samples were vortexed and then covered in tin foil and placed in the dark for 10 minutes. 
The samples were then placed lying flat on ice and exposed to light for 15 minutes (250 
watts) (placed 30 cm above the samples) in a cold room. The cells were spun at 10,000 rpm 
for 10 minutes, the supernatant discarded and resuspended in nuclease free water three 
times. After the final spinning step, the sample was stored in 100 µL of nuclease free water 
and stored at -80 °C until time for DNA extraction. 
2.2.5 DNA Extraction 
DNA from the 100 µL cell pellets was extracted using the DNeasy® Powersoil® HTP 96 
Kit (Qiagen, Toronto, Ontario, Canada), as per the manufacturer’s instructions with the 
following modification: a centrifuge speed of 3700 rpm for 10 minutes was used. Extracted 
DNA was stored at -20 °C until amplification. 
2.2.6 DNA Amplification  
The BioMek® 3000 Laboratory Automation Workstation for automated PCR reagent set 
up was used to load 10 µL (2.3 pmol/µL) of 32 primers (16 left and 16 right) with unique 
barcodes into 96 well plates. Amplifications of the V4 region of the 16S ribosomal 
RNA gene were carried out with the primers (5′-3′) 
ACACTCTTTCCCTACACGACGCTCTTCCGATCTNNNNxxxxxxxxGTGCCAGCMG






NNNNxxxxxxxxGGACTACHVGGGTWTCTAAT (xxxxxxxx is a sample 
specific nucleotide barcode and the preceding sequence is a portion of the Illumina adapter 
sequence for library construction). The BioMek® robot was then used to transfer 2 µL of 
template DNA into the primer containing 96 well plates. Then 20 μl of Promega GoTaq® 
Colourless Master Mix (Promega, Maddison, WI) was added to the DNA template and 
primers. The final plate was firmly sealed with a foil PCR plate cover. This plate was placed 
in the Eppendorf Mastercycler® thermal cycler (Eppendorf, Mississauga, Ontario, 
Canada), where the lid was kept at 105 °C. An initial warm-up temperature of 95 °C was 
used for 2 min to activate the GoTaq®. Afterwards, the volumes underwent 25 cycles of 
95 °C for 1 min, 50 °C for 1 min, and 72 °C for 1 min. After completion, the temperature 
of the thermal cycler was held at 4 °C, and amplicons were then stored at − 20 °C. 
2.2.7 DNA Sequencing and Data Analysis 
Amplified DNA was sent to the London Regional Genomics Centre at Robarts Research 
Institute (Western University, London, Ontario, Canada). The samples were quantified 
(Quant-it, Life Technologies, Burlington, Ontario, Canada) and pooled at equimolar 
concentrations. The pooled libraries were cleaned using QIAquick (Qiagen, Germantown, 
Maryland, USA) and then sequenced using the MiSeq Illumina® platform, with 2 × 300 bp 
paired-end chemistry. The reads were demultiplexed and filtered using dada2 (version 1.8) 
and custom R scripts written by Greg Gloor (github.com/ggloor/miseq_bin). The 
demultiplexed are available at NCBI SRA (BioProject: PRJNA557215). Taxonomy was 
assigned using an RDP classifier provided by the dada2 package and trained against version 
132 of the SILVA database. Compositional distance between communities was quantified 
using the Aitchison distance with a prior count of 0.5 to avoid taking the log or ratio of 
zero counts and the following packages: philr, MCMCpack, tidyverse, and gtools in R24. 
Diversity of the stool microbiota was quantified based on Shannon Diversity and was 
calculated using the Vegan package (github.com/vegandevs/vegan) in R. Compositional 
distance between communities was quantified using the Aitchison distance with a prior 
count of 0.5 to avoid taking the log or ratio of zero counts24. ALDEx2 was used to identify 






2.2.8 Statistical Analysis 
Bacterial viability data at 4 °C, -20 °C and -80 °C, Aitchison distance, and Shannon 
diversity passed the Shapiro-Wilk test for normality. Levene’s test of homogeneity was 
significant and as a result an ordinary one-way ANOVA with Dunnett’s multiple 
comparison test was used to compare bacterial viability, Aitchison distance, and Shannon 
diversity over time within a single diluent. One-way ANOVA was used to compare 
bacterial viability, Aitchison distance, and Shannon diversity of different diluents at each 
time point with Tukey’s multiple comparison test used post-hoc. Results of the one-way 
ANOVA tests and post-hoc tests for bacterial viability at 4 °C, -20 °C, and -80 °C can be 
found in Supplementary Tables 1-36. An effect size cut-off of >|3| was used with ALDEx2 
to determine what bacterial taxa were differentially abundant. The Benjamini-Hochberg 
corrected p-value of the Wilcoxon Rank Sum test was used to identify differentially 
abundant taxa. 
2.3 Results 
2.3.1 Common methods of FMT sample preparation and storage 
impact bacterial survival 
Changes in bacterial viability during storage at 4 °C, -20 °C and -80 °C were measured 
using anaerobic and aerobic culture-based techniques (Figures 2.2, 2.3, and 2.4). The 
samples were blended in either 10% glycerol, saline, water, or remained as whole stool. 
There was a significant loss of total anaerobes immediately after suspension when samples 
were blended in water, but not in samples that were blended with saline or 10% glycerol 
or remained as whole stool (Figure 2.2a). Samples stored in 10% glycerol at 4 °C did not 
experience a significant loss of total anaerobes throughout storage (Figure 2.2a). Samples 
stored in saline and as whole stool did not experience a significant loss of anaerobic 
bacteria until 3 days of storage (Figures 2.2a and 2.2b). Whole stool samples were the only 
samples to undergo a significant loss of lactobacilli throughout 7 days of storage at 4 °C 
(Figure 2.2c). There was no change in the concentration of bifidobacteria in samples stored 






storage at 4°C, there was no difference in the change in concentration of Gram-negative 
aerobes when 10% glycerol, whole stool, saline, and water were compared (Figure 2.2e). 
Ten percent glycerol was the only diluent to not experience a significant loss of viable 
Gram-positive aerobes when stored at 4 °C for 1 week (Figure 2.2f).  
 
Figure 2.2 Suspension in water resulted in a significant loss of total anaerobes 
immediately following blending. Stool samples were suspended 1:5 in saline, water, 10% 
glycerol, or remained as whole stool and stored for 12 weeks. At each time point (fresh, 
immediately following blending, 4 hours, 1 day, 3 days, 5 days, and 7 days) a 1 mL aliquot 
of the sample was thawed and plated on selective media in aerobic and anaerobic 
conditions and incubated at 37 °C for 24-48 hours. Data displayed is three biological 
replicates from one donor (n=1) and each biological replicate had six technical replicates. 
Change in concentration was calculated by converting the CFU/mL data into logCFU/mL 
and subtracting the values of subsequent time points from the baseline concentration. * 
p<0.05, **p<0.01, ***p< 0.001, ****p<0.0001. * on the graph are the results of the one-
way ANOVA comparing diluents at each time point. One-way ANOVA was used to 
compare differences in the mean change in concentration of the four different diluents at 






of each diluent to each other. A detailed summary of statistics including the results of post-
hoc tests can be found in Supplementary Tables 2.1-2.12. 
A) Total anaerobes. After blending, 0.01 days (**p=0.0047). 4 hours, 0.167 days 
(**p=0.0025). 1 day (*p=0.0315). 3 days (****p<0.0001). 5 days (p=0.8215). 7 
days (p=0.0850). 
B) Gram-positive anaerobes. After blending, 0.01 days (***p=0.0001). 4 hours, 0.167 
days (**p=0.0010). 1 day (**p=0.0018). 3 days (p=0.6730). 5 days (p=0.7733). 7 
days (p=0.1132). 
C) Lactobacilli. After blending, 0.01 days (**p=0.0024). 4 hours, 0.167 days 
(****p<0.0001). 1 day (***p=0.0002). 3 days (****p<0.0001). 5 days 
(****p<0.0001). 7 days (****p<0.0001). 
D) Bifidobacteria. After blending, 0.01 days (****p<0.0001). 4 hours, 0.167 days 
(p=0.3809). 1 day (p=0.4177). 3 days (**p=0.0081). 5 days (p=0.1607). 7 days 
(**p=0.0651). 
E) Gram-negative aerobes. After blending, 0.01 days (***p=0.0001). 4 hours, 0.167 
days (***p=0.0060). 1 day (p=0.1269). 3 days (p=0.1612). 5 days (p=0.2192). 7 
days(p=0.1465). 
F) Gram-positive aerobes. After blending, 0.01 days (***p=0.0001). 4 hours, 0.167 
days (****p<0.0001). 1 day (****p<0.0001). 3 days (***p=0.0005). 5 days 
(***p0.0004). 7 days (****p<0.0001). 
One-way ANOVA was used to compare differences in change in concentration over time 
for each diluent; Dunnett’s multiple comparison test was used post-hoc to compare the 
mean of each time point to baseline for a single diluent. 
A) Total anaerobes. 10% glycerol (**p=0.0036). Whole stool (****p<0.0001). Saline 
(***p=0.0002). Water (**p=0.0027) 
B) Gram-positive anaerobes. 10% glycerol (****p<0.0001). Whole stool 
(****p<0.0001). Saline (**p=0.0013). Water (p=0.1186). 
C) Lactobacilli. 10% glycerol (*p=0.0481). Whole stool (****p<0.0001). Saline 






D) Bifidobacteria. 10% glycerol (p=0.1383). Whole stool (**p=0.0022). Saline 
(****p<0.0001). Water (p=0.3703). 
E) Gram-negative aerobes. 10% glycerol (****p<0.0001). Whole stool (*p=0.0204). 
Saline (****p<0.0001). Water (****p<0.0001). 
F) Gram-positive aerobes. 10% glycerol (****p<0.0001). Whole stool (**p=0.0077). 
Saline (****p<0.0001). Water (*p=0.0311). 
When samples were stored at -20 °C, saline had a significant decrease in the concentration 
of total anaerobes and Gram-positive anaerobes at 1 week of storage (Figures 2.3a and 
2.3b). Samples stored in water had a significant loss of total anaerobes at 2 weeks of storage 
(Figure 2.3a) while samples stored in 10% glycerol or as whole stool did not experience a 
significant loss of total anaerobes until 3 months of storage (Figure 2.3a). Samples stored 
in 10% glycerol and water did not have any significant loss of lactobacilli throughout 
storage at -20 °C (Figure 2.3c). Samples stored suspended in saline or as whole stool had 
a significant loss of lactobacilli at 2 weeks’ time (Figure 2.3c). Viable bifidobacteria 
remained stable in samples stored as whole stool (Figure 2.3d). The different diluents only 
differed in the concentration of viable bifidobacteria at 8 weeks of storage; whole stool was 
significantly higher than samples stored in 10% glycerol or water (Figure 2.3d). Samples 
stored in 10% glycerol were the only samples to not undergo a significant loss of Gram-
negative aerobes during storage at -20 °C (Figure 2.3e). Gram-positive aerobes 
significantly decreased in samples suspended in saline and water at 1 week of storage 
(Figure 2.3f). Samples stored as whole stool did not experience any loss over the 12 weeks 
and samples stored in 10% glycerol did not experience a loss of Gram-positive aerobes 







Figure 2.3 Storage as whole stool or suspended in glycerol resulted in the most stable 
bacterial viability at -20 °C. Stool samples were suspended 1:5 in saline, water, 10% 
glycerol, or remained as whole stool and stored for 12 weeks. At each time point (baseline, 
1 week, 2 weeks, 4 weeks, 8 weeks, and 12 weeks) a 1 mL aliquot of the sample was thawed 
and plated on selective media in aerobic and anaerobic conditions and incubated at 37 °C 
for 24-48 hours. Data displayed is three biological replicates from one donor (n=1) and 
each biological replicate had six technical replicates. Change in concentration was 
calculated by converting the CFU/mL data into logCFU/mL and subtracting the values of 
subsequent time points from the baseline concentration. * p<0.05, **p<0.01, ***p< 0.001, 
****p<0.0001. * on the graph are the results of the one-way ANOVA comparing diluents 
at each time point. One-way ANOVA was used to compare differences in the mean change 
in concentration of the four different diluents at each time point; Tukey’s multiple 
comparison test was used post-hoc to compare the mean of each diluent to each other. A 
detailed summary of statistics including the results of post-hoc tests can be found in 






A) Total anaerobes. 1 week (****p<0.0001). 2 weeks (***p<0.0001). 4 weeks 
(***p<0.0001). 8 weeks (***p<0.0001). 12 weeks (**p=0.0011).  
B) Gram-positive anaerobes. 1 week (****p<0.0001). 2 weeks (p=0.1016). 4 weeks 
(****p<0.0001). 8 weeks (****p<0.0001). 12 weeks (**p=0.0034). 
C) Lactobacilli. 1 week (*p=0.0388). 2 weeks (**p=0.0011). 4 weeks (***p=0.0008). 
8 weeks (****p<0.0001). 12 weeks (****p<0.0001). 
D) Bifidobacteria. 1 week (p=0.1249). 2 weeks (p=0.9620). 4 weeks (p=0.3414). 8 
weeks (**p=0.0049). 12 weeks (p=0.1594). 
E) Gram-negative aerobes. 1 week (****p<0.0001). 2 weeks (****p<0.0001). 4 
weeks (****p<0.0001). 8 weeks (****p<0.0001). 12 weeks (****p<0.0001). 
F) Gram-positive aerobes. 1 week (****p<0.0001). 2 weeks (****p<0.0001). 4 weeks 
(**p=0.0037). 8 weeks (****p<0.0001). 12 weeks (****p<0.0001). 
One-way ANOVA was used to compare differences in change in concentration over time 
for each diluent; Dunnett’s multiple comparison test was used post-hoc to compare the 
mean of each time point to baseline for a single diluent.  
A) Total anaerobes. 10% glycerol (****p<0.0001). Whole stool (****p<0.0001). 
Saline (****p<0.0001). Water (****p<0.0001). 
B) Gram-positive anaerobes. 10% glycerol (****p<0.0001). Whole stool 
(****p<0.0001). Saline (****p<0.0001). Water (****p<0.0001). 
C) Lactobacilli. 10% glycerol (p=0.5214). Whole stool (****p<0.0001). Saline 
(****p<0.0001). Water (p=0.3037). 
D) Bifidobacteria. 10% glycerol (****p<0.0001). Whole stool (p=0.0624). Saline 
(**p=0.0082). Water (**p=0.0028). 
E) Gram-negative aerobes. 10% glycerol (**p=0.0044). Whole stool (****p<0.0001). 
Saline (****p<0.0001). Water (**p=0.0016). 
F) Gram-positive aerobes. 10% glycerol (*p=0.0301). Whole stool (**p=0.0074). 
Saline (****p<0.0001). Water (****p<0.0001). 
When samples were stored at -80 °C, samples stored as whole stool did not experience any 






storage (Figure 2.4a and b). Samples stored in 10% glycerol, saline, and water had 
significant losses of total anaerobes at 1 week of storage at -80 °C (Figure 2.4a). Samples 
stored in 10% glycerol and water did not have any significant changes in the concentration 
of lactobacilli throughout storage (Figure 2.4c). Samples stored as whole stool did not have 
any significant decreases in the concentration of bifidobacteria over time (Figure 2.4d). 
Only samples stored in saline had a loss of Gram-negative aerobes throughout storage and 
this started at 1 weeks’ time (Figure 2.4e). Samples stored in 10% glycerol and whole stool 
did not have a significant loss of Gram-positive aerobes (Figure 2.4f).  
Figure 2.4 Storage as whole stool resulted in the most stable bacterial viability at -
80°C. Stool samples were suspended 1:5 in saline, water, 10% glycerol, or remained as 
whole stool and stored for 12 weeks. At each time point (baseline, 1 week, 2 weeks, 4 
weeks, 8 weeks, and 12 weeks) a 1 mL aliquot of the sample was thawed and plated on 
selective media in aerobic and anaerobic conditions and incubated at 37 °C for 24-48 hours. 
Data displayed are three biological replicates from one donor (n=1) and each biological 
replicate had six technical replicates. Change in concentration was calculated by converting 






from the baseline concentration. * p<0.05, **p<0.01, ***p< 0.001, ****p<0.0001. * on 
the graph are the results of the one-way ANOVA comparing diluents at each time point. 
One-way ANOVA was used to compare differences in the mean change in concentration 
of the four different diluents at each time point; Tukey’s multiple comparison test was used 
post-hoc to compare the mean of each diluent to each other. A detailed summary of 
statistics including the results of post-hoc tests can be found in Supplementary Tables 25-
36.  
A) Total anaerobes. 1 week (****p<0.0001). 2 weeks (****p<0.0001). 4 weeks 
(****p<0.0001). 8 weeks (****p<0.0001). 12 weeks (****p<0.0001).  
B) Gram-positive anaerobes. 1 week (*p=0.0131). 2 weeks (***p=0.0003). 4 weeks 
(****p<0.0001). 8 weeks (****p<0.0001). 12 weeks (**p=0.0028). 
C) Lactobacilli. 1 week (*p=0.0480). 2 weeks (*p=0.0247). 4 weeks (***p=0.0001). 
8 weeks (**p=0.0029). 12 weeks (***p=0.0001). 
D) Bifidobacteria. 1 week (****p<0.0001). 2 weeks (****p<0.0001). 4 weeks 
(p=0.0549). 8 weeks (****p<0.0001). 12 weeks (**p=0.0028). 
E) Gram-negative aerobes. 1 week (****p<0.0001). 2 weeks (****p<0.0001). 4 
weeks (****p<0.0001). 8 weeks (****p<0.0001). 12 weeks (****p<0.0001). 
F) Gram-positive aerobes. 1 week (****p<0.0001). 2 weeks (***p=0.0006). 4 weeks 
(p=0.0876). 8 weeks (****p<0.0001). 12 weeks (****p<0.0001). 
One-way ANOVA was used to compare differences in change in concentration over time 
for each diluent; Dunnett’s multiple comparison test was used post-hoc to compare the 
mean of each time point to baseline for a single diluent.  
A) Total anaerobes. 10% glycerol (****p<0.0001). Whole stool (****p<0.0001). 
Saline (****p<0.0001). Water (****p<0.0001). 
B) Gram-positive anaerobes. 10% glycerol (****p<0.0001). Whole stool 
(**p=0.0067). Saline (****p<0.0001). Water (**p=0.0042). 
C) Lactobacilli. 10% glycerol (p=0.4776). Whole stool (****p<0.0001). Saline 






D) Bifidobacteria. 10% glycerol (****p<0.0001). Whole stool (****p<0.0001). Saline 
(****p<0.0001). Water (*p=0.0276). 
E) Gram-negative aerobes. 10% glycerol (****p<0.0001). Whole stool (p=0.1095). 
Saline (****p<0.0001). Water (**p=0.0100). 
F) Gram-positive aerobes. 10% glycerol (p=0.0570). Whole stool (*p=0.0158). Saline 
(****p<0.0001). Water (****p<0.0001). 
 
2.3.2 The composition of viable bacteria is stable during storage  
Differences between baseline microbiota composition and subsequent time-points were 
quantified using the Aitchison distance which provides a compositionally robust alternative 
to standard β-diversity metrics24. Aitchison distance increases as the bacterial composition 
of two samples are less similar to one another. There was a significant initial increase in 
Aitchison distance following collection of the stool sample (Figure 2.5a). Aitchison 
distance was stable throughout the duration of storage at 4 °C, -20 °C, and -80 °C for 
samples stored in 10% glycerol, whole stool saline, and water (Figure 2.5). The resulting 
Aitchison distance of different diluents was compared at each time point for storage at 4 
°C, -20 °C, and -80°C. Diluents did not differ in Aitchison distance when stored at 4 °C 
(Figure 2.5a). When stored at -20 °C, water had significantly lower Aitchison distances 
compared to whole stool and saline at one week of storage (Figure 2.5b). There were no 
differences in Aitchison distance at other time points. When stored at -80 °C, water had 
significantly lower Aitchison distances compared to whole stool and saline when stored for 
1 month and 3 months. When samples were stored for 2 months at -80 °C, 10% glycerol 
had significantly lower Aitchison distances compared to whole stool and saline (Figure 
2.5c). These findings indicated that there was no superior diluent when samples were stored 
at 4 °C and -20 °C, but when samples were stored at -80 °C, whole stool and saline 






Figure 2.5 The greatest change in the composition of viable bacteria occurs after 
initial sample collection. Stool samples were suspended 1:5 in saline, water, 10% glycerol, 
or remained as whole stool and stored for one week at 4 °C or twelve weeks at -20 °C and 
-80 °C. At each time point (fresh: baseline, immediately following preparation, 4 hours, 1 
day, 3 days, 5 days, 7 days; frozen: baseline, 1 week, 2 weeks, 4 weeks, 8 weeks, 12 weeks) 
a 1 mL aliquot of the sample was thawed and treated with PMA under anaerobic conditions 
and sent for next-generations sequencing. Aitchison distance was calculated on the 
resulting sequencing reads. Data displayed are three biological replicates from one donor 
(n=1). * p<0.05, **p<0.01, ***p< 0.001, ****p<0.0001. * on the graph are the results of 
the one-way ANOVA comparing diluents at each time point. One-way ANOVA was used 
to compare differences in the mean Aitchison distance of the four different diluents at each 
time point; Tukey’s multiple comparison test was used post-hoc to compare the mean of 
each diluent to each other.  































































A) Samples stored at 4 °C. Fresh, 0.001 days (p=0.3649). After blending, 0.01 days 
(p=0.5938). 4 hours, 0.167 days (p=0.1478). 1 day (p=0.2270). 3 days (p=0.4727). 
5 days (p=0.6080). 7 days (p=0.8217) 
B) Samples stored at -20 °C. 1 week (*p=0.0440; post-hoc whole stool vs water: 
**p=0.0018). 2 weeks (p=0.1028). 4 weeks (p=0.1055). 8 weeks (p=0.6716). 12 
weeks (p=0.1515). 
C) Samples stored at -80 °C. 1 week (p=0.2883). 2 weeks (p=0.1688). 4 weeks 
(*p=0.0233; post-hoc whole stool vs water: **p=0.0076; post-hoc saline vs water: 
***p=0.0004). 8 weeks (**p=0.0065; post-hoc 10% glycerol vs whole stool: 
*p=0.0145; post-hoc 10% glycerol vs saline: **p=0.0056). 12 weeks (*p=0.0149; 
post-hoc whole stool vs water: *p=0.0289; post-hoc saline vs water: **p=0.0075). 
One-way ANOVA was used to compare differences in change in Aitchison distance over 
time for each diluent; Dunnett’s multiple comparison test was used post-hoc to compare 
the mean of each time point to baseline for a single diluent. 
A) Samples stored at 4 °C. 10% glycerol (p=0.9346). Whole stool (p=0.9956). Saline 
(p=0.5476). Water (p=0.4788) 
B) Samples stored at -20 °C. 10% glycerol (p=0.0765). Whole stool (p=0.8198). Saline 
(p=0.4057). Water (p=0.6790). 
C) Samples stored at -80 °C. 10% glycerol (p=0.2335). Whole stool (p=0.8955). Saline 
(p=0.6661). Water (p=0.1977). 
The largest change in composition occurred during the initial collection of stool samples 
from the donor (Figure 2.5). The five most abundant genera in the fresh fecal samples were 
Bacteroides, Faecalibacterium, Alistipes, Parabacteroides, and Parasutterella. ALDEx2 
was used to compare the composition of fresh fecal samples with and without PMA that 
had not been processed for FMT; this comparison is an indication of the impact the 
collection process in aerobic conditions had on viable bacterial composition. An effect size 
cut-off of >|3| was used. There were no bacterial taxa that had an effect size of >|3|.The 
Benjamini-Hochberg corrected p-value of the Wilcoxon Rank Sum test was used to 






from previously published studies that did not use effect size to identify differentially 
abundant taxa20-22. It was found that the relative abundances of Alistipes, Bacteroides, and 
Parasutterella increased when the stool samples were exposed to oxygen during collection 
(Figure 2.6). Three Alistipes OTUs increased in relative abundance during sample 
collection (Alistipes OTU 1: effect size= 1.305, p-value= 0.0079; Alistipes OTU 2: effect 
size= 1.141, p-value= 0.0011; Alistipes OTU 3: effect size= 1.161, p-value= 0.00096). Six 
Bacteroides OTUs increased in relative abundance during sample collection. (Bacteroides 
OTU 1: effect size=1.063, p-value=0.018; Bacteroides OTU 2: effect size= 1.493, p-
value=0.0057; Bacteroides OTU 3: effect size=1.092, p-value=0.015; Bacteroides OTU 4: 
effect size=1.195, p-value=0.018; Bacteroides OTU 5: effect size=1.449, p-value=0.0048; 
Bacteroides OTU 6: effect size=1.141, p-value=0.016). One Parasutterella OTU increased 







Figure 2.6 Significant changes in the composition of viable bacteria occur during 
initial collection of stool samples. Fresh stool samples were collected from one healthy 
donor at the research facility and processed with PMA within one hour of collection. The 
samples presented are from baseline, before any diluent or storage had taken place. They 
represent the viable bacteria in stool within the body (Baseline No PMA) and the viable 
bacteria in stool after exposure to oxygen during the collection process (Baseline PMA). 
DNA from each sample was extracted and sent for next-generation sequencing. Each 
































































































































































































































































































was used to calculate effect size to determine significant changes in viable relative 
abundance of bacteria after stool sample collection. Three Alistipes OTUs increased in 
relative abundance during sample collection (Alistipes OTU 1: effect size= 1.305, p-value= 
0.0079; Alistipes OTU 2: effect size= 1.141, p-value= 0.0011; Alistipes OTU 3: effect size= 
1.161, p-value= 0.00096). Six Bacteroides OTUs increased in relative abundance during 
sample collection. (Bacteroides OTU 1: effect size=1.063, p-value=0.018; Bacteroides 
OTU 2: effect size= 1.493, p-value=0.0057; Bacteroides OTU 3: effect size=1.092, p-
value=0.015; Bacteroides OTU 4: effect size=1.195, p-value=0.018; Bacteroides OTU 5: 
effect size=1.449, p-value=0.0048; Bacteroides OTU 6: effect size=1.141, p-value=0.016). 
One Parasutterella OTU increased in relative abundance during sample collection (effect 
size=1.100, p-value=0.028). 
2.3.3 Diversity of viable bacteria remains stable throughout the 
storage process. 
Shannon diversity was calculated and bacterial diversity over time within a diluent and 
between diluents were compared. There was not a significant change in diversity of 
samples stored in 10% glycerol, whole stool, saline, or water over time at 4 °C, -20 °C or 
-80 °C (Figure 2.7a, b, c). When stored at -20 °C at two weeks’ time, water had significantly 
lower viable bacterial diversity than 10% glycerol or whole stool (Figure 2.7b). There were 
no time points that the diversity of viable bacteria differed between the diluents or whole 







Figure 2.7 Duration of storage did not significantly decrease the diversity of viable 
bacteria. Stool samples were suspended 1:5 in saline, water, 10% glycerol, or remained as 
whole stool and stored for one week at 4 °C or twelve weeks at -20 °C and -80 °C. At each 
time point (fresh: baseline, immediately following preparation, 4 hours, 24 hours, 3 days, 
5 days, 7 days; frozen: baseline, 1 week, 2 weeks, 4 weeks, 8 weeks, 12 weeks) a 1 mL 
aliquot of the sample was thawed and treated with PMA under anaerobic conditions and 
sent for next-generations sequencing. Shannon diversity index was calculated on the 
resulting sequencing reads. Data displayed are three biological replicates from one donor 
(n=1). * p<0.05, **p<0.01, ***p< 0.001, ****p<0.0001. * on the graph are the results of 
the one-way ANOVA comparing diluents at each time point. One-way ANOVA was used 
to compare differences in the mean Shannon diversity index of the four different diluents 
at each time point; Tukey’s multiple comparison test was used post-hoc to compare the 
mean of each diluent to each other.  



































































A) Samples stored at 4 °C. Fresh, 0.001 days (**p=0.0088; whole stool vs water: 
***p=0.0008; saline vs water: *p=0.0291). After blending, 0.01 days (**p=0.0098; 
10% glycerol vs whole stool: *p=0.0352; 10% glycerol vs saline: *p=0.0282; whole 
stool vs saline: **p=0.0012; saline vs water: *p=0.0102). 4 hours, 0.167 days 
(p=0.0802). 1 day (p=0.4580). 3 days (p=0.9210). 5 days (p=0.7002). 7 days 
(p=0.1339) 
B) Samples stored at -20 °C. 1 week (p=0.3146). 2 weeks (*p=0.0102; 10% glycerol 
vs water: *p=0.0247; whole stool vs water: *p=0.0182). 4 weeks (p=0.4898). 8 
weeks (p=0.2309). 12 weeks (p=0.4033). 
C) Samples stored at -80 °C. 1 week (p=0.8478). 2 weeks (p=0.8294). 4 weeks 
(p=0.1048). 8 weeks (p=0.1977). 12 weeks (p=0.1196). 
One-way ANOVA was used to compare differences in change in Shannon diversity index 
over time for each diluent; Dunnett’s multiple comparison test was used post-hoc to 
compare the mean of each time point to baseline for a single diluent.  
A) Samples stored at 4 °C. 10% glycerol (p=0.5694). Whole stool (p=0.0531). Saline 
(p=0.0686). Water (p=0.6896) 
B) Samples stored at -20 °C. 10% glycerol (p=0.1023). Whole stool (p=0.5948). Saline 
(p=0.3345). Water (p=0.0.2564). 
C) Samples stored at -80 °C. 10% glycerol (p=0.6993). Whole stool (p=0.4506). Saline 
(p=0.8268). Water (p=0.1097). 
2.4 Discussion 
This study showed that some preparatory and storage methods used by FMT clinics result 
in loss in the number and change in composition of viable bacteria. This may impact the 
success and long-term outcomes of FMT. The is the first description of using PMA in 
conjunction with next-generation sequencing to investigate storage duration and diluents 
(water, saline, 10 % glycerol) on the composition of viable bacteria in feces during long-







There was a significant initial loss of viable bacteria when samples were blended with 
water (Figure 2.2) and this effect was not observed in samples blended in saline or 10% 
glycerol. This was likely due to the hypotonic nature of water that may have caused 
bacterial cell lysis. The diluent used was significant in storage at -20 °C (Figure 2.3) and   
-80 °C (Figure 2.4). These findings suggest that the effect of freeze-thawing different 
diluents could be a contributing factor to bacterial loss during long-term storage. Storage 
in saline and water resulted in greater losses of viable bacteria than storage in whole stool 
or 10% glycerol when stored at -20 °C and -80 °C. Ten percent glycerol is a known 
cryoprotectant and whole stool may behave in the same way due to its limited water 
content. The cell death observed in samples stored in saline and water could be caused by 
greater amounts of ice crystals formed during the freeze-thaw process that sheared the 
bacterial cells. Samples stored at -80 °C (Figure 2.4) experienced less total bacterial loss 
compared to the same samples stored at -20 °C (Figure 2.3). Many FMT clinics do not have 
access to a -80 °C freezer, but it could help to preserve the donor stool for longer. Screening 
donors for FMT can be costly25. Being able to store stool for longer durations will allow 
clinics to bank higher quantities of stool from donors between their rescreening visits, and 
potentially reduce the frequency that donors will have to be rescreened. 
The largest change in Aitchison distance, and therefore the greatest change in the 
composition of viable bacteria, occurred after the initial collection of the stool sample, 
without any further processing (Figure 2.5a). Each preparation method resulted in a similar 
initial increase in Aitchison distance, this was likely a result of oxygen exposure. These 
samples were collected at the lab site and were processed within an hour of collection. In 
normal practice, samples are typically delivered within four hours of collection and 
processed when they arrive at the clinic, so it is possible that this change in composition 
could be greater in these centres. After the initial increase in Aitchison distance, the 
composition of the viable bacteria in stool remained stable at 4 °C for one week and -20 
°C and -80 °C for three months within each diluent (Figure 2.5). For samples stored at -80 
°C, whole stool and saline resulted in significantly higher Aitchison distances at 1 month, 






cause proportional death of microbes, which is why they resulted in a lower Aitchison 
distance as the composition of viable microbes stayed more similar to baseline.  
We found that the relative abundances of Alistipes, Bacteroides and Parasutterella 
increased following stool collection (Figure 2.6). This does not mean that these bacteria 
replicated during storage, but rather the treatment with PMA and the compositional nature 
of this data caused bacteria that died to decrease in relative abundance and made these 
genera appear to increase in relative abundance. Other researchers have found similar 
losses during the initial sample collection period. One study noted that the genera that 
decreased after oxygen exposure were Faecalibacterium, Subdoligranulum, Eubacterium 
hallii, Eubacterium rectale, Roseburia and Anaerostipes21. They found that 
Escherichia/Shigella and Alistipes increased after oxygen exposure21. All the previous 
studies examining the composition of stool for FMT have found a decrease in the relative 
abundance of Faecalibacterium following exposure to oxygen during sample collection20-
22. Another study that utilized PMA to investigate fecal sample collection for FMT also 
noted that there was an increase in the relative abundance of Alistipes, indicating that these 
bacteria are able to survive these conditions21. Potentially, methods to collect stool samples 
anaerobically should be implemented by FMT clinics and stool banks to reduce the change 
in viable composition that occurs during the collection phase. One study suggested 
collecting samples in a Stomacher® 400 bag inside of an anaerobic jar and processing the 
sample under anaerobic conditions to overcome this problem22.  
Previous studies have investigated the effect of different diluents on the survival of bacteria 
for FMT including: normal saline, saline solutions with maltodextrin and trehalose22, 10% 
glycerol solutions21, 50% glycerol solutions and the use of cysteine buffers20, but none have 
directly compared the suspension fluids currently used by FMT clinics. We found that not 
all diluents had the same effect on viable bacterial diversity when stored at 4 °C or -20°C 
(Figure 2.7). Diversity remained stable over time when samples were stored at -80 °C 
diluted in 10% glycerol, saline, water or as whole stool (Figure 2.7c), however water 






are superior for long-term storage of stool samples for FMT. An increased diversity in 
donor stool has been shown to be highly beneficial when treating rCDI26 as well as 
inflammatory bowel diseases27,28. Diluting samples in water before long-term storage 
resulted in the largest decrease in diversity over time and this method of preparation and 
storage is not recommended for FMT stool processing. Suspension in water resulted in an 
immediate reduction in the concentration of viable total anaerobes as well (Figure 2.2a).  
The uniqueness of this study was the use of PMA-seq to determine changes in the 
composition of viable bacteria in stool samples, and the data showing that commonly used 
diluents affect the composition of viable bacteria. A limitation of this study was that only 
one donor was used to measure changes over time. Past studies have shown that different 
donor stools undergo varying changes in viable bacterial composition and 
concentration21,22. There can be significant variations in the composition of the gut 
microbiota between individuals, so even if more than one donor had been sampled, 
comparisons could only be made within not between each individual. It is possible that 
baseline PMA treated samples had an altered composition because not all bacteria in stool 
are viable when passed; some may have died within the body before being exposed to 
oxygen. Not all bacteria are culturable and while a variety of selective media was used to 
recover bacteria, some bacteria may not have been cultured, and the total number of viable 
organisms may have been underestimated.  
Successful FMT for rCDI has been reported using sterile fecal transplants23, spores29, and 
donor bacteriophage30 so the need for viable bacteria may not be paramount. However, 
until the mechanisms of action of FMT are understood for the different potential 
applications, fecal samples should be stored in ways that maintain the viability of as many 
bacteria as possible. Optimization of the preparation and storage conditions of FMT at -80 
°C in 10% glycerol or whole stool has the potential to improve efficacy and is 
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Chapter 3  
3 Characterization of viable bacteria throughout preparation 
and storage of fecal microbiota transplantation capsules 
3.1 Introduction 
Fecal microbiota transplantation has proven to be an effective method for treating recurrent 
rCDI. Fresh stool was first used to treat rCDI with FMT1-5 until frozen stool was found to 
be as effective and a shift began to use frozen material for FMT6-8. These FMT studies used 
a variety of delivery methods including: colonoscopy2,3,5,7, enema4,8, nasogastric1, or 
nasojejunal tube4 and there were no differences in success of curing rCDI. While FMT is 
an effective method for treating rCDI, there is still a stigma surrounding the procedure, as 
some patients believe it is unpleasant or unappealing.  
FMT capsules are emerging as a favoured alternative to the previously mentioned methods 
as they are better tolerated, less invasive and more cost-effective9. Capsules have been 
shown to be just as effective as FMT delivered via other methods. Kao et al.9 showed that 
capsules had a resolution rate of 96% in both their capsule and colonoscopy treated groups. 
This result is comparable to Hirsch et al.10 that found an 89% resolution rate when treating 
patients with FMT capsules and Youngster et al.11,12 that found resolution rates of 90-91% 
after 2 courses of FMT capsules.  
The majority of bacteria in stool are anaerobic and there is an increased processing time to 
manufacture FMT capsules versus an enema or colonoscopy delivered FMT. While the 
resolution rates of capsules are comparable to other FMT methods, this new processing 
technique may impact the number and composition of viable bacteria present in the 
capsules. FMT therapy is being tested for an increasing list of medical conditions, such as: 
metabolic syndrome13,14, inflammatory bowel diseases15-17, and irritable bowel syndrome 
18,19. Changes to the composition of viable bacteria in an FMT may impact the effectiveness 
for treating other diseases. Past studies have documented changes in viable bacteria when 






investigated if the process of manufacturing FMT capsules influences the composition of 
viable bacteria. The aim of this study was to determine if the encapsulation of fecal material 
resulted in changes to the number and composition of viable bacteria delivered. Culture-
based and 16S rRNA gene sequencing analyses were conducted to answer this question. 
Propidium monoazide was used in conjunction with 16S rRNA gene analysis to sequence 
only live bacteria. 
3.2 Methods 
3.2.1 Sample Collection 
Fecal samples were collected from three healthy donors from a local FMT clinic, one male 
and two females with a median age of 22 (range 21-24 years old). Donors were screened 
using a previously published protocol23. The experiments were carried out in accordance 
with the approved guidelines (REB CER 106715). Informed consent was given from the 
donors. The encapsulation process was started within one hour of sample collection.  
3.2.2 FMT Capsule Preparation 
Eighty to one hundred grams of donor stool was mixed with 200 mL of sterile normal saline 
(0.9%) and 40 mL of 100% glycerol inside of a BA614/STR filter bag (Seward, Islandia, 
NY) using the Stomacher® 400 Circulator (Seward, Islandia, NY) at 230 rpm for 30 
seconds. Following this step, the slurry was aliquoted into 15 mL conical tubes and 
centrifuged at 400 g for 20 minutes at 4 °C to remove the remaining fibre. The supernatant 
was collected and centrifuged at 10 000 x g for 30 minutes at 4 °C. The supernatant was 
discarded and 450 μL of the resulting pellet was used to fill each No. 1 gelatin capsules 
(Medisca, Plattsburgh, NY), which were then encapsulated with No. 0 (Medisca, 
Plattsburgh, NY) and No. 00 capsules (Medisca, Plattsburgh, NY). A single donor sample 






Figure 3.1 Methodology for the formation of FMT capsules. 
3.2.3 Bacterial Culture 
Samples were tested at initial sample collection, immediately after the encapsulation 
process, 1 day, 3 days, 5 days, 7 days, 2 weeks, 1 month, and 2 months’ post-encapsulation. 
At each time point three capsules from each donor were thawed and dissolved in 10 mL of 
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pre-reduced sterile PBS inside of an anaerobic chamber. The sample was serially diluted 
in PBS and plated on 5 different agar plates: BHIS agar (BD, Mississauga, ON) (selective 
for total anaerobes), MacConkey agar (BD) (selective for Enterobacteriaceae), CBA (BD) 
(selective for anaerobic staphylococci and streptococci), Columbia CNA Blood agar (BD) 
(selective for aerobic staphylococci, streptococci and enterococci), and Rogosa agar (BD) 
(selective for lactobacilli and bifidobacteria). BHIS, Rogosa, and CBA plates were 
incubated at 37 °C for 48 hours in an anaerobic chamber. Columbia CNA and MacConkey 
agar plates were incubated at 37 °C for 24 hours in aerobic conditions. 
3.2.4 PMA Exposure 
At each time point 2.5 µL of 20 mM propidium monoazide (PMA; Biotium, Scarborough, 
ON) was added to 500 µL of diluted capsule material in 1.5 mL Eppendorf tubes for a final 
concentration of 100 µM PMA. The samples were vortexed and then covered in tin foil 
and placed in the dark for 10 minutes. The samples were then placed lying flat on ice and 
were exposed to light for 15 minutes (650 watts) that was 30 cm above the samples in a 
cold room. The cells were spun at 10 000 x g for 10 minutes, the supernatant discarded and 
resuspended in nuclease free water three times. After the final spinning step, the sample 
was stored in 100 µL of nuclease free water and stored at -80 °C until time for DNA 
extraction. 
3.2.5 DNA Extraction 
DNA from the 100 µL cell pellets was extracted using the DNeasy® Powersoil® HTP 96 
Kit (Qiagen, Toronto, Ontario, Canada), as per the manufacturer’s instructions with the 
following modification: a centrifuge speed of 3 700 g for 10 minutes was used. Extracted 
DNA was stored at -20 °C until amplification.  
3.2.6 DNA Amplification 
The BioMek® 3000 Laboratory Automation Workstation for automated PCR reagent set 






barcodes into 96 well plates. Amplifications of the V4 region of the 16S rRNA gene were 
carried out with the primers (5′-3′) ACACTCTTTCCCTACACGACGCTCTTCCGATCT 
NNNNxxxxxxxxGTGCCAGCMGCCGCGGTAA and (5′-3′) CGGTCTCGGCATTCCT 
GCTGAACCGCTCTTCCGATCTNNNNxxxxxxxxGGACTACHVGGGTWTCTAAT 
(xxxxxxxx is a sample specific nucleotide barcode and the preceding sequence is a portion 
of the Illumina adapter sequence for library construction). The BioMek® robot was then 
used to transfer 2 µL of template DNA into the primer containing 96 well plates. Then 
20 μl of Promega GoTaq® Colourless Master Mix (Promega, Maddison, WI) was added to 
the DNA template and primers. The final plate was sealed with a foil PCR plate cover. This 
plate was placed in the Eppendorf Mastercycler® thermal cycler (Eppendorf, Mississauga, 
Ontario, Canada), where the lid was kept at 105 °C. An initial warm-up temperature of 
95 °C was used for 2 min to activate the GoTaq®. Afterwards, the volumes underwent 
25 cycles of 95 °C for 1 min, 50 °C for 1 min, and 72 °C for 1 min. After completion, the 
temperature of the thermal cycler was held at 4 °C, and amplicons were stored at −20 °C. 
3.2.7 DNA sequencing and data analysis 
Amplified DNA was sent to the London Regional Genomics Centre at Robarts Research 
Institute (Western University, London, Ontario, Canada). The samples were quantified 
(Quant-it, Life Technologies, Burlington, Ontario, Canada) and pooled at equimolar 
concentrations. The pooled libraries were cleaned using QIAquick (Qiagen, Germantown, 
Maryland, USA) and then sequenced using the MiSeq Illumina® platform, with 2 × 250 
bp paired-end chemistry. The reads were demultiplexed and filtered using dada2 (version 
1.8) and custom R scripts written by Greg Gloor (github.com/ggloor/miseq_bin). The 
demultiplexed reads will be available at NCBI SRA following submission of this paper for 
publication. Reads with 97% sequence similarity were grouped into OTUs. Taxonomy was 
assigned using an RDP classifier provided by the dada2 package and trained against version 
132 of the SILVA database. Diversity of the stool microbiota was quantified based on 






(github.com/vegandevs/vegan) in R (version 3.6.0). Bar plots and dendrogram were 
constructed in base R. OTUs with the same genus were grouped together in the bar plot. 
The 30 most prevalent genera are displayed in the bar plot. DNA extracted from capsules 
stored for 2 months from Donor 1 and stored for 2 weeks from Donor 2 were not adequate 
for sequencing and were not included in this analysis.  
3.2.8 Statistical Analysis: 
Bacterial viability data and Shannon diversity index passed the Shapiro-Wilk test for 
normality. Levene’s test of homogeneity was significant and as a result One-way ANOVA 
was used to compare bacterial viability of fresh samples to subsequent time points as well 
as Shannon Diversity Index. Dunnett’s multiple comparisons test, with a single pooled 
variance, was used post-hoc. One-way ANOVA was used to compare differences in the 
concentration of viable bacteria as well as Shannon Diversity Index between donors at each 
time point. Tukey’s multiple comparison test, with a single pooled variance, was used post-
hoc. The ALDEx2 package in R24 was used to identify differentially abundant taxa with an 
effect size cutoff of > |3| to determine what bacterial taxa were differentially abundant from 
fresh stool that had not been treated with PMA at each time point. Effect size was used to 
identify differentially abundant OTUs, instead of a p-value, because effect size measures 
the magnitude of change and it is not affected by sample size25.     
3.3 Results 
3.3.1 Significant reductions in bacterial viability occurred during 
encapsulation 
FMT capsules were manufactured and changes in bacterial viability during preparation and 
storage at -80 °C were measured using culture-based techniques (Figure 3.2). The largest 
decrease in the viability of bacteria occurred during the encapsulation process (Figure 3.2). 
All three donors did not differ in the concentration of total anaerobes present in fresh stool, 
before encapsulation (Figure 3.2a). There were significant decreases in the concentration 






in all three donors following encapsulation (Figure 3.2a, b, c, f). Stool from Donor 3 was 
the only sample to experience a significant decrease in bifidobacteria immediately 
following encapsulation (Figure 3.2d). Stool from Donor 2 was the only sample to 
experience a significant decrease in Gram-negative aerobes immediately following 
encapsulation (Figure 3.2e). The concentration of viable bacteria from all bacterial groups 
remained stable following encapsulation during storage at -80 °C (Figure 3.2). Statistics 
for only the comparison of the concentration of viable bacteria in fresh stool versus freshly 
made capsules were included in Figure 3.2. If there was a decrease in concentration after 
the capsules were made, this change persisted for subsequent time points. The full summary 
of statistics can be found in Supplementary Tables 3.1-3.2 (Figure 3.2a), Supplementary 
Tables 3.3-3.4 (Figure 3.2b), Supplementary Tables 3.5-3.6 (Figure 3.2c), Supplementary 
Tables 3.7-3.8 (Figure 3.2d), Supplementary Tables 3.9-3.10 (Figure 3.2e), Supplementary 
Tables 3.11-3.12 (Figure 3.2f). 
 
Figure 3.2 Bacterial viability was stable throughout storage in FMT capsules. Eighty 
to one hundred grams of stool was mixed with 200 mL of saline and 40 mL of 100% 






pellet was used to fill each FMT capsule. Capsules were stored at -80 °C. At each time 
point (immediately after collection, immediately after encapsulation, 1 day, 3 days, 5 days, 
1 week, 2 weeks, 4 weeks, and 8 weeks) three 1 g aliquots or 3 capsules from each donor 
were thawed and plated on selective media in aerobic and anaerobic conditions and 
incubated at 37 °C for 24-48 hours. Data displayed is three biological replicates (n=3) and 
each biological replicate had six technical replicates. One-way ANOVA was used to 
compare differences in the concentration of different bacterial groups at baseline (fresh 
stool) to subsequent time points. This analysis was completed for each individual donor. A 
detailed summary of statistics including the results of the post-hoc tests can be found in 
Supplementary Tables 1-12. Results of the post-hoc test to determine if there was a 
significant change in the concentration of viable bacteria of fresh stool compared to freshly 
made capsules are listed below.   
A) Total anaerobes. Donor 1: ****p<0.0001; Donor 2 ****p<0.0001; Donor 3 
****p<0.0001.  
B) Gram-positive anaerobes. Donor 1: ****p<0.0001; Donor 2: ****p<0.0001; 
Donor: 3 ****p<0.0001. 
C) Lactobacilli. Donor 1: ****p<0.0001; Donor 2: ***p=0.0002; Donor 3: 
****p<0.0001. 
D) Bifidobacteria. Donor 1: p=0.8050; Donor 2: p=0.6683; Donor 3: ****p<0.0001. 
E) Gram-negative aerobes. Donor 1: p=0.6474; Donor 2: *p=0.0362; Donor 3: 
p=0.3978. 
F) Gram-positive aerobes. Donor 1: ****p<0.0001; Donor 2: ***p=0.0005; Donor 3: 
*p=0.0121. 
3.3.2 Fecal microbiota profiles of donors are distinct throughout 
storage. 
Since there were changes in the concentration of viable bacteria in the FMT capsules, we 
wanted to determine if the donor microbiota composition was still distinct from other 






group fecal samples based on compositional similarity. Individual donors clustered 
separately regardless of the duration of storage or if the encapsulation process had taken 












Figure 3.3 The composition of viable bacteria was stable throughout storage and each 
donor microbiota profile remained distinct from one another. Eighty to one hundred 
grams of stool was mixed with 200 mL of saline and 40 mL of 100% glycerol and spun at 
10 000g for 30 minutes. The cell pellet was collected and 450 µL of pellet was used to fill 
each FMT capsule. Capsules were stored at -80 °C. At each time point (immediately after 
collection, immediately after encapsulation, 1 day, 3 days, 5 days, 1 week, 2 weeks, 1 
month, and 2 months) three 1 g aliquots or 3 capsules from each donor were thawed and 
treated with PMA under anaerobic conditions and sent for next-generations sequencing. 
The resulting reads were used to generate a bar plot and dendrogram in R (version 3.6.0). 
The bar plot was ordered by the dendrogram grouping. Donor 1 is missing data points for 
2 months storage and Donor 3 is missing data points for 2 weeks storage because the 
samples were not adequate for sequencing. The three donors had distinct viable microbiota 
compositions throughout storage.  
This was confirmed with a principal component analysis (PCA) that showed that the three 
individual donors have unique microbiota compositions and the microbiota profiles of a 
donor remained distinct from other donors irrespective of the duration of storage (Figure 
3.4). The distance between two points on a PCA is representative of their similarity in 







Figure 3.4 Each donor microbiota profile remained distinct from one another 
throughout storage. Eighty to one hundred grams of stool was mixed with 200 mL of 
saline and 40 mL of 100% glycerol and spun at 10 000g for 30 minutes. The cell pellet was 
collected and 450 µL of pellet was used to fill each FMT capsule. Capsules were stored at 
-80 °C. At each time point (immediately after collection, immediately after encapsulation, 
1 day, 3 days, 5 days, 1 week, 2 weeks, 1 month, and 2 months) three 1 g aliquots or 3 
capsules from each donor were thawed and treated with PMA under anaerobic conditions 
and sent for next-generations sequencing. The resulting reads were used to generate a 
PCoA in R (version 3.6.0) with custom R scripts written by Greg Gloor 
(github.com/ggloor/miseq_bin) and the package zCompositions. Sixty-nine percent of the 
variance is explained in the first two components. Each point represents the composition 
of one FMT capsule (each time point has three technical replicates that are displayed). The 
donors cluster separately from one another regardless of the duration of storage. Donor 1 
is missing data points for 2 months storage and Donor 3 is missing data points for 2 weeks 






3.3.3 Fecal diversity was stable throughout storage 
Since there were significant reductions of the viable bacteria in the FMT capsules, diversity 
was measured to determine if the loss of viability related to a change in diversity. Diversity 
was measured using Shannon Diversity Index and differences in diversity between fresh 
stool and stored capsules were calculated. Initial diversity varied between donors (Figure 
3.5). Donor 1 had an initial fecal diversity of 3.61 ± 0.11, Donor 2: 3.55 ± 0.09 and Donor 
3: 3.12 ± 0.20. Changes in diversity over time were different for each donor. Stool from 
Donor 3 did not exhibit any significant change in diversity of viable bacteria during 
encapsulation or storage (Figure 3.5). Stool from Donor 1 had a significant decrease in 
diversity immediately after encapsulation, but this effect was not observed during storage 
at -80 °C (Figure 3.5). Stool from Donor 2 experienced significant increases in diversity 
immediately after encapsulation, 1 day, 1 week, 2 weeks, 1 month and 2 months of storage 
(Figure 3.5).  
 
Figure 3.5 Diversity of donor stool was maintained through storage in FMT capsules. 
Eighty to one hundred grams of stool was mixed with 200 mL of saline and 40 mL of 100% 
glycerol and spun at 10 000 x g for 30 minutes. The cell pellet was collected and 450 µL 






















of pellet was used to fill each FMT capsule. Capsules were stored at -80 °C. At each time 
point (immediately after collection, immediately after encapsulation, 1 day, 3 days, 5 days, 
1 week, 2 weeks, 1 month, and 2 months) three 1 g aliquots or 3 capsules from each donor 
were thawed and treated with PMA under anaerobic conditions and sent for next-
generations sequencing. Shannon diversity index was calculated on the resulting 
sequencing reads. Each data point is the average of three technical replicates. Donor 1 is 
missing data points for 2 months storage and Donor 3 is missing data points for 2 weeks 
storage because the samples were not adequate for sequencing. One-way ANOVA was 
used to compare changes in Shannon Diversity Index of fresh stool samples to subsequent 
time points. A summary of statistics including the result of post-hoc tests are included in 
Supplementary Tables 3.13-3.14. This analysis was completed for each individual donor. 
Only significant decreases in diversity are shown on the graph. Donor 1: *p=0.0103. No 
other comparisons of fresh stool to subsequent time points resulted in significant decreases 
in diversity for any of the three donors. 
3.3.4 Viable fecal microbiota composition varied by donor 
throughout encapsulation and storage.  
The largest decrease in viable bacteria occurred during the encapsulation process and 
remained stable throughout storage. There was not a reduction in diversity of viable 
bacteria inside of the capsules following encapsulation, but it was not yet known what 
specific genera may have changes in relative abundance. The ALDEx2 tool was used to 
determine the differentially abundant bacteria that increased or decreased in relative 
abundance throughout encapsulation and storage for each donor. Each donor had a different 
change in viable bacterial composition throughout processing and storage (Table 3.1).  
During initial sample collection, the fecal sample from Donor 1 had a decrease in the 
relative abundance of viable Anaerostipes and increases in the relative abundances of 
viable Bacteroides, Parasutterella, and Roseburia (Table 3.1; Figure 3.6). Donors 2 and 3 
had no significant changes in the relative abundances of viable bacteria during sample 






immediately after the stool was formed into capsules. Donor 1 showed decreases in the 
relative abundances of viable Anaerostipes and Faecalibacterium and increases in the 
relative abundances of viable Alistipes, Bacteroides, Escherichia/Shigella and 
Parasutterella (Table 3.1; Figure 3.6). Encapsulated stool from Donor 2 showed decreases 
in the relative abundances of viable Anaerostipes, Bacteroides, Faecalibacterium and 
Ruminococcus_1 and increases in the relative abundances of viable Alistipes and 
Pseudobutyrivibrio (Table 3.1; Figure 3.6). Donor 3 exhibited no changes in the 
composition of viable bacteria following the encapsulation process (Table 3.1; Figure 3.6). 
Following this, the capsules were frozen at -80 °C and three capsules from each donor were 
thawed after 24 hours to examine the changes in viable bacteria that may occur during the 
freeze-thaw of the capsules when used in clinics. Capsules from Donor 1 had decreases in 
the relative abundances of viable Alistipes, Blautia, and Escherichia/Shigella and increases 
in the relative abundances of viable Anaerostipes and Dorea (Table 3.1; Figure 3.6). 
Capsules from Donor 2 had a decrease in the relative abundances of viable 
Bifidobacterium, Pseudobutryrivibrio and increases in the relative abudnances of viable 
Anaerostipes, Bacteroides, Faecalibacterium, Lachnospira, Ruminococcus_1, and 
Lachnoclostridium (Table 3.1; Figure 3.6). Capsules from Donor 3 showed no significant 








Table 3.1 Summary of differentially abundant genera of encapsulated stool compared 
to unprocessed stool.  
 Donor 1 Donor 2 Donor 3 
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Differentially abundant genera were determined using ALDEx2 (Fernandes et al. 2013) and fresh samples 
without PMA treatment were compared to subsequent time points. An effect size > |3| was considered a 
significant change in relative abundance. There were multiple OTUs that had the same genus but were 
similar enough in sequence to be sorted into the same OTUs.  













































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Figure 3.6 Changes in the composition of viable bacteria during the sample collection 
and encapsulation process. Eighty to one hundred grams of stool was mixed with 200 mL 
of saline and 40 mL of 100% glycerol and spun at 10 000 x g for 30 minutes. The cell pellet 
was collected and 450 µL of pellet was used to fill each FMT capsule. Samples displayed 
in this figures are three aliquots of the fresh stool collected from donors without PMA 
treatment (Fresh [No PMA]), three aliquots of fresh stool collected from donors with PMA 
treatment (Fresh), three freshly prepared capsules from each donor (Fresh Capsule), and 
three capsules that had been frozen for 24 hours (Frozen Capsule). The DNA was extracted 
from these samples and sequenced using the Illumina Mi-Seq. The resulting reads were 
used to generate bar plots in R (version 3.6.0).  
The capsules were stored for 2 months to simulate the duration of storage they would likely 
experience in an FMT clinic. Donor 3 did not have any significant changes to the 
composition of viable bacteria throughout the storage process. Capsules made from stool 
from Donors 1 and 2 did undergo changes in the composition of viable bacteria during 
long-term storage. Capsules from both donors had decreases in the relative abundances of 
viable Anaerostipes, Bacteroides, Faecalibacterium, and Lachnoclostridium following one 
and two months of storage (Table 3.1).  
3.4 Discussion 
FMT capsules are quickly replacing conventional FMT delivery methods, such as enema, 
colonoscopy, or nasojejunal tube. It is not known how this different manufacturing 
technique impacts the concentration and composition of viable microbes delivered during 
FMT. This was the first study to investigate the composition of viable bacteria in FMT 
capsules with bacterial culture and PMA next-generation sequencing. We have shown that 
FMT capsule preparation caused a reduction in viable bacteria during the encapsulation 
phase and that FMT capsules were stable during long-term storage.  
The largest decrease in viable bacteria occurred during the manufacturing of the FMT 






Faecalibacterium and capsules from Donor 2 lost viable Anaerostipes, Bacteroides, 
Faecalibacterium, and Ruminococcus_1 (Table 3.1; Figure 3.6). FMT capsules take longer 
to prepare compared to enemas. In our clinic, it takes approximately an hour and fifteen 
minutes to thaw and prepare a fecal sample for an enema delivered FMT, whereas the 
process of manufacturing FMT capsules takes approximately four hours and involves much 
more processing and handling. The increase in processing time and duration of oxygen 
exposure may be responsible for the decline in viability that we observed during the 
encapsulation process, as two studies have shown that oxygen exposure has the greatest 
effect on the composition of viable bacteria in donor stool 20,22. Another potential cause for 
the reduction in viable bacteria could be that the dietary fibre is removed during the 
encapsulation process and any bacteria bound to this would have also been removed. It is 
necessary to remove fibre during the encapsulation process to prevent obstructions in the 
pipettes used to fill the capsules and to ensure that each capsule contains the same 
concentration of bacteria.  
Each capsule on average contained approximately 1.0 x 1011 viable bacteria after two 
months of storage at -80 °C (Figure 3.2). At our clinic, a single dose consists of 40 capsules, 
therefore patients receive approximately 4.0 x 1012 bacteria in one dose. This is comparable 
to other studies that have published the number of viable bacteria in a single FMT delivered 
by capsule at their clinics. Hirsch et al.10 estimated that one FMT dose was 9.7 x 1010 viable 
bacteria in 10 capsules. Staley et al.26 estimated 2.1-2.5 x 1011 bacteria were delivered in 
2-3 capsules. Kao et al.9 estimated that approximately 1013 bacteria were delivered in one 
dose of 40 capsules. While there is a range of viable bacteria delivered in different studies, 
the clinical resolution rates of rCDI remain similar. Hirsch et al.10 achieved a resolution 
rate of 89% (17/19), Staley et al.26 achieved a resolution rate of 93.3% (28/30), and Kao et 
al.9 achieved a resolution rate of 96.2 % (51/53. Kao et al.9 also treated a group of rCDI 
patients with colonoscopy delivered FMT and found that 96.2 % (50/52) of patients 
achieved clinical resolution, proving that capsules were just as effective at treating rCDI as 






There were some significant changes in the composition of viable bacteria during storage 
and we found that each donor experienced different changes over time (Table 3.1). Donors 
1 and 2 had a decrease in the relative abundance of Faecalibacterium and two studies have 
also found that Faecalibacterium is lost during oxygen exposure20,22 because it is a strict 
anaerobe. Faecalibacterium prausnitzii, a known butyrate producer, has been shown to 
promote the release of anti-inflammatory cytokines27, and could potentially be protective 
against obesity and insulin resistance28. The loss of this genus may cause capsule based 
FMTs to be less effective for treating obesity-related disorders. However, there have been 
no clinical trials to support or oppose this. Anaerostipes decreased in relative abundance in 
both Donors 1 and 2. Species of Anaerostipes are also known butyrate producers29,30 and a 
decrease in Anaerostipes has been found to be associated with irritable bowel syndrome 
and colorectal cancer31,32. 
The differences that occurred over time within each donor were significantly smaller than 
the differences in composition between donors. When samples were clustered in a 
dendrogram and a PCA based on their similarity in composition, we saw that each 
individual donor clustered separately, regardless of the duration of storage (Figures 3.3, 
3.4). Maintaining the composition of viable microbes is important as an altered microbial 
composition could pass along the phenotype of undesired conditions or lack the bacteria 
necessary for a successful FMT. Only one of the three donors experienced a decrease in 
fecal bacterial diversity during encapsulation and storage. (Figure 3.5). This finding is 
particularly important because increased fecal microbiota diversity has been shown to be 
associated with resolution of and protection against rCDI9,33,34, and FMT material with 
lower bacterial diversity may have decreased efficacy. Stool from Donor 2 had an increase 
in diversity during storage (Figure 3.5), which likely occurred as an artefact of PMA 
treatment. Donor 2 had a decrease in the relative abundance viable Bacteroides over time, 
and this created more bacterial evenness as other bacterial genera appeared to increase in 






FMT via capsule delivery has a number of advantages. Delivering FMT by capsule is 
cheaper than colonoscopy with the average capsule treatment costing $395 CAD versus 
$1120 for colonoscopy9. Capsules are a less invasive delivery method than enema or 
colonoscopy. Kao et al.9 found that 66% of participants that received an FMT in the form 
of capsules rated the experience as not at all unpleasant versus 44% of participants who 
received an FMT in the form of colonoscopy.  
The use of FMT capsules is relatively recent and we believe that there are a variety of 
options to improve the manufacturing of FMT capsules; however, they may be met with 
additional difficulties. Preparation of capsules in anaerobic conditions may prevent some 
of the reduction in viable bacteria that occurs during the encapsulation process. This might 
be difficult to achieve as anaerobic chambers are often limited in their size and this process 
requires a centrifuge. There is also a decrease in dexterity when working in an anaerobic 
chamber and this would likely increase the processing time of capsules. Alternatively, 
whole stool could be lyophilized and ground into a powder to fill FMT capsules26,35. Fibre 
would not have to be removed from the stool for lyophilization for which bacteria are 
known to strongly be associated with and adhere to this material. Additionally, the freeze-
dried material would likely have a longer shelf life than the liquid filled FMT capsules and 
could potentially be stored without refrigeration, making it more accessible globally. The 
cost of purchasing and maintaining an anaerobic chamber or lyophilizer may be a limitation 
for a number of clinics that manufacture their own FMT material. 
This study was the first to examine changes in the composition of viable bacteria in FMT 
capsules during encapsulation and storage. Strengths of this study include that we studied 
multiple donors as past studies have shown that survival of microbes in stool differs by 
donor21,22. Three capsules at each time point were examined to account for any variation in 
composition or concentration of viable bacteria between capsules. One of the limitations 
of this study was that not all bacteria are culturable. While a variety of selective media, and 
anaerobic and aerobic conditions were used to enumerate viable bacteria, the total number 






overcome this by using 16S rRNA gene analysis combined with PMA to sequester DNA 
from dead bacteria and free DNA. While the focus of this study was on the viable bacteria 
present in the capsules, past studies have shown that engraftment of the donor microbiota 
is not necessary for successful FMT36, and that sterile FMTs37, bacteriophage38, and 
spores39 have been shown to be associated with resolution of rCDI. There may be other 
components of FMT capsules beyond the viable bacteria that are delivered that are 
responsible for the resolution of rCDI.    
The encapsulation of stool into FMT capsules and subsequent storage resulted in a 
significant loss of viable bacteria and while there were changes in the composition of viable 
bacteria in two of the three donors, the bacterial composition still closely resembled the 
initial composition of stool from each donor. Alternative methods for collecting and 
processing samples under anaerobic conditions should be investigated to prevent the initial 
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Chapter 4  
4 Extended screening costs associated with selecting donors 
for fecal microbiota transplantation for treatment of 
metabolic syndrome-associated diseases 
4.1 Introduction 
Fecal microbiota transplantation has been most commonly used to treat recurrent rCDI1. 
The impact of the gut microbiome on many other conditions and therefore the list of other 
potential indications for FMT, has been rapidly increasing2. Many aspects of human health, 
such as metabolism, autoimmune disease3 and even mental health4, are hypothesized to be 
impacted by the microbiome and FMTs are undergoing trials to assess their efficacy in 
many of these conditions2.  
The concerns regarding potential transmission of pathogenic organisms and thus the need 
for extensive pre-transplant donor-screening have been well known. To our knowledge 
there have been no reports of an infectious disease being transmitted through a screened 
FMT donor although there has been a report of possible cytomegalovirus transmission in 
an FMT from a non-screened donor5. However, the actual number of potential 
transmissible agents screened for has been a subject of practice variation and recently some 
authorities have released guidance documents to recommend minimum screening criteria6. 
A small number of clinical exclusion criteria for donation, such as recent antibiotic use, 
have been used for many years to improve the chances of success in prevention of recurrent 
C. difficile7. However, data on the myriad of potential diseases associated with the gut 
microbiome has steadily increased the number of conditions for which stool donation may 
carry a risk of transmission. The need to exclude donors with evidence of these conditions 
or even evidence of being at increased risk of having a microbiome associated with these 
conditions (such as having a family history of the disease, as the microbiome can be similar 
amongst family members that live together8) has left uncertainty regarding the cost and 






establishing a new donor-screening program for FMTs for metabolic syndrome-related 
diseases and compared it to other groups screening processes and outcomes. 
4.2 Methods 
4.2.1 Donor Recruitment 
Potential donors (PDs) were recruited through a hospital workplace, a university monthly 
newsletter, as well as by word of mouth amongst staff at St. Joseph’s Health Care (a 
teaching hospital with over 4,000 employees, 2,000 residents and fellows, 1,100 
physicians, and 1,000 health care student placements), Western University (with over 
28,000 students, 2,400 employees, and 1,400 faculty members) and Lawson Health 
Research Institute (a hospital based research facility with over 1500 principal investigators, 
researchers, technicians, support staff and trainees distributed amongst ten sites) in 
London, Ontario, Canada. Recruitment took place from March 2015 to July 2016. The 
recruitment materials used listed a small number of the donor screening exclusion criteria 
including: BMI >25, abnormal metabolic profile, recent antibiotic use, family history of 
diabetes or coronary disease, and any known transmissible agent. PDs that expressed 
interest in being screened contacted the research coordinator to obtain more information 
on the screening process, to schedule screening, and provide written informed consent. A 
list of the full screening procedure and exclusion criteria was provided to PDs before 
screening was scheduled and those who believed that they would qualify proceeded to have 
a full history and examination by a physician. 
4.2.2 Donor Screening 
PDs written consent was obtained and medical histories and examinations of PDs were 
conducted by a physician. A summary of questions asked during the history and exam is 
detailed in Table 4.1. If the PD passed the initial screening criteria they were subjected to 
stool, urine and blood testing for transmissible diseases and other health markers. Donor 
screening practices of our program are outlined in Table 4.1. Lab screening was performed 






treatment of Clostridium difficile infection not responsive to standard therapies”6.  
In addition to testing for transmissible agents, laboratory screening included; screening for 
metabolic abnormalities (including HbA1C and fasting lipids), celiac disease (using anti-
tissue transglutaminase antibodies), liver function tests and urinalysis. PDs were required 
to have: a healthy weight (BMI 18-25), no underlying conditions, a normal metabolic 
profile (no hypertension, normal fasting lipid profile), no history of injection drug use, no 
new sexual partners (within the last 3 months), no ongoing or recent use of any prescription 
or over the counter mediations (including antidiarrheal drugs, mineral oil, bismuth, 
magnesium or kaolin), a maximum alcohol intake of <10 g/day in women and <20 g/day 
in men, no recent antibiotic use (within 3 months) and no recent hospitalizations (within 3 
months). No personal or family history of: diabetes, coronary disease or metabolic disease 
(hypertension, hyperlipidemia, diabetes, insulin insensitivity, atherosclerosis), 
gastrointestinal, liver or biliary disease (including: gastroesophageal reflux, peptic ulcer 
disease, celiac disease, inflammatory bowel disease, Crohn’s disease, ulcerative colitis, 
microscopic colitis, or motility disorders). Those with previous surgery to the intestine, 
liver or gallbladder (except remote appendectomy) were also excluded. Any history of 
malignancy removed the PD for donation consideration.   
PDs were screened for the following transmissible agents in blood: HIV type 1 and 2, 
Human T-cell lymphotropic virus 1 and 2, Hepatitis A, Hepatitis B, Hepatitis C, 
Helicobacter pylori, syphilis, Stronglyoides, schistosomiasis, amebiasis, cytomegalovirus 
(IgM), adenovirus, and Epstein Barr virus (IgM). Stool was analyzed for the detection of 
Shigella, Salmonella, Yersinia, Campylobacter, Escherichia coli 0157-H7, Plesiomonas, 
Aeomonas, Listeria, shiga toxins, ova, parasites, microsporidia, C. difficile, rotavirus, and 
norovirus. Pharyngeal and rectal swabs were assessed for gonococcal and chlamydia 
culture, as well as urine was assessed for the presence of gonorrhea and chlamydia by 
nucleic acid amplification tests. Nasal and rectal swabs were obtained to detect the 
presence of methicillin-resistant Staphylococcus aureus and the rectal swab was also 






lactamase producing Enterobacteriaceae, and carbapenem-resistant Enterobacteriaceae. 
If PDs had a history of travel to endemic areas, additional testing was performed for: 
Chagas disease, malaria, and babesiosis. If PDs traveled to Zika-endemic regions in the 
last 3 months, they were excluded. There were no PDs that had traveled to endemic areas 
and the additional testing was not performed. All laboratory test results were returned 
within 3 weeks’ time and potential donors were asked to not engage in high risk behaviour 
after their screening took place. 
Our donor screening methods were compared to 4 other programs, which have published 
their full screening methods and acceptance rates to illustrate the inconsistencies in 
screening PDs (Table 4.1).  
The acceptance rates of these programs were contrasted with our own to determine what 
effect expanded screening-programs had on overall donor enrollment (Table 4.2). The cost 
of the screening program was estimated by itemizing costs with all values given in US 
dollars (Table 4.3).  
4.3 Results 
PDs were screened as per the methods mentioned previously and these methods were 






Table 4.1 Comparison of donor exclusion criteria between different FMT research 
groups. 
Exclusion Criteria and Tests 
Performed 
Craven 










Between 18 and 65 years of age X X X X X 
Any medications X  X X X 
Antibiotics, antifungals, or antivirals in 
the last 3 months 
X X X X X 
Probiotics in the last 3 months X  X X  
Hospitalization in the last 3 months X    X 
Travel to high-risk areas of infectious 
diarrhea in the last 3 months 
X X X X X 
Acute diarrhea within the past 6 months     X 
Tattoo or body piercing in the last 6 
months 
X X X X X 
Known HIV or viral hepatitis exposure 
in the last 12 months 
X X X X X 
High risk sexual behaviour X X X X X 
Illicit drug use X X X X X 
Incarceration or a history of 
incarceration 
 X X X X 
Household members with active GI 
infection 
  X X  
Chronic constipation     X 
Any gastrointestinal disorder X X X X X 
Overweight (BMI>25) X X    
Obese (BMI >30)   X X X 
Hypertension X X X  X 
Type 2 diabetes X X  X X 
Insulin sensitivity X X X  X 
Hyperlipidemia X X X X X 
Atherosclerosis X X X   
Malnutrition (BMI<18) X  X X  
Autoimmune disease X X X X X 
Atopic disease  X X X  
Psychiatric history  X X  X X 
Infection with HIV, Syphilis, Hepatitis B 
or C 
X X X X X 
Malignancy X X X X X 
Chronic pain syndromes, neurologic or 
neurodevelopmental disorders 
 X X X X 
History of major gastrointestinal surgery X X X   
Any kind of liver disease X     
Alcoholic intake >10g/day women and 
>20g/day men 
X     
Family history of colorectal carcinoma X X X X  
Family history of diabetes X     
Family history of early onset coronary 
disease, gastrointestinal or liver disease 
X X    
Stool Tests 
Ova, cysts and parasites X X X X X 
Microscopy and culture X X X X X 
Rotavirus  X X  X  






Adenovirus X X  X  
Clostridium difficile toxin X X X X X 
Vancomycin resistant enterococcus 
screen 
X X  X X 
Carbapenem-resistant 
Enterobacteriaceae 
X X    
Extended spectrum beta-lactamase 
producing Enterobacteriaceae 
X X    
Fecal Giardia antigen X X X  X 
Fecal Cryptosporidium antigen X X X  X 
Isospora  X    
Cyclospora  X    
Microsporidia X X   X 
Blood Tests 
Complete blood count X X X X  
Electrolytes, urea and creatinine X  X X  
Liver function tests X X X X  
Erythrocyte sedimentation rate   X X  
C-reactive protein  X X X  
Fasting lipids and blood sugar level X   X  
Anti-tTG antibody for celiac disease X     
Antinuclear antibody    X  
HIV type 1 and 2 X X X X X 
Hepatitis A virus IgM  X X X X X 
Hepatitis B virus surface antigen, 
Hepatitis B virus core antibody (IgM and 
IgG), Hepatitis B virus surface antibody 
X X X X X 
Hepatitis C virus antibody X X X X X 
Human T-cell lymphotropic virus 1 and 
2 
X X X X  
Epstein Barr Virus IgM  X   X  
Cytomegalovirus IgM  X   X  
Strongyloides stercoralis, Entamoeba 
histolytica, Helicobacter pylori serology 
X X  X  
H. pylori X X  X  
Treponema pallidum screening cascade X X  X  




X X    
Urine Tests 
Gonorrhea and chlamydia X     







Forty-six potential donors were screened in total (Figure 4.1) including 25 females and 21 
males aged 20-73 yrs (median: 35 yrs). Of the 46 PDs that were screened, 23 passed the 
history and examination by a physician. The most common reasons for exclusion included 
having a BMI>25 and not providing a medical history. Of those 23 participants, 5 passed 
all blood, urine, stool and pharyngeal/rectal swab screening. The most common reasons for 
excluding PDs after blood and stool testing were positive tests for Blastocystis hominis, 
Dientamoeba fragilis and Helicobacter pylori. Of those five, two were subsequently 
excluded after they had acute gastroenteritis and another two were excluded because they 
travelled to tropical countries after screening. One of these potential donors also moved 
out of the region after screening. Therefore, after full screening of 46 potential volunteers, 
only 1 donor was able to donate on a regular basis for the program. The rate of acceptance 
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The cost of a full work-up (including history, examination, blood, stool, and urine 
screening, and administration) at our centre was approximately $440 USD per person and 
those that were excluded after the history and examination cost $150 USD per person 
(Table 4.3). The cost of the history, examination and administration was based on the fee 
of a one-hour doctor’s appointment and three hours of the research coordinator’s time. The 
costs of laboratory tests performed in hospital were provided by a lab manager at St. 
Joseph’s Health Care, London, Ontario, Canada (where the tests were performed) in 
October 2016. The exchange rate on June 20th, 2017 of Canadian to US dollars (0.75) was 
used to convert the cost of donor screening to USD. Out of the 46 donors that were screened 
23 had the full work-up and 23 were excluded before full screening took place. The total 
for patients who had full screening was approximately $10,120 USD and the total for 
patients with only a doctor’s visit was $3,450 USD. Eighteen PDs had abnormal laboratory 
results and they had a follow-up appointment with a physician adding an additional $1,620 
USD in costs. To find a single donor approximately $15,190 USD was spent. If the same 
testing were to be completed in the United States it would cost approximately $3,770 USD 







Table 4.3 Cost of screening a single donor for fecal transplant. 
 Cost per person in 
Canada (USD) 
Cost per person in US 
(USD) 
Stool Tests 
Ova, cysts and parasites $21.00 $138.84 
Microscopy and culture $13.50 NA† 
Rotavirus NA‡ $97.94 
Norovirus  NA‡ $108.70 
Adenovirus NA‡ $78.02 
Clostridium difficile toxin GDH and toxin $30 $100.09 
Vancomycin resistant enterococcus  $2.63 NA† 
Fecal Giardia antigen $10.88 $88.15 
Fecal Cryptosporidium antigen $10.88 $86.10 
H. pylori NA‡ $169.69 
Extended spectrum beta-lactamase 
producing Enterobacteriaceae 
NA‡ $77.49 
Microsporidia NA‡ $72.11 
Blood Tests 
Complete blood count $6.20 $42.18 
Electrolytes $7.77 $39.69 
Urea $1.94 $49.04 
Creatinine $1.94 $46.64 
Alanine aminotransferase $1.94 $19.03 
Alkaline phosphatase $1.94 $49.04 
Total bilirubin $1.94 $19.03 
Albumin $1.94 $41.16 
Fasting lipids  $10.48 $147.35 
HbA1c NA‡ $71.39 
Glucose $1.94 $34.80 
Anti-tTG antibody (for celiac disease) $11.95 $156.68 
HIV type 1 and 2 NA‡ $110.85 
Hepatitis A virus IgM $15.00 $96.86 
Hepatitis B virus surface antigen $17.25 $398.44 
Hepatitis B virus core antibody IgM and 
IgG 
$14.42 $107.63§ 
Hepatitis B virus surface antibody $15.46 $52.28 
Hepatitis C virus antibody $15.14 $66.73 
Human T-cell lymphotropic virus 1 and 2 NA‡ $110.85 
Epstein Barr Virus IgM  $26.25 $75.34 
Cytomegalovirus IgM  $30.00 $76.41 
Strongyloides stercoralis serology NA‡ $145.29 
Entamoeba histolytic serology NA‡ $96.86 
Helicobacter pylori serology NA‡ NA† 
Treponema pallidum screening cascade NA‡ $75.78 
Listeria NA‡ $127.00 
Swabs 
Gonorrhea NA‡ $150.68 






MRSA $15.00 $159.60 
Carbapenem-resistant Enterobacteriaceae NA‡ $171.12 
Total per person (laboratory testing) $287.39 $3,772.49 
Other Costs 
Administrative fee  $56.25 NA 
Doctor’s visit $90.00 NA 
Advertising $4.88 NA 
Total per person $438.52 NA 
NA†: not available because same test isn’t offered by diagnostic service.  
NA‡: not available because cost was not publicly available in Canada by the provincial 
health laboratory.  
§: IgM only 
Canadian costs include the fixed cost of advertising, supply costs of materials used, and 
time spent scheduling and screening donors. American costs include the supply costs of 
materials used and labor.  
4.4 Discussion 
The demand for donors for FMTs is increasing. The criteria for donor screening amongst 
institutions are inconsistent and recruitment of donors for FMT clinics and studies can be 
very difficult. Knowing the total number of people to screen to find a suitable number of 
donors is helpful when determining how much recruitment will need to be done. This also 
determines the program feasibility and costs of establishing a program. We found that of 
46 volunteers screened, only 5 passed clinical and laboratory screening and due to 
subsequent events only 1 out of 5 was available for ongoing donation. Of the 4 donors who 
were successfully screened and passed all of the tests, but subsequently excluded, 2 may 
be available for donation at a later date after completing repeat screening as the other 2 
declined repeat screening. Tariq et al.12 had a similar experience in which almost half of 
their accepted donor pool were excluded after passing screening, with one donor becoming 
pregnant, two testing positive for Shiga toxin in stool and one opted out of being a donor. 
It was found that 11% of our potential donors screened were eligible to be donors for FMTs. 
This 11% success rate is comparable to both Kazerouni et al.9 and Paramsothy et al.10 who 






OpenBiome, the longest standing international stool bank, currently reports that less than 
3% of PDs applying to their program are accepted to be donors13. Costello et al.11 found 
higher rates of success for stool tests (68%) compared to our data and that of others8,9. We 
found that the most common reasons for exclusion in our cohort were B. hominis, D. 
fragilis and H. pylori. Both B. hominis and D. fragilis were also the leading reasons for 
exclusion found by Paramsothy et al.10. While common problems, the loss of successful 
PDs to acute gastroenteritis and travel to tropical countries appears to be 
uncharacteristically high in this pool of PDs. It would be very difficult to prevent these 
problems from occurring in the future as we have no control over the wide variety of factors 
that may cause acute gastroenteritis and a donor’s vacation plans. None of the PDs had 
plans for upcoming travel when screened, however, many were University undergraduate 
or graduate students and last-minute travel was a common phenomenon. If restrictions were 
placed on donors about where they could travel, donor retention would likely suffer.   
Kazerouni et al.9 estimated the cost of screening one donor for their public stool bank 
(OpenBiome) to be $885 USD per person. We estimated the cost of this screening program 
at $440 USD per person in Canada, with the total cost of screening to find one viable donor 
being $15,190 USD. The difference in costs is likely, at least partially, related to a lower 
cost for medical procedures, laboratory tests, and physician time in Canada than in the US. 
For example, the cost of laboratory test in Canada versus the United states are; ova, cysts 
and parasites: $21.00 USD versus $138.84 USD, C. difficile toxin: $30.00 USD versus 
$100.09 USD, and Hepatitis B virus core antibody IgM: $14.42 USD versus $107.63 USD 
(The pricing of Quest Diagnostics laboratory tests was used to provide costs in the US). 
Overall, the cost of the same laboratory testing in Canada versus the United States was 
approximately $290 and $3,770, respectively. There are several tests that were provided 
free of charge in Canada by the provincial public health laboratory (ex. Gonorrhea, 
chlamydia, and HTLV 1 and 2) and this was also a contributing factor as to why the price 
of screening a PD in Canada was significantly lower than in the US. No cost estimates were 







The one donor successfully selected will require ongoing intermittent routine rescreening 
every six months. At present, there is no consensus on the frequency of rescreening, nor 
have they been specified in clinical guidelines3. Interim testing varies amongst programs 
from every month11 to six months’ time. Other common reasons for donor subsequent 
exclusion could include travel to the tropics, requiring antibiotics, or starting a new sexual 
relationship. This has now necessitated rescreening a large cohort of new volunteers. Three 
additional donors were recruited using these screening criteria before the NAFLD or MS 
randomized controlled trials commenced. 
 Finally, there is data suggesting that the efficacy of FMT for different diseases with 
microbiome indications varies by donor characteristics that are difficult to predict. 
Repeated donations from different donors were required for success in a landmark C. 
difficile therapy study14. Furthermore, a particular donor appeared to be especially effective 
in a study of FMT for ulcerative colitis15, but whether the same donor’s microbiome would 
also be ideal for other indications is unknown. We included a wide range of ages (18-65) 
in PD screening. Although some authorities note that microbiome senescence may lead to 
lower efficacy with an older donor, the longer a patient has lived without complications, 
the more likely they may have a healthy microbiome. Ideally multiple donors would be 
screened to find ones that are repeatedly successful for different diseases treated by FMT. 
This would dramatically increase the number of donors required for screening and increase 
costs to have a stool bank that specializes in treating multiple diseases.   
Limitations of this study include that the sample size was small (n=46) and the reasons for 
exclusion after PDs passed screening may not be generalizable for other populations, as 
the rates of acute gastroenteritis and tropical travel in the 5 accepted PDs were unusually 
high. The cost of screening a PD for FMT is underestimated because the costs of tests from 
the provincial health laboratory were not made available and these tests were performed in 
Canada where the cost of physician’s time and laboratory testing is significantly lower than 
in the United States. The strengths of this study are that it shows a minimum cost estimate 






difficulties that can be anticipated to establish and maintain a donor pool from a single 
center without significant funding.  
Our data raise the concern regarding the feasibility of individual centers establishing and 
maintaining FMT donor pools. Reimbursement for FMT is not high enough to counter the 
costs of screening PDs for programs, for example in the US an FMT is reimbursed $76 
USD through Medicare. In Ontario, there is no reimbursement whatsoever. Central banks 
with storage and shipment of frozen samples may be necessary to maintain programs16. 
However, to enable this, full transparency and reporting of all screening protocols will be 
necessary to enable clinicians and regulators to determine the acceptability and potential 
efficacy of biobank stools for their clinical context. 
Novel uses for FMTs, as well as new insights on how the microbiome affects human health, 
have created a demand for stricter exclusion criteria for donors. Anticipating the number 
of potential donors that must be screened to find a suitable donor can help to determine the 
amount of recruitment that must be done and the funds required to accomplish this. The 
large number of donors who require screening and the resultant cost may make the 
establishment of multiple local programs a nonviable goal with central processing and 
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Chapter 5  
5 Insulin resistance, percentage liver fat, and intestinal 
permeability of patients with non-alcoholic fatty liver 
disease following fecal microbiota transplantation  
5.1 Introduction 
Non-alcoholic fatty liver disease is an obesity-related disorder characterized by having 
more than 5% fat by volume in the liver. NAFLD affects 20-30% of North American adults 
and 80% of obese individuals1. The metabolic syndrome is present in 67% of NAFLD 
patients2. It has been well-established that the gut microbiome plays a role in metabolism3-
6. Many have postulated that one of the reasons that obese individuals develop NAFLD is 
due to differences in the composition of bacteria in the gut. Evidence from animal studies 
showed that transfer of the gut microbiota from obese mice or from obese humans into 
germ-free mice reproduced the obese phenotype7. Yet, there have been numerous studies 
that have compared the gut microbiota of NAFLD, obese, and healthy individuals without 
finding consistent differences at the phylum or genus level8-12.  
As opposed to certain bacteria being responsible for the pathogenesis of NAFLD, bacterial 
metabolites may be the driving force. Butyrate is a short-chain fatty acid produced by the 
breakdown of fibre by a variety of bacteria in the gut. It increases intestinal barrier integrity 
and reduces the amount of LPS that passes through the intestinal membrane. A decrease in 
butyrate and an increase in the amount of LPS passing through the intestinal membrane has 
been shown in mice to cause NAFLD and insulin resistance13. Genetic susceptibility14, 
hyperglycemia15, and bacterial pathogens16 can also increase gut permeability. One study 
found that administering butyrate to mice fed a high-fat diet increased their energy 
expenditure and protected them from developing insulin resistance17. A human study has 
also demonstrated that NAFLD patients have significantly increased gut permeability 
compared to healthy controls, and there was a correlation with greater amounts of fat in the 






Given the relationship between the microbiome, NAFLD and the metabolic syndrome, 
FMT is being investigated to alter the microbiota composition of the intestine and treat 
some of these diseases. A study in mice demonstrated that insulin resistance and the fatty 
liver phenotype could be transmitted via FMT19. A human study that administered FMT to 
18 metabolic syndrome patients (9 allogenic (from a thin donor) and 9 autologous 
transplants) reported a significant increase in insulin sensitivity in the allogenic transplant 
group (26.2 to 45.3 µmol/kg/min)20. Notably, the autologous transplant group did not 
experience a change in insulin sensitivity. The authors suggested that the improvement in 
insulin sensitivity was due to an increased abundance of butyrate-producing bacteria 
although a subsequent study did not confirm the butyrate hypothesis but questioned the 
impact of microbial acetate production21. 
We hypothesized that an FMT from a lean, healthy donor given to NAFLD patients with 
metabolic syndrome would result in a decrease in insulin resistance (the primary outcome), 
and small intestinal permeability (a secondary outcome) both at 6 weeks post-FMT, and 
hepatic PDFF at 6 months (a secondary outcome). A pilot study of twenty-one subjects 
was carried out to test the hypothesis.  
5.2 Methods 
5.2.1 Patient Recruitment and Randomization 
Between June 2016 to April 2018, twenty-one NAFLD patients were recruited by 
hepatologists in London, ON, Canada. This was a double-blinded randomized controlled 
trial. Patients were randomly assigned at a ratio of 3:1 to receive an allogenic or autologous 
FMT and had follow-up appointments for 6 months’ post-transplant. A summary of the 
timeline of appointments and tests performed can be found in Supplementary Table 5.1. 
5.2.2 Sample Size Calculation: 
Using the individual patient data from Vrieze et al.20, the mean (standard deviation) rate of 
glucose disappearance for patients receiving allogenic FMT infusion was estimated to be 






points was 0.91. The sample size calculation for paired sample t-test, using a two-sided 
test, power of 80%, and alpha of 0.05, yielded a minimum sample size of 12 allogenic 
patients. 
5.2.3 Patient Inclusion Criteria 
• Attendance at the gastroenterology/hepatology clinic with a diagnosis of NAFLD 
as per the AASLD criteria22.  
• Willingness to provide informed Consent.  
• > 18 yrs old 
5.2.4 Patient Exclusion Criteria 
• Type 1 or 2 diabetes requiring insulin (oral hypoglycemics were not excluded as 
long as there was no change in dosage for at least three months and no plan to adjust 
the dose).  
• Inability to attend follow-up visits.  
• Inability to provide informed written consent.  
• Ongoing use of antibiotics or probiotics.  
• Previous or planned bariatric surgery.  
• Presence of a chronic intestinal disease e.g. celiac disease, malabsorption, or 
colonic tumor.  
• Immunosuppression from transplantation, HIV, cancer chemotherapy or ongoing 
use of any immune-suppressive agents.  
• Pregnancy  
5.2.5 Donor Selection 
Forty-six potential donors were screened to find three suitable donors for this study. The 
methods of selection have been described elsewhere23. Potential donors were excluded if 
there was any history in the patient or immediate family (i.e. parents, siblings or children) 
of metabolic disease (i.e. hypertension, hyperlipidemia, diabetes, or obesity), vascular, 






acquire infectious agents (new sexual partner, hospitalization or travel to the tropics within 
3 months) or antibiotic therapy within 3 months were excluded. Potential donors underwent 
a full physical examination as well laboratory testing to rule out body mass index (BMI) 
>25 kg/m2, hypertension, hyperlipidemia, elevated transaminases or glycated hemoglobin 
(HbA1c) prior to donation. If they passed the medical examination, their stool, blood and 
urine were tested for 30 different bacterial, viral and protozoan agents to ensure that known 
transmissible diseases would not be passed along to recipients through FMT. Only 1 in 10 
potential donors qualified for this study. Three donors in total were identified and all 
provided fresh stool for the allogenic transplants. Donor characteristics are summarized in 
Supplementary Table 5.2.  
5.2.6 Fibrosis Staging 
Liver fibrosis stage was diagnosed using a variety of methods as various clinicians were 
involved with recruitment for this study. Biopsy (n=9), FibroScan (n=7), and MR 
elastrography (n=5) were used. All patients had hepatic steatosis documented by 
ultrasound. Liver biopsies were analyzed by experienced hepatopathologists and fibrosis 
staged using the Brunt methodology24 (F0 = no fibrosis; F1 = zone 3 pericellular/sinusoidal 
fibrosis, focal or extensive; F2 = zone 3 plus focal or extensive periportal fibrosis; F3 = 
bridging fibrosis, focal or extensive; and F4 = cirrhosis). The method of histologic scoring 
used was the Non-Alcoholic Fatty Liver Disease Activity Score (NAS), a validated scoring 
system for the evaluation of histologic changes in NAFLD25. For FibroScan, fibrosis stage 
was determined according to that established by Wong et al. (F0-1 ≤ 7.0 kPa, F2 7.1 – 8.6 
kPa, F3 8.7 - 10.3 kPa, F4 ≥ 10.4 kPa)26. For MR elastography, fibrosis stage was 
determined according to that established by Loomba et al.27. 
5.2.7 Fecal Microbiota Transplant 
All patients were asked to drop off a fresh fecal sample within 72 hours of their scheduled 
FMT to keep them blinded as to whether they were going to receive an allogenic or 
autologous FMT. Whole stool was stored at 4 °C and processed immediately prior to 






envelopes/sachets of Pico Sulphate preparation immediately after donating a baseline stool 
sample and prior to the FMT. To prepare the FMT material, 2 g of stool (from either the 
donor or autologous sample) and 125 mL of sterile saline were placed inside of a 
BA614/STR filter bag (Seward, Islandia, NY) and mixed using the Stomacher® 400 
Circulator (Seward, Islandia, NY) at 230 rpm for 30 seconds. The filtered material was 
then transferred into sterile sample collection containers, transferred to the endoscopy unit 
and used within 2 hours. The FMT (allogenic or autologous) was delivered to the 
duodenum using an endoscope. Dr. Adam Rahman performed the FMT delivery under 
general anesthesia at University Hospital, London, ON. 
5.2.8 Small Intestinal Permeability 
Patients were asked to drink a solution of 5 g of lactulose (Calbiochem®, EMD Millipore 
Corp., Billerica, MA), 2 g of mannitol powder (BDH®, VWR analytical, Mississauga, 
ON), 1.5 g of Kool Aid (Kraft Foods, Ingleside, ON), 100 g of sucrose, and 450 mL of tap 
water the evening before their baseline and 6 weeks appointments. The subjects were asked 
to collect all the urine that they passed throughout the night and morning of their 
appointment and store it in a urine collection bottle. This bottle was brought to the clinic, 
the total volume of urine was recorded and then aliquoted into 10 mL amounts. 
Concentrations of lactulose, mannitol and sucrose were determined using high 
performance liquid chromatography28. Urine samples were sent to the lab of Dr. Jon 
Meddings in Calgary, AB, at the end of the study to be analyzed. 
5.2.9 Blood Samples 
Blood was collected from patients (fasting) at baseline, 2 weeks, 6 weeks and 6 months 
post-FMT. The blood was used to examine: CBC, albumin, bilirubin, glucose, fasting 
insulin, HbA1c, non-esterified fatty acids, cholesterol, total cholesterol, high-density 
lipoprotein (HDL) cholesterol, low-density lipoprotein (LDL) cholesterol, total: HDL 
cholesterol ratio, triglycerides, apolipoprotein A1 (ApoA1), apolipoprotein B (ApoB), 
alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase 






Magnetic Resonance Elastography. Blood samples were collected by Ms. Mala Ramu at 
the Centre for Clinical Investigations and Therapeutics at University Hospital, London, 
ON. 
5.2.10 Fecal Sample Collection 
The fecal samples were collected to assess changes in the fecal microbiota composition 
following FMT using a previously validated protocol29. Briefly, patients collected a visibly 
soiled piece of toilet paper after passing a stool at baseline, 2 days, 7 days, 2 weeks, 6 
weeks, 3 months, and 6 months post-transplant. The subjects placed the fecal sample in a 
Fisherbrand™ Opaque Sterile Sampling Bag (Fischer Scientific, ThermoFisher Scientific, 
Mississauga, ON) and brought it to their appointments. The samples were then frozen at - 
80 °C until DNA extraction took place.  
5.2.11 DNA Extraction 
DNA from the toilet paper samples was extracted using the DNeasy® Powersoil® HTP 96 
Kit (Qiagen, Toronto, Ontario, Canada), as per the manufacturer’s instructions with the 
following modification: A centrifuge speed of 3700 rpm for 10 minutes was used. 
Extracted DNA was stored at -20 °C until amplification.  
5.2.12 DNA Amplification 
The BioMek® 3000 Laboratory Automation Workstation for automated PCR reagent set 
up was used to load 10 µL (2.3 pmol/µL) of 32 primers (16 left and 16 right) with unique 
barcodes into 96 well plates. Amplifications of the V4 region of the 16S ribosomal 
RNA gene were carried out with the primers (5′-3′) 
ACACTCTTTCCCTACACGACGCTCTTCCGATCTNNNNxxxxxxxxGTGCCAGCMG
CCGCGGTAA and (5′-3′) CGGTCTCGGCATTCCTGCTGAACCGCTCTTCCGATCT 
NNNNxxxxxxxxGGACTACHVGGGTWTCTAAT (xxxxxxxx is a sample 
specific nucleotide barcode and the preceding sequence is a portion of the Illumina adapter 






template DNA into the primer containing 96 well plates. Then 20 μl of Promega GoTaq® 
Colourless Master Mix (Promega, Maddison, WI) was added to the DNA template and 
primers. The final plate was firmly sealed with a foil PCR plate cover. This plate was placed 
in the Eppendorf Mastercycler® thermal cycler (Eppendorf, Mississauga, Ontario, 
Canada), where the lid was kept at 105 °C. An initial warm-up temperature of 95 °C was 
used for 2 min to activate the GoTaq®. Afterwards, the volumes underwent 25 cycles of 
95 °C for 1 min, 50 °C for 1 min, and 72 °C for 1 min. After completion, the temperature 
of the thermal cycler was held at 4 °C, and amplicons were then stored at − 20 °C. 
5.2.13 DNA Sequencing and Data Analysis 
Amplified DNA was sent to the London Regional Genomics Centre at Robarts Research 
Institute (Western University, London, Ontario, Canada). The samples were quantified 
(Quant-it, Life Technologies, Burlington, Ontario, Canada) and pooled at equimolar 
concentrations. The pooled libraries were cleaned using QIAquick (Qiagen, Germantown, 
Maryland, USA) and then sequenced using the MiSeq Illumina® platform, with 2 × 300 bp 
paired-end chemistry. The reads were demultiplexed and filtered using dada2 (version 1.8) 
and custom R scripts written by Greg Gloor (github.com/ggloor/miseq_bin). The 
demultiplexed reads will be available at NCBI SRA. Any taxa with less than 3 counts in 
30% of the samples were removed. Taxonomy was assigned using an RDP classifier 
provided by the dada2 package and trained against version 132 of the SILVA database. 
Diversity of the fecal microbiota was quantified based on Shannon’s index and was 
calculated using the Vegan package (github.com/vegandevs/vegan). ALDEx2 was used to 
identify differentially abundant taxa between patients with abnormal permeability and 
normal permeability as well as patients with abnormal permeability at baseline and 6 weeks 
following FMT30. ALDEx2 was also used to identify differentially abundant taxa between 
baseline and all subsequent time points for allogenic and autologous FMT recipients. An 






5.2.14 Magnetic Resonance Imaging (MRI) 
Patients underwent an abdominal MRI (3T), including 3D chemical shift encoded MRI31, 
at their baseline and 6-month appointment (conducted at the Robarts Research Institute). 
MRI data were analyzed to determine abdominal total volume (cm3), abdominal 
subcutaneous adipose volume (cm3), abdominal visceral volume (cm3), and liver proton 
density fat fraction (PDFF, %)32. Two patients were unable to have an MRI; one had a 
pacemaker and one was unable to fit into the apparatus. MRIs were received by Dr. Charles 
McKenzie at University Hospital, London, ON. 
5.2.15 Diet History Questionnaire 
Prior to their FMT and six weeks after their FMT, participants completed the online diet 
history questionnaire version 2 (DHQII) with portion sizes, which measured intake over 
the previous month. Downloaded nutrient data were reviewed by the study dietitian for 
plausibility: e.g. whether energy and nutrient intakes were likely to be physiologically 
possible and if appropriate this was checked with participants. Under-reporters were 
included in the analysis. Due to inaccuracies in estimation, all dietary data are reported to 
a maximum of two significant figures. Students’ t-tests were used to compare differences 
in changes in intakes. The diet history questionnaire was collected and analyzed by Dr. 
Ruth Harvie at St. Joseph’s Health Care, London, ON. 
5.3 Results 
5.3.1 Insulin resistance and PDFF were not improved with 
allogenic FMT 
Patients were randomly assigned to either the allogenic (n=15) or autologous (n=6) FMT 
group. By chance, patients who were randomized to the autologous FMT group had less 
severe disease scoring and healthier levels of a variety of biochemical markers (Table 5.1). 







Table 5.1 Characterization of patients at baseline. 





Age (years) 47.6 (14.9) 57.5 (13.0)  
Sex (Female:male) 10:5 5:1  
Height (cm) 168.7 (10.2) 169.1 (7.4)  
Weight (kg) 103.6 (18.0) 107.6 (31.4)  
Waist to Hip Ratio 0.962 (0.053) 0.961 (0.048)  
BMI 36.3 (5.0) 37.4 (9.5) 18.5-25 
Chemistry 
Albumin (g/L) 44.4 (2.0) 42.5 (2.3) 35-50 
Bilirubin (µmol/L) 8.4 (2.0) 8.7 (4.6) <20.5 
Glucose, fasting (mmol/L) 7.3 (1.8) 7.9 (2.8) 3.5-5.8 
Insulin (pmol/L) 196 (177) 166 (129) <174 
HOMA-IR 3.5 (1.3) 4.4 (2.1) <1.7 
HbA1c (%) 6.3 (0.9) 6.4 (1.0) 4-6 
Lipids 
Total cholesterol (mmol/L) 4.68 (1.15) 3.53 (1.08) <5.2 
HDL cholesterol (mmol/L) 1.04 (0.25) 1.18 (0.25) >0.9 
LDL cholesterol (mmol/L) 2.68 (1.09) 1.76 (0.84) <2.0  
Total: HDL cholesterol ratio  4.8 (1.6) 3.0 (0.5) <5.0 
Triglycerides (mmol/L) 2.30 (1.43) 1.31 (0.25) 1.7 
Non-esterified fatty acids 
(µmol/L) 
562 (238) 616 (269) 720  
Apo A1 (g/L) 1.59 (0.26) 1.69 (0.23)  
Apo B (g/L) 1.13 (0.35) 0.78 (0.22)  
ApoB:ApoA1 ratio 0.72 (0.21) 0.46 (0.10)  
Liver Enzymes 
Alanine Aminotransferase (U/L) 59 (27) 37 (7) 17-63 
Aspartate Aminotransferase 
(U/L) 






Alkaline Phosphatase (IU/L) 71 (19) 74 (16) 38-126 
Abdominal Total Volume (cm3) 17945 (4414) 10747 (6914)  
Abdominal Subcutaneous Adipose 
Volume (cm3) 
11911 (3951) 8021 (3277)  
Abdominal Visceral Fat Volume (cm3) 6041 (1878) 6776 (877)  
Hepatic PDFF (%) 19.24 (8.33) 23.87 (14.56) <5 
Liver Fibrosis Scoring 
F0 4 3  
F1 5 1  
F2 2 0  
F3 1 0  
F4 4 2  
 
Data presented are the mean (SD) of patients at baseline.  
Normal Ranges are defined by the Medical Council of Canada33. 
The primary outcome for this study was insulin resistance, as measured by the HOMA-IR 
score. Wilcoxon matched-pairs signed rank test was used to compare HOMA-IR at baseline 
and 6 weeks post-FMT in both the allogenic and autologous groups. There was no 
significant decrease in the insulin resistance of patients who received an allogenic or 
autologous FMT (Figure 5.1a and b). One patient in the allogenic group had specific insulin 
and fasting glucose concentrations above the limit used to calculate the HOMA-IR score 







Figure 5.1 Insulin resistance was not significantly altered by allogenic nor autologous 
FMT. HOMA-IR score was calculated using fasting glucose and insulin (specific) 
concentrations. Wilcoxon matched-pairs signed rank test was performed to compare the 
HOMA-IR scores at baseline and 6 weeks post-FMT in both the allogenic and autologous 
groups (p=0.216 and p=0.688, respectively). A) Individual changes in insulin resistance in 
patients receiving an allogenic FMT (n=14). Median (IQR); baseline: 3.88 (2.840-5.345), 
2 weeks: 3.12 (2.56-4.57), 6 weeks: 3.45 (2.32-5.10), and 6 months: 3.52 (2.78-5.05). B) 
Individual changes in insulin resistance in patients receiving an autologous FMT (n=6). 
Median (IQR); baseline: 4.88 (2.57-6.79), 2 weeks: 4.07 (2.29-5.96), 6 weeks: 5.09 (2.55-
6.25), and 6 months: 4.96 (2.73-6.53 HOMA-IR). HOMA-IR: homeostatic model 
assessment – insulin resistance. The dotted line represents the cutoff for a normal HOMA-
IR score, <1.7.  
There was no significant difference in the hepatic PDFF 6 months’ post-transplant in 
patients who received an allogenic or an autologous FMT (Figure 5.2a and b). Wilcoxon 
matched-pairs signed rank test was used to compare the hepatic PDFF at baseline and 6 
months’ post-FMT in both the allogenic and autologous groups. Two patients in the 
autologous group were unfit to have an MRI. A detailed report of each patient’s NAS can 






Figure 5.2 The hepatic PDFF in NAFLD patients was not significantly altered by 
FMT. The hepatic PDFF was determined by MRI. Wilcoxon matched-pairs signed rank 
test was performed to compare the hepatic PDFF at baseline and 6 months’ post-FMT in 
both the allogenic and autologous groups (p=0.804 and p=0.875, respectively). A) The 
hepatic PDFF over time in patients who received an allogenic FMT (n=15). Median (IQR); 
baseline: 17.52 % (12.1-21.29 %) and 6 months: 16.6% (12.26-24.8 %). B) The hepatic 
PDFF over time in patients who received an autologous FMT (n=4). Median (IQR); 
baseline 30.38% (8.759-32.48 %) and 6 months: 25.52 % (8.06-32.89 %). C) The change 
in the hepatic PDFF in patients who received an allogenic FMT (n=15). D) The change in 
the hepatic PDFF in patients who received an autologous FMT (n=4). The dotted line 






5.3.2 Abnormal small intestinal permeability improved following 
allogenic FMT 
Small intestine permeability was assessed using the lactulose:mannitol urine test. Seven 
patients in the allogenic FMT group had elevated small intestinal permeability prior to 
FMT. Five received an FMT from donor 1, one from donor 2, and one from donor 3.After 
the allogenic FMT from a lean, healthy donor, all seven patients had a decrease in their 
small intestinal permeability (Figure 5.3a), with two decreasing to within the normal range 
of permeability (defined by test values less than 0.025). There was no relationship between 
abnormal small intestinal permeability and fibrosis score as determined by the Kruskal-
Wallis test (p=0.7767) (Supplementary Figure 5.1). There was no association of specific 
donors with an improvement in intestinal permeability. All three donors were successful at 
lowering small intestinal permeability in patients that had abnormal permeability. Elevated 
baseline small intestinal permeability was observed in one of patients who received an 
autologous FMT and it improved to within the normal range of permeability, however one 
patient in the autologous group had a normal baseline permeability which rose above 
normal at 6 weeks (Figure 5.3b). Overall there was a significant improvement in small 
intestinal permeability in the allogenic group (p=0.018), but not in the autologous group 








Figure 5.3 Patients who received an allogenic FMT from a thin and healthy donor 
showed improved intestinal permeability. Small intestine permeability was calculated 
using the lactulose:mannitol urine test. Ratios were non-zero and Wilcoxon matched-pairs 
signed rank test was performed to compare the lactulose:mannitol ratio at baseline and 6 
weeks post-FMT in both the allogenic and autologous groups (*p=0.018 and p=0.563, 
respectively). A) Lactulose:mannitol ratio of patients who received an allogenic FMT 
(n=15). Median (IQR); baseline: 0.026 (0.021-0.047) and 6 weeks: 0.023 (0.018-0.032). 
B) Lactulose:mannitol ratio of patients who received an autologous FMT (n=6). Median 
(IQR); baseline: 0.017 (0.0138-0.0215) and 6 weeks: 0.0205 (0.0145-0.0245). The dotted 
line represents the cutoff for the normal lactulose:mannitol ratio, <0.02535.  
5.3.3 Fecal microbiota diversity did not relate to metabolic or 
intestinal permeability responders 
A recent study of patients with metabolic syndrome suggested that peripheral insulin 
sensitivity improved (>10%) only in the subset of allogenic transplants that had reduced 
fecal microbial diversity at baseline (although the FMT did not change the fecal microbial 
diversity in either group)21. Allogenic insulin sensitivity responders (>10% improvement 

























































in baseline fecal diversity between the two groups, although paradoxically the diversity did 
increase post-FMT in the non-responder group (Figure 5.4).  
 
Figure 5.4 Fecal bacterial diversity is not related to metabolic response. Shannon 
Diversity Index at baseline and 6 weeks’ post allogenic FMT is shown. A responder was 
characterized by having >10% reduction in HOMA-IR, a non-responder was characterized 
by having <10% reduction in HOMA-IR. Mann-Whitney t-test was used to compare the 
Shannon diversity at baseline in the responder (n=6) and non-responder groups (n=9) 
(p=0.797). Wilcoxon matched-pairs signed rank test was used to compare Shannon 
Diversity Index at baseline and 6 weeks’ post-FMT in the non-responder and responder 
groups (p=0.0078, p=0.813, respectively). One patient in the non-responder group did not 

























































Additionally, fecal microbiota diversity of allogenic intestinal permeability responders 
(defined as a patient that experienced an improvement in small intestinal permeability and 
had a baseline >0.025 lactulose:mannitol) and other allogenic patients (defined as a patient 
that did not initially have elevated small intestinal permeability; baseline <0.025 
lactulose:mannitol) were compared. There was no difference in baseline fecal microbial 
diversity between the two groups, although intestinal permeability responders experienced 
an increase in fecal microbial diversity that approached significance 6 weeks post-FMT 









Figure 5.5 Fecal bacterial diversity and improvement in small intestinal permeability. 
Shannon Diversity Index at baseline and 6 weeks’ post allogenic FMT is shown. A 
responder was characterized by having an initial lactulose:mannitol reading above 0.025 
and having a reduction in this ratio at 6 weeks’ post allogenic FMT. Mann-Whitney t-test 
was used to compare the Shannon Diversity Index at baseline in the responder (n=7) and 
non-responder groups (n=8) (p=0.142). Wilcoxon matched-pairs signed rank test was used 
to compare Shannon Diversity Index at baseline and 6 weeks’ post-FMT in the non-
responder and responder groups with a trend towards increasing diversity seen in the 
responder group (p=0.383, p=0.063, respectively). One patient in the responder group did 

























































ALDEx2 was used to identify if any particular taxa were differentially abundant in patients 
with abnormal permeability (>0.025 lactulose:mannitol) compared to those with normal 
permeability and did not find any significant differences (an effect size cut-off of >|3| was 
used) (Supplementary Figure 5.2). We also compared the composition of fecal bacteria in 
patients with abnormal permeability at baseline and 6 weeks following FMT and did not 
find any differentially abundant taxa (Supplementary Figures 5.3 and 5.4).  
5.3.4 Changes in the fecal microbiota of FMT recipients 
The fecal microbiota composition of Donor 1 and allogenic and autologous FMT recipients 
following transplant were examined. These changes were variable by individual in both the 
allogenic and autologous group (Figures 5.6 and 5.7, respectively). Detailed per subject 
analysis was also conducted on Donor 1 and all patients that received an allogenic or 
autologous transplant (Supplementary Figures 5.5-5.24). Two patients did not collect fecal 
samples at baseline and were excluded in this analysis; one patient from the allogenic group 
and one patient from the autologous group. Donors 2 and 3 moved away during the RCT 
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Figure 5.6 Fecal microbiota composition of allogenic FMT transplant recipients over 
six months. All patients except for patients 2, 10, and 11 received an allogenic FMT from 
Donor 1. Toilet paper samples were collected from patients at baseline, 2 days, 7 days, 2 
weeks, 6 weeks, 3 months, and 6 months post-FMT. The DNA was extracted and the V4 
region of the 16S rRNA gene was amplified and sent for Illumina MiSeq next-generation 
sequencing. The resulting reads were used to generate bar plots in base R (version 3.5.3). 




































































Figure 5.7 Fecal microbiota composition of autologous FMT transplant recipients 
over six months. Toilet paper samples were collected from patients at baseline, 2 days, 7 
days, 2 weeks, 6 weeks, 3 months, and 6 months post-FMT. The DNA was extracted and 
the V4 region of the 16S rRNA gene was amplified and sent for Illumina MiSeq next-
generation sequencing. The resulting reads were used to generate bar plots in base R 
(version 3.5.3). Each column represents the fecal microbiota composition at one time point. 
5.3.5 FMT did not alter lipid profiles with the exception of NEFA 
Several metabolic biochemical markers were examined in blood samples collected from 
the patients at each clinical visit. Exploratory analysis suggested that compared to baseline, 
patients 6 weeks post-allogenic FMT had lower concentrations of non-esterified fatty acids 
(NEFA) (mean decrease of 146.3 µmol/L; Supplementary Figure 5.25a). This was not 
observed in those receiving autologous FMT, Supplementary Figure 5.25b). Patients who 
received the allogenic FMT had a higher total:HDL cholesterol ratio than patients assigned 
to the autologous FMT group at baseline. A decrease in the total:HDL cholesterol ratio was 
observed at 6 months post-FMT in the group of patients receiving an allogenic FMT (mean 
decrease of 0.674; Supplementary Figure 5.26a).   
No changes were observed in total cholesterol, HDL cholesterol, LDL cholesterol, and 
triglycerides between baseline and 6 weeks post-FMT in both the allogenic and autologous 
groups. (Supplementary Figures 5.27-5.30). No changes were observed in the 
concentration of fasting glucose over time in both the allogenic and autologous groups 
(Supplementary Figure 5.31). No changes were observed in the ratio of ApoB:ApoA1 
between baseline and 6 weeks post-FMT in both the allogenic and autologous groups 
(Supplementary Figure 5.32). Weight, waist-to-hip ratio, and BMI were measured and 
calculated at each clinical visit (baseline, 2 weeks, 6 weeks, and 6 months post-FMT). 
Patients did not experience a change in their weight, waist-to-hip ratio, or BMI following 
an allogenic or an autologous FMT (Supplementary Figures 5.33-5.35). Seventeen patients 






weeks post-FMT (11 allogenic and 6 autologous). No changes in patients’ caloric or 
nutrient intakes were detected (Supplementary Figure 5.36).  
5.4 Discussion 
To our knowledge, this is the first reported clinical trial of FMT in NAFLD patients. These 
data demonstrated that FMT from lean healthy donors failed to improve insulin sensitivity 
(Figure 5.1), the primary outcome. FMT also did not improve the percentage of fat in the 
liver on MRI at 6 months (Figure 5.2), a secondary outcome, but did improve intestinal 
permeability at 6 weeks (Figure 5.3). 
The lack of improvement of insulin sensitivity stands in contrast to the findings of Vrieze 
et al.20 in metabolic syndrome patients where insulin sensitivity improved with allogenic 
transplants (n=9 allogenic transplants). The present study of 15 allogenic patients did not 
demonstrate this finding; this discrepancy could be due to either technical or biological 
factors. Technical factors of relevance include the metric of insulin sensitivity and the study 
sample size. Past studies used an insulin clamp method to identify insulin sensitivity 
whereas this study used a HOMA-IR score for the same purpose20,21. Insulin clamp 
technology is not widely available, including at any site in Ontario. The HOMA-IR score 
has been shown to have excellent correlation with the insulin clamp technique34. 
Furthermore HOMA-IR is reflective of both hepatic insulin sensitivity and peripheral 
insulin sensitivity34. Past studies noted an improvement in peripheral insulin sensitivity 
(p<0.05) that was modest and did not persist, but not in hepatic insulin sensitivity20,21. In 
contrast, the present study had a larger number of patients receiving allogenic FMT than in 
the original study by Vireze et al.. and a smaller number of patients receiving autologous 
FMT20. While the small number of autologous samples likely did not provide sufficient 
statistical power to detect changes in the autologous group, our primary hypothesis 
(improved insulin sensitivity in allogenic FMT patients) relied solely on baseline vs. 6-
week comparison within the allogenic group and therefore sample size likely does not 
explain the discrepancy between this study and that of Vrieze et al.20. Changes in HOMA-






peripheral but not hepatic insulin sensitivity may not have been adequately reflected in the 
HOMA-IR measure. The lack of change in the HOMA-IR raises a concern regarding the 
clinical impact of the small metabolic change in peripheral Insulin sensitivity seen 
previously.     
The improvement in small intestinal permeability associated with allogenic FMT was 
encouraging and this is the first study to show an improvement in small intestinal 
permeability in NAFLD and metabolic syndrome patients following FMT. A strength of 
this study was the use of the gold standard lactulose/mannitol ratio as the measure of 
intestinal permeability. Mannitol absorption is proportional to small bowel intestinal 
surface area (with low values seen in conditions such as celiac disease) and lactulose has a 
molecular weight which normally prevents significant absorption28. Therefore, an increase 
in the ratio of urinary excretion reflects increased intestinal permeability to large 
molecules. It has been hypothesized that increased gut permeability is a central mechanism 
of gut microbiome related autoimmune diseases (such as systemic lupus, type 1 diabetes, 
etc.), inflammatory bowel disease, systemic inflammation and infection as well as 
metabolic syndrome and NAFLD35. To our knowledge, this is the first study to demonstrate 
that manipulation of the microbiome is associated with an improvement in intestinal 
permeability in patients with a syndrome which has been associated with intestinal 
microbiome changes, other than C. difficile infection. This raises the possibility of FMT or 
other microbiome-altering techniques being able to prevent complications of increased 
intestinal permeability35. In the future, screening patients for elevated gut permeability may 
be a method to select patients likely to benefit from FMT.  
This is the first FMT study to monitor changes in hepatic PDFF longitudinally after FMT. 
No improvement in the hepatic PDFF was detected on MRI testing at 6 months’ post FMT. 
This may be a result of changes in the microbiome associated with allogenic FMT not 
persisting for as long as 6 months. The reason for choosing this time point was to detect a 






NEFA (Supplementary Figure 5.25) and at 6 months’ post-FMT the total cholesterol: HDL 
cholesterol ratio (Supplementary Figure 5.26) improved in the allogenic group.  
 There has been very limited data assessing long term changes in the gut microbiome after 
a single FMT in patients who are transplanted for a condition other than C. difficile36,37. 
Arguably, the microbiome alterations are more easily obtained in C. difficile patients where 
microbiota diversity and richness at baseline are extremely low38. It may be a key reason 
for the sustainability of the transplant in that condition36,37. On the other hand, repeated 
FMT for other conditions may require repetitive interventions to prevent reversion of the 
microbiome to baseline. This may explain why persistent use of a probiotic led to 
improvement of hepatic PDFF at 6 months39, but the single FMT in this study failed to do 
so. It is also notable that although our study did not discern changes in specific taxa within 
the fecal microbiota with allogenic transplant, we did however observe a trend towards an 
increase in the fecal microbiota diversity in patients who had improvement in intestinal 
permeability (Figure 5.5). The lack of changes in specific bacterial taxa may reflect that 
the FMT was administered into the duodenum, but microbiome analysis was limited to 
stool specimens. Analysis of the stool may not reflect changes in the microbiome of the 
small bowel or proximal colon. In fact, a recent FMT study which used duodenal 
administration in metabolic syndrome noted this phenomenon with changes in the small 
intestinal bacterial taxa which were not reflected by changes in the specific fecal bacterial 
taxa and also not associated with a change in fecal microbial diversity21. Alternative 
combination approaches for FMT administration such as pretreatment with antibiotics or 
co-administration via the colonic and duodenal route may need to be explored. Another 
hypothesis would be that the changes we observed in the small intestinal permeability of 
the allogenic group were not dependent on specific bacterial engraftment. Sterile fecal 
filtrates have been shown to successfully treat patients with C. difficile infection40. This 
may be on the basis of bacterial metabolites or possibly bacteriophages. Further studies to 






Limitations of this study include that by random chance the autologous and allogenic 
groups differed regarding fibrosis staging, intestinal permeability, and biochemical data. 
This was likely due to the small sample size of this study. Additionally, as fibrosis staging 
was done prior to enrollment to the study as part of routine care, three different methods of 
staging fibrosis were used and more than one pathologist was involved in the evaluation of 
biopsies; this may have resulted in interobserver variability regarding NASH diagnosis, 
grading activity and staging fibrosis. However, our outcome measures did not involve 
comparing pre- and post-treatment histological findings, so this would not affect the study 
outcome. A single radiologist read all MRI’s for hepatic fat content both pre- and post-
treatment. This adds to the reliability of our secondary outcome of PDFF. Finally, a single 
low dose FMT was used, and this may not have been a sufficient dose of bacteria to cause 
significant changes to the gut microbiome. A bowel prep was given to patients before the 
FMT, but in the future antibiotics may be used to improve donor engraftment. 
In conclusion, duodenoscopy administered FMT did not improve insulin sensitivity 
(measured via HOMA-IR) or hepatic PDFF in NAFLD patients, but it did contribute to 
repair of intestinal permeability. The use of FMT warrants further investigation to modulate 
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Chapter 6  
6 Safety, intestinal permeability, and changes in fecal 
microbiota composition following fecal microbiota 
transplantations in patients with multiple sclerosis  
6.1 Introduction 
Multiple sclerosis is an autoimmune, inflammatory, demyelinating disease of the central 
nervous system influenced by genetic susceptibility and some environmental factors. 
Patients with MS experience loss of motor function and vision, bladder and bowel 
dysfunction, muscle spasms, and cognitive impairment, which significantly decrease their 
quality of life. The life expectancy of these patients has been estimated to be decreased by 
7 years on average1. 
There are no existing therapies available to stop the progression of MS. Current 
medications are used to slow the progression of MS, manage relapse symptoms, and speed 
up recovery from relapse2. Investigation into novel therapies is needed. Past studies have 
shown that MS patients have alterations in their gut microbiota composition compared to 
healthy individuals. The most common trends that have been observed are a decrease in 
butyrate-producing bacteria including Clostridium cluster XIVa, Faecalibacterium 
prausnitzii, Eubacterium rectale, Lachnospiraceae, Ruminococcaceae, Fusobacterium 
and Butyricimonas3-5. Butyrate is preferentially used by intestinal epithelial cells as a 
source of energy and it promotes intestinal barrier integrity6. A decrease in butyrate may 
cause an increase in intestinal permeability, and this may allow microbial and dietary 
antigens to pass through the intestinal epithelium and trigger autoimmune responses in the 
host. Rumah et al. identified an MS patient with epsilon toxin (ETX)-producing 
Clostridium perfringens Type B7. It can disrupt the blood-brain barrier and bind myelin 
making it a potential MS trigger. Ten percent of MS patients in the study had antibodies 






possible factor contributing to the development of MS as Pseudomonas peptides are 
capable of activating myelin basic protein (MBP)-specific T-cell clones from MS patients8.  
Due to the links between MS and the gut microbiome, fecal microbiota transplantation 
(FMT) is being considered as a possible treatment for MS. We hypothesized that FMTs 
from healthy donors without a personal or family history of autoimmune diseases would 
be safe and well tolerated, alter the balance of cytokines in the peripheral blood to become 
more anti-inflammatory, and alter the microbiota composition of MS patients. 
6.2 Methods 
6.2.1 Patient Recruitment and Group Randomization 
Ten patients (three males and seven females) with RRMS (n=9) and SPMS (n=1) were 
recruited to the study between October 2017 to May 2018 at a neurology clinic at 
University Hospital in London, ON, Canada. [ClinicalTrials.gov (NCT03183869)] The 
study was approved by Health Canada as well as Western University’s Research Ethics 
Board (REB: 109306). All patients provided written informed consent. Patients were 
randomly assigned to either the early (n=4) or late intervention group (n=6). Early 
intervention patients received one FMT per month for six months in the first six months of 
the study and were monitored for six months post-FMTs. Late intervention patients were 
recruited to the study and were monitored for six months prior to intervention. They then 
received one FMT per month for six months in the last six months of the study. Patients 
were randomly assigned to receive FMTs from either Donor 1 (n=4) or Donor 2 (n=6). 
6.2.2 Donor Selection 
Potential donors were screened using our previously published protocol9 with the 
additional exclusion criteria of any family or personal history of autoimmune diseases. 
Two donors were selected for this study. Donor 1 provided FMTs to four patients, Donor 
2 provided FMTs to six patients. Donor 2 in this study was Donor 1 from the NAFLD-






6.2.3 Fecal Microbiota Transplant 
Stool samples of 50-70 g were collected from donors and stored as whole stool at -80 °C 
for less than three months. The stool samples were thawed in a 37 °C water bath for one 
hour prior to preparation of the enema. Two hundred and twenty millilitres of saline and 
50-70 g of donor stool were placed inside of a BA614/STR filter bag (Seward, Islandia, 
NY) and were mixed using the Stomacher® 400 Circulator (Seward, Islandia, NY) at 230 
rpm for 30 seconds. The filtered material was then transferred into an AMSure® Enema 
Bag (Amsino, Pomona, CA). The enema was prepared thirty minutes before the scheduled 
FMT and was stored at room temperature until the procedure took place.   
6.2.4 Blood, Urine, Vitals 
Routine blood work, urinalysis, and vitals were taken at each visit (once per month for up 
to twelve months). Blood and urine were collected, and vitals were taken prior to 
administering the FMT at each appointment. A summary of tests performed can be found 
in Supplementary Tables 6.1-6.3. These samples were collected and analyzed as a part of 
standard of care at St. Joseph’s Health Care, London, ON.  
6.2.5 EDSS and MRI 
Clinical and radiological signs of disease activity or progression were measured using the 
EDSS10 once per month for twelve months and MRI at baseline, six months, and twelve 
months. EDSS was administered by Dr. Ana Wing and Dr. Marcelo Kremenchutzky at St. 
Joseph’s Health Care, London, ON. MRI data was reviewed by Dr. Sarah Morrow at 
University Hospital, London, ON.  
6.2.6 Intestinal Permeability 
Patients were asked to drink a solution of 5 g of lactulose (Calbiochem®, EMD Millipore 
Corp., Billerica, MA), 2 g of mannitol powder (BDH®, VWR analytical, Mississauga, 
ON), 1.5 g of Kool Aid (Kraft Foods, Ingleside, ON), 100 g of sucrose, and 450 mL of tap 






subjects were asked to collect all the urine that they passed throughout the night and 
morning of their appointment and store it in a urine collection bottle. This bottle was 
brought to the clinic, the total volume of urine was recorded and then aliquoted into 10 mL. 
Concentrations of lactulose, mannitol and sucrose were determined using high 
performance liquid chromatography11. Urine samples were sent to the lab of Dr. Jon 
Meddings in Calgary, AB, at the end of the study to be analyzed. 
6.2.7 Fecal sample collection 
Fecal samples were collected from patients at each time point using a toilet paper sampling 
method12. Briefly, patients collected a visibly soiled piece of toilet paper after passing a 
stool 1-3 days before their scheduled appointment. The subjects placed the fecal sample in 
a Fisherbrand™ Opaque Sterile Sampling Bag (Fischer Scientific, ThermoFisher 
Scientific, Mississauga, ON). and brought it to their appointments. The samples were then 
frozen at - 80 °C until DNA extraction took place. Fecal samples were collected once per 
month for up to twelve months.  
6.2.8 DNA Extraction 
DNA from the toilet paper samples was extracted using the DNeasy® Powersoil® HTP 96 
Kit (Qiagen, Toronto, Ontario, Canada), as per the manufacturer’s instructions with the 
following modification: A centrifuge speed of 3700 x g for 10 minutes was used. Extracted 
DNA was stored at -20 °C until amplification.  
6.2.9 DNA Amplification 
The BioMek® 3000 Laboratory Automation Workstation for automated PCR reagent set 
up was used to load 10 µL (2.3 pmol/µL) of 32 primers (16 left and 16 right) with unique 
barcodes into 96 well plates. Amplifications of the V4 region of the 16S ribosomal 
RNA gene were carried out with the primers (5′-3′) 
ACACTCTTTCCCTACACGACGCTCTTCCGATCTNNNNxxxxxxxxGTGCCAGCMG







CHVGGGTWTCTAAT (xxxxxxxx is a sample specific nucleotide barcode and the 
preceding sequence is a portion of the Illumina adapter sequence for library construction). 
The BioMek® robot was then used to transfer 2 µL of template DNA into the primer 
containing 96 well plates. Then 20 μL of Promega GoTaq® Colourless Master Mix 
(Promega, Maddison, WI) was added to the DNA template and primers. The final plate 
was sealed with a foil PCR plate cover. This plate was placed in the Eppendorf 
Mastercycler® thermal cycler (Eppendorf, Mississauga, Ontario, Canada), where the lid 
was kept at 105 °C. An initial warm-up temperature of 95 °C was used for 2 min to activate 
the GoTaq®. Afterwards, the volumes underwent 25 cycles of 95 °C for 1 min, 50 °C for 
1 min, and 72 °C for 1 min. After completion, the temperature of the thermal cycler was 
held at 4 °C, and amplicons were then stored at -20 °C. 
6.2.10 DNA sequencing and data analysis 
Amplified DNA was sent to the London Regional Genomics Centre at Robarts Research 
Institute (Western University, London, Ontario, Canada). The samples were quantified 
(Quant-it, Life Technologies, Burlington, Ontario, Canada) and pooled at equimolar 
concentrations. The pooled libraries were cleaned using QIAquick (Qiagen, Germantown, 
Maryland, USA) and then sequenced using the MiSeq Illumina® platform, with 2 × 250 bp 
paired-end chemistry. The reads were demultiplexed and filtered using dada2 (version 1.8) 
and custom R scripts written by Greg Gloor (github.com/ggloor/miseq_bin). The 
demultiplexed reads will be available at NCBI SRA. Any taxa with less than 3 counts in 
30% of the samples were removed. Reads with 97% similarity were grouped into OTUs. 
Taxonomy was assigned using an RDP classifier provided by the dada2 package and 
trained against version 132 of the SILVA database. Diversity of the fecal microbiota was 
quantified based on Shannon’s index and was calculated using the Vegan package 
(github.com/vegandevs/vegan). Compositional distance between communities was 
quantified using the Aitchison distance with a prior count of 0.5 to avoid taking the log or 
ratio of zero counts13. ALDEx2 was used to identify differentially abundant taxa between 






6.2.11 Statistical Analysis 
Friedman test was used to compare EDSS at baseline to all subsequent time points. 
Wilcoxon matched-pairs signed rank test was used to compare biochemical test results in 
MS patients before and after FMT. Wilcoxon matched-pairs signed rank test was used to 
compare cytokine concentrations at baseline to subsequent time points. Wilcoxon matched-
pairs signed rank test was used to compare gut microbiota diversity of MS patients at 
baseline to subsequent time points. Mann-Whiney test was used to compare the gut 
microbiota diversity of donors to MS patients at baseline. Mann-Whitney test was used to 
compared Aitchison distance of patients that had received FMT to patients waiting to 
receive FMT. An effect size cutoff of > |3| was used for the ALDEx2 analysis. 
6.3 Results 
6.3.1 FMT was safe and tolerable in MS patients. 
The patients had a mean age of 46.1 ± 10.2 years, the average age of diagnosis was 32.1 ± 
8.5 years of age, and the average duration of MS was 15.9 ± 7.7 years. Adverse events were 







Table 6.1 Summary of adverse events  
Adverse Event Treatment Group (n=10) Related to Treatment 
Mild Moderate Severe Mild Moderate Severe 
Difficulty 
swallowing 
1 0 0 0 0 0 
Yeast Infection 1 0 0 0 0 0 
Influenza virus 1 0 0 0 0 0 
Diarrhea 2 0 0 0 0 0 
Common cold 1 0 0 0 0 0 
Nausea 2 0 0 0 0 0 
Vomiting 1 0 0 0 0 0 
Hypertension 0 1 0 0 0 0 
Kidney Stone 1 0 0 0 0 0 
Cramping 1 0 0 0 0 0 
Abdominal 
discomfort 
1 0 0 0 0 0 
Ear infection 1 0 0 0 0 0 
Extreme fatigue 1 0 0 0 0 0 
Routine blood work and urinalysis were performed, and vitals were taken at each 
appointment. There were no significant differences in these parameters following the 
administration of six FMTs (Supplementary Tables 6.1-6.3). At baseline the mean EDSS 
was 3.5 ± 2.0 (n=10). EDSS was measured at every visit and there was no significant 
change in EDSS following repeated FMTs (Figure 6.1). MRI was performed at baseline 
and 6 months as a safety measure since patients may have MRI activity even in the absence 






Figure 6.1 EDSS is stable following multiple FMTs. Patients received one FMT per 
month for six months and EDSS was measured at each visit. Six patients received all six 
FMTs and ten patients received at least one FMT. EDSS was calculated by the neurologist. 
Friedman test was used to compare the EDSS at baseline and subsequent time points, 
p=0.898.  
6.3.2 The gut microbiota composition was altered and differed by 
patient. 
Principal component analysis (PCA) plots of the fecal microbiota samples collected from 
patients that received FMTs from Donors 1 and 2 were constructed. The distance between 
samples represents how similar in microbial composition two samples are; samples that are 
close together are more similar in composition than samples that are farther apart. The PCA 
plots showed that 34.6 % and 28.1 % of the variance was explained in the first two principal 






































individual differences in fecal microbiota composition (Figures 6.2 and 6.3). Donors 1 and 
2 did not have a fecal microbiota composition that clustered separately from MS patients 
(Figures 6.2 and 6.3). Patients that received an FMT had a fecal microbiota composition 
that still closely resembled their initial profile at baseline compared to other patients or 










Figure 6.2 Principal component analysis of the fecal microbiota composition following 
FMT from Donor 1. Fecal samples were collected from patients one to three days before 
their scheduled appointments, the DNA was extracted and the V4 region of the 16S rRNA 
gene was amplified and sent for Illumina MiSeq next-generation sequencing. The resulting 
reads were used to generate a PCA in R (version 3.5.3). The first two components explain 
34.6 % of the variance. Donor 1 is shown in black (n=1; five time points) and each MS 






at baseline. Circles represent fecal microbiota samples collected following FMT. The 
number indicates how many FMTs had been received at that time point.  
 
Figure 6.3 Principal component analysis of the fecal microbiota composition following 
FMT from Donor 2. Fecal samples were collected from patients one to three days before 
their scheduled appointments, the DNA was extracted and the V4 region of the 16S rRNA 
gene was amplified and sent for Illumina MiSeq next-generation sequencing. The resulting 
reads were used to generate a PCA in R (version 3.5.3). The first two components explain 
28.1 % of the variance. Donor 2 is shown in black (n=1; five time points) and each MS 






at baseline. Circles represent fecal microbiota samples collected following FMT. The 
number indicates how many FMTs had been received at that time point. 
Differences between baseline microbiota composition and subsequent time-points were 
quantified using the Aitchison distance which provides a compositionally robust alternative 
to standard β-diversity metrics13. Aitchison distance increases as the bacterial composition 
of two samples are less similar to one another. There was no significant increase in the 
Aitchison distance of allogenic FMT recipient patients after six FMTs compared to MS 
patients that waited six months before receiving FMTs (Figure 6.4). Shannon’s diversity 
index was also calculated, and the donors were found to have a fecal microbiota diversity 
that was comparable to MS patients at baseline. MS patients did not undergo an increase 
in fecal microbiota diversity following repeated FMTs (Figure 6.5). 
Figure 6.4 The microbiota composition of patients that received an FMT did not 
change more than patients waiting to receive an FMT. Fecal samples were collected 
from patients one to three days before their scheduled appointments, the DNA was 
extracted and the V4 region of the 16S rRNA gene was amplified and sent for Illumina 
MiSeq next-generation sequencing. Compositional distance between communities was 
























quantified using the Aitchison distance with a prior count of 0.5 to avoid taking the log or 
ratio of zero counts. Data displayed is Aitchison distance from the baseline fecal microbiota 
composition compared to subsequent time points (1 month, 2 months, 3 months, 4 months, 
5 months, and 6 months) pre- (n=8) or post-FMT (n=10). Mann-Whitney t-test was used 
to compare Aitchison distance of patients who had received an FMT to patients that were 
waiting for an FMT at each time point.  
1 m FMT vs no FMT, p=0.1562 (Mann-Whitney) 
2 m FMT vs no FMT, p=0.4079 (Mann-Whitney) 
3 m FMT vs no FMT, p=0.3969 (Mann-Whitney) 
4 m FMT vs no FMT, p=0.2086 (Mann-Whitney) 
5 m FMT vs no FMT, p=0.8357 (Mann-Whitney) 
6 m FMT vs no FMT, p=0.3095 (Mann-Whitney) 
Figure 6.5 Fecal bacterial diversity of MS patients is not different from healthy 
donors and does not increase following repeated FMTs. Fecal samples were collected 
from patients one to three days before their scheduled appointments, the DNA was 
extracted and the V4 region of the 16S rRNA gene was amplified and sent for Illumina 
MiSeq next-generation sequencing. The resulting reads were used to calculate Shannon 
Diversity Index using the vegan package in R (version 3.5.3) 


















(github.com/vegandevs/vegan). Shannon Diversity Index of MS (n=10) patients at baseline 
and after 1 month (1 FMT), 2 months (2 FMTs), 3 months (3 FMTs), 4 months (4 FMTs), 
5 months (5 FMTs), 6 months (6 FMTs) and healthy donors (n=2) are displayed. Mann-
Whitney t-test was used to compare Shannon Diversity Index of healthy donors to MS 
patients at baseline. Wilcoxon match-pairs signed rank test was used to compare Shannon 
Diversity Index of MS patients at baseline to subsequent time points.  
Donors vs 0 m, p=0.353 (Mann-Whitney) 
MS 0 m vs 1 m (n=9), p=0.910 (Wilcoxon match-pairs signed rank test) 
MS 0 m vs 2 m (n=9), p>0.999 (Wilcoxon match-pairs signed rank test) 
MS 0 m vs 3 m (n=9), p=0.359 (Wilcoxon match-pairs signed rank test) 
MS 0 m vs 4 m (n=7), p=0.219 (Wilcoxon match-pairs signed rank test) 
MS 0 m vs 5 m (n=7), p=0.156 (Wilcoxon match-pairs signed rank test) 
MS 0 m vs 6 m (n=6), p=0.563 (Wilcoxon match-pairs signed rank test) 
ALDEx2 was used to identify any differentially abundant taxa between the gut microbiota 
composition at baseline and after one (n=10), two (n=9), three (n=8), four (n=7), five (n=7), 
or six (n=6) FMTs (Supplementary Figures 6.1-6.6). There were no significant changes in 
the composition of the gut microbiota of MS patients following FMTs that were conserved 
across all study participants (effect size > |3|)  
There were differences in the fecal microbiota composition observed at an individual level. 
A visual inspection was conducted on the bar plots of individual patients to determine what 
changes in relative abundance occurred throughout the course of the study. These changes 
are summarized in Table 6.2. Bar plots that show the relative abundance of bacterial genera 
of each patient before and after FMT are shown in Figure 6.6. A detailed analysis of each 
individual can be in Supplementary Figures 6.7-6.16. Seven of the ten participants, MK-
FMT-001, MK-FMT-004, MK-FMT-007, MK-FMT-008, MK-FMT-010, MK-FMT-011, 
MK-FMT-012, experienced a noticeable change in their overall microbiota composition 
following FMTs (Supplementary Figures 6.7, 6.10, 6.11, 6.12, 6.14, 6.15, 6.15) and three 






6.13). Three of the seven patients, MK-FMT-001, MK-FMT-010, MK-FMT-011, had 
persistent changes in their microbiota that were still present at the end study observation 
period (Supplementary Figures 6.7, 6.14, 6.15). One patient required three FMTs before a 
consistent change was observed in their microbiota and the other two patients required four 
FMTs. The other four patients, MK-FMT-004, MK-FMT-007, MK-FMT-008, MK-FMT-
012 had variable microbiota compositions that were different from baseline, but 
continually changed following subsequent FMTs (Supplementary Figures 6.10 and 6.11) 
or the duration of follow-up was too short to determine if the changes were persistent 
(Supplementary Figures 6.12 and 6.16). All patients experienced some change in the 
relative abundance of Bacteroides following FMT. Seven out of the ten participants had 
consistently decreased relative abundance of Bacteroides and the other three patients had 
an increase in the relative abundance of Bacteroides (Table 6.2). Donor 2 was characterized 
by a large relative abundance of Prevotella and three out of five MS patients that received 
FMTs from Donor 2 had an increase in the relative abundance of Prevotella (Figure 6.6). 
In one patient in particular, MK-FMT-011, it appeared that the increase in relative 
abundance of Prevotella was cumulative with subsequent FMT (Supplementary Figure 
6.15). Two patients experienced changes in the relative abundance of Faecalibacterium, 
one increased, MK-FMT-008, and one decreased, MK-FMT-004 following FMT 






Figure 6.6 Fecal microbiota composition of MS patients following FMTs. Fecal 
samples were collected from patients one to two days before their scheduled appointments, 
the DNA was extracted and the V4 region of the 16S rRNA gene was amplified and sent 
for Illumina MiSeq next-generation sequencing. The resulting reads were used to generate 
bar plots in base R (version 3.5.3). Each column represents the fecal microbiota 
composition at one time point. Four patients received FMTs from Donor 1 and six patients 
received FMTs from Donor 2. Patients that received FMTs from Donor 1 are in the top 
row of bar plots. Patients that received FMTs from Donor 2 are on the bottom row of bar 
plots. * represents the sample taken at baseline before any FMTs were administered. 
Subsequent time points include 1st FMT, 2nd FMT, 3rd FMT, 4th FMT, 5th FMT, and 6th 
FMT. One patient that received FMTs from Donor 1 did not submit a stool sample 
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Table 6.2 Individual changes in gut microbiota composition following FMT.  
Patient Donor 1st FMT 2nd FMT 3rd FMT 












MK-FMT-002 Donor 2 ↑ Bacteroides 
↓ Escherichia/ Shigella 
↑ Anaerofilum 
↑ Bacteroides 
↓ Escherichia/ Shigella 
↓ Unknown   
     Bacteroidetes 
↑ Bacteroides 
↓ Escherichia/Shigella 
↓ Unknown   
     Bacteroidetes 
MK-FMT-003 Donor 1  ↓ Bacteroides 
↑ Escherichia/Shigella 
↓ Bacteroides 
↑ Escherichia/ Shigella 























MK-FMT-009 Donor 2 ↑ Odoribacter ↓ Bacteroides ↓ Bacteroides 




MK-FMT-011 Donor 2  ↑ Akkermansia ↑ Bacteroides 
↑ Escherichia/Shigella 














Patient 4th FMT 5th FMT 6th FMT 














MK-FMT-002 ↑ Bacteroides 
↓ Escherichia/Shigella 
↓ Unknown   
     Bacteroidetes 
↑ Anaerofilum 
↑ Bacteroides 
↓ Escherichia/ Shigella 
↓ Unknown   
     Bacteroidetes 
↑ Bacteroides 
↓ Escherichia/Shigella 
↓ Unknown   
     Bacteroidetes 
























MK-FMT-008    
MK-FMT-009    
MK-FMT-010 ↑ Bacteroides 
 
↓ Bacteroides   
MK-FMT-011 ↓ Bacteroides 
↑ Prevotella 
↓ Bacteroides 




MK-FMT-012    
 
6.3.3 Abnormal intestinal permeability was improved following 
FMT in MS patients  
Five patients had their small intestinal permeability assessed at both baseline and following 
all six FMTs. Two patients had abnormal small intestinal permeability at baseline (>0.025 
Lactulose:Mannitol) (Figure 6.7). Both patients had normal small intestinal permeability 






Figure 6.7 Small intestinal permeability remained stable following repeated FMTs. 
Patients were asked to drink a solution of 5 g of lactulose, 2 g of mannitol powder, 1.5 g 
of Kool Aid, 100 g of sucrose, and 450 mL of tap water the evening before their 
appointments at baseline and following six FMTs. The subjects were asked to collect all 
the urine that they passed throughout the night and morning of their appointment and store 
it in a urine collection bottle. Concentrations of lactulose, mannitol and sucrose were 
determined using high performance liquid chromatography. Five patients had data for both 
baseline and following six FMTs (n=5). Wilcoxon matched-pairs signed rank test was used 
to compare lactulose:mannitol at baseline and six months (p=0.375). Abnormal intestinal 
permeability is > 0.025 lactulose:mannitol, which is represented by the red dotted line.  
6.4 Discussion 
This study was the largest to date of FMT therapy for MS patients. Overall, this study 
showed that FMT was safe in MS patients and that some patients experienced a change in 
the composition of the gut microbiota. The most common being the relative abundance of 
























increase in relative abundance in three of five patients that received an FMT from Donor 
2. Adverse events were documented throughout the course of the study and none were 
found to be related to the FMT therapy given (Table 6.1). Blood chemistry, hematology 
markers, and vitals, were taken at each appointment and there were no significant changes 
found in any of the parameters that were measured (Supplementary Tables 6.1-6.3). There 
were no significant changes observed in patients’ MRIs or EDSS over the duration of the 
study (Figure 6.1). Normal small intestinal permeability was found to be restored in both 
patients that had elevated small intestinal permeability (Figure 6.7). This data supported 
that FMT was a safe and well-tolerated intervention for MS patients. 
Aitchison distance was measured and the composition of the gut bacteria at baseline, before 
any FMTs, was compared to subsequent time points. A higher value of Aitchison distance 
would indicate that the composition of gut bacteria at that time point was more different in 
composition compared to the baseline sample it was being compared to. There was a trend 
that patients waiting for an FMT had a lower increase in Aitchison distance over time than 
those who received an FMT, but this was not statistically significant, likely due to the small 
sample size (Figure 6.4).   
An increase in fecal diversity of MS patients following FMT was not observed (Figure 
6.5). The MS patients had fecal diversity similar to that of the healthy donors so it would 
be unlikely that there would be an increase in fecal diversity if these patients did not have 
low fecal diversity at baseline. Additionally, a review of the literature did not find that low 
fecal diversity has been found as an alteration in the microbiome of MS patients15.  
Overall, there were no conserved changes in the fecal microbiota composition of MS 
patients following an FMT from a healthy donor (Table 6.2). However, at an individual 
level, there were patients that experienced a change in the gut microbiota composition 
following FMT. Seven patients had a change in their microbiota composition 
(Supplementary Figures 6.7, 6.10, 6.11, 6.12, 6.14, 6.15, 6.15). Three of these patients had 
persistent changes in the microbiota composition after three (Supplementary Figure 6.7) or 






FMTs were necessary to drive long-lasting changes in the microbiome. Three patients did 
not appear to have an alteration in the composition of their fecal microbiota following 
FMT, indicating that the donor microbiota may not have engrafted in these patients 
(Supplementary Figures 6.8, 6.9, 6.13). Two patients had variable microbiota compositions 
over time, and it was not apparent what changes were due to FMT or natural fluctuation in 
their microbiota composition (Supplementary Figures 6.10 and 6.11).  
Three patients that received FMTs from Donor 2 had an increase in the relative abundance 
of Prevotella and this persisted for the duration of observation (Supplementary Figures 
6.12, 6.15, and 6.16). Prevotella was the genus in highest relative abundance in Donor 2 
and it has been thought to be associated with health because it is found in higher relative 
abundance in people who eat a vegetarian diet16. Prevotella has been found to be in higher 
abundance in healthy controls versus MS patients17,18, but alternatively it has been found 
that a higher relative abundance of Prevotella can be related to an increase risk of 
developing rheumatoid arthritis19, another autoimmune disease. The relative abundance 
Bacteroides was altered in all patients after receiving an FMT. Seven out of ten patients 
had a decrease in the relative abundance Bacteroides following FMT. This change could 
be because the hosts’ Bacteroides was displaced by the FMT or it is possible that this 
decrease was due to the addition of the donor microbiota making the hosts’ Bacteroides 
appear less abundant because this is compositional data. Bacteroides has not been shown 
to be associated with MS.  
One patient had increased Akkermansia following FMT (Supplementary Figure 6.7) and 
Akkermansia has been shown to be elevated in MS patients compared to healthy controls, 
where it may be promoting the activation of pro-inflammatory T-cells17. This patient also 
had an increase in Parabacteroides following FMT and this genus has been found to be 
increased in healthy controls compared to MS patients5,18. Another patient had an increase 
in the relative abundance of Escherichia/Shigella following two FMTs and decreased after 
the fourth FMT (Supplementary Figure 6.9); this patient had diarrhea in the days leading 






history of recurrent yeast infections and reported subsequent yeast infections following the 
FMTs. Two patients experienced changes in the relative abundance of Faecalibacterium, 
one increased and one decreased following FMT (Supplementary Figures 6.12 and 6.10, 
respectively). Faecalibacterium has been found to be decreased in MS patients3,4 and since 
it is a known butyrate producer, FMT may be a beneficial method to increase the prevalence 
of Faecalibacterium and increase the concentration of butyrate in the gut. An increase in 
the relative abundance of butyrate producers, such Faecalibacterium species, through FMT 
may be the driving cause of improved gut barrier function20. 
Two of five MS patients had increased intestinal permeability (Figure 6.6). There have 
been several studies that have found a decrease in butyrate producing bacteria in MS 
patients compared to healthy controls3-5 and therefore it has been hypothesized that patients 
with MS would have increased small intestinal permeability. A review of the literature 
shows that 20%-73% of MS patients have abnormal small intestinal permeability, using 
the same methodology of measuring permeability as this study21,22. This was comparable 
to the 40% (2/5) of patients in this study that had abnormal small intestinal permeability. 
Both patients with abnormal intestinal permeability improved to within the normal range 
(<0.025 lactulose:mannitol) following FMT (Figure 6.6). A study with a larger sample size 
is needed to determine what changes in the microbiota may have caused this effect.  
Strengths of this study include that the microbiota of MS patients was followed for six 
months without any microbiome intervention as well as for six months following FMT. To 
our knowledge, this is the first longitudinal study of the microbiome of MS patients and 
shows that the gut microbiota composition of MS patient can fluctuate over time without 
microbial intervention. Also, repeated FMTs were administered in this study to ensure that 
changes in the gut microbiome persisted over time. Maintenance FMTs have proved to be 
beneficial at improving the efficacy of FMT for treating rCDI23,24 and were used in a 
previous FMT study involving three MS patients25. One of the limitations of this study was 
that patients did not receive a bowel prep or antibiotics prior to the initial FMT procedure, 






Additionally, the differences in fecal microbiota composition between individuals were 
larger than the changes in composition caused by administration of the FMT from a healthy 
donor, which made it difficult to determine what changes in the composition of bacteria 
were a result of an FMT.  
Overall, FMT was well tolerated and has the ability to alter the gut microbiota composition 
of MS patients, the changes in composition are variable between patients, and these 
alterations can persist with repeated FMT. Larger studies will be required to assess the 
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Chapter 7  
7 General Discussion 
7.1 Experimental Approach 
While significant research has gone into NAFLD and MS, both diseases continue to 
increase in prevalence each year. Exercise and diet are proven methods of treating and 
preventing NAFLD, while the cause of MS is poorly understood, and curative measures 
have not been found. The increase in prevalence of these conditions, as well as the 
reduction in quality of life that can be faced by these patients as these diseases progress, 
has led to the need of novel therapies. As both conditions have been shown to have 
alterations in the gut microbiome, FMT has been proposed as a potential treatment.  
While FMT has become more widely used, questions must be raised about the safety of 
donor selection and stool processing. The first goal of this thesis was to identify optimal 
methods to select healthy donors, and store and prepare fecal matter for FMT that result in 
the highest yield of viable bacteria, as this may be related to successful outcomes.  Stringent 
donor screening criteria were developed. The resultant FMT material was then tested in 
FMT clinical trials with patients with NAFLD or MS. This work provided valuable 
information about the role of the gut microbiome in these diseases, potentially through 
modulating intestinal permeability, which improved in patients that had abnormal intestinal 
permeability at baseline. This work justifies new larger studies to provide further 
information about how intestinal permeability is altered with FMT and if these benefits can 
be applied to patients with other conditions that are associated with abnormal intestinal 
permeability.  
7.2 Main Findings 
Diluents from published studies1-6, including water, saline, and 10 % glycerol, as well as 
stored as whole stool, were used to store samples at 4 °C for up to 7 days to test if samples 






also stored at -20 ° C and -80 °C long-term for 3 months. All samples experienced the 
greatest change in the composition of viable bacteria during the initial collection of the 
stool sample (Chapter 2; Figure 2.4a), which was approximately an hour or less in ambient 
air. Increases in the relative abundance of Alistipes, Bacteroides, and Parasutterella 
occurred during sample collection, meaning that these bacteria survived better than others, 
and therefore increased in relative abundance. Another study of FMT material stability 
noted that Alistipes increased in relative abundance after oxygen exposure and 
Faecalibacterium, Subdoligranulum, Eubacterium hallii, Eubacterium rectale, Roseburia, 
and Anaerostipes decreased7. These findings are interesting and add to the literature. It is 
difficult to determine how these changes in composition of the viable fecal microbiota 
would affect outcomes of FMT, as the composition of bacteria necessary for successful 
FMT has yet to determined. At a future date, when more is known about the essential 
bacteria required for FMT, results of this work can be used to determine if those bacteria 
are affected by storage and preparation. If a study showed lack of efficacy of FMT, then 
the composition of stool used could be compared to the results of this work to see if storage 
and handling impacted efficacy. 
Suspending samples in water resulted in an immediate and significant loss of total 
anaerobes, and the same effect was not observed when samples were suspended in saline 
or 10% glycerol (Figure 2.2). It was suspected that the initial drop in viability in samples 
stored in water was due to the hypotonic nature of water that caused cell lysis. Storage in 
saline and water resulted in greater losses of viable bacteria when samples were stored at -
20 °C and -80 °C (Figure 2.3 and 2.4, respectively). Saline and water did not offer any 
cryopreservative benefits and likely form more ice crystals during freezing than suspension 
with 10 % glycerol, or whole stool, which has a lower liquid content. Storage at -80°C 
suspended in 10 % glycerol or as whole stool resulted in the highest viability (Figure 2.4) 
and diversity of viable bacteria remained stable in these samples (Figure 2.7). 
 With the emergence of FMT capsules that occurred during this project, the stability of 






protocol from Kao et al.6. Their protocol had two separate freeze-thaws of the fecal material 
to form the capsules, and the protocol for this project fully formed the capsules before 
freezing to avoid a second freeze-thaw that may have impacted bacterial viability. The 
composition and concentration of viable bacteria was tested on fresh stool, immediately 
after encapsulation, and throughout storage at -80°C to examine the effects of capsule 
preparation, freeze-thaw, and storage at -80 °C. The largest decrease in bacterial viability 
occurred during the encapsulation process (Figure 3.2). Following this, viability was stable 
throughout storage (Figure 3.2). There were some differentially abundant bacteria that were 
identified to increase or decrease in relative abundance throughout storage and these varied 
by donor (Table 3.1). This is consistent with other studies that the stability of stool varies 
by donor7,8. The composition of the fecal microbiota of individual donors remained distinct 
throughout storage (Figure 3.3), despite the small changes in composition that were 
observed. This was important, as a significant change in the composition of bacteria being 
delivered during FMT may increase the risk of developing phenotypes of diseases with 
known alterations to the gut microbiome. After the appropriate method of storing and 
preparing fecal material for FMT was determined, the selection of FMT donors took place 
for the FMT clinical trials. 
Forty-six PDs offered to be tested, all of whom believed that they met the inclusion criteria. 
They underwent stringent screening for infectious and gastrointestinal diseases, and 
personal and family history of a variety of diseases with implications to the gut 
microbiome. Twenty-three of the 46 potential donors met exclusion criteria during pre-
screening. The most common reason for exclusion being a BMI > 25. Eighteen of the 
remaining 23 PDs failed the blood, urine, and stool screening for infectious diseases and 
biochemical tests. The most common reasons for exclusion at this step were the detection 
of B. hominis, D. fragilis, and H. pylori. Detection of B. hominis and D. fragilis were found 
by others to be leading reasons for exclusion9. Overall, 11% (5/46) PDs qualified to donate, 
which was at the lower end of reported rates of 10%-37% 9-12. Four of the five donors were 
excluded after two traveled to tropical countries and two experienced acute gastroenteritis 






agreement with other studies have mentioned the difficulty in retaining donors after initial 
successful screening10,12. The overall low acceptance and retention rates of PDs led to an 
increased cost of finding a suitable donor, as it cost approximately $15 190 USD to find a 
single donor. This led to our recommendation that a centralized stool bank be established 
as individual FMT clinics would likely be unable to fund their own donor screening 
programs, and to ensure that stool was available when patients came in for transplantation.  
After FMT donors were identified that met the inclusion criteria for extended screening for 
metabolic related diseases, the NAFLD-FMT clinical trial commenced. Twenty-one 
patients with NAFLD were randomized to receive an FMT from a thin and healthy donor 
(n=15; allogenic FMT) or their own stool (n=6; autologous FMT). The primary outcome 
of this study was insulin resistance, as measured by HOMA-IR. Previous work documented 
that insulin sensitivity could be improved in patients with metabolic syndrome when given 
an FMT from a thin and healthy donor13,14, but this study was not able to reproduce these 
findings (Figure 5.1). This could have been due to using different FMT donors, or 
measuring insulin resistance using HOMA-IR, instead of the more sensitive insulin clamp 
technique used by Vrieze et al.13 and Kootte et al.14, which was not available in London, 
ON or the surrounding area. Secondary outcomes of this study were magnetic resonance 
imaging-derived proton density fat fraction (PDFF) and small intestinal permeability. 
PDFF was not significantly different than baseline 6 months post-FMT (Figure 5.2). Seven 
of the fifteen patients in the allogenic FMT group had abnormal intestinal permeability 
(>0.025 lactulose:mannitol) before FMT and all seven patients experienced a reduction in 
small intestinal permeability following treatment (Figure 5.3a).  
There were no differentially abundant bacteria identified when baseline fecal microbiota 
compositions of all allogenic or autologous FMT recipients were compared to subsequent 
time points. Differences in the fecal microbiota composition of FMT recipients varied by 
individual (Figures 5.6 and 5.7), and therefore statistical analysis could not identify any 
differentially abundant bacteria that were consistent amongst all group members. This was 






composition. Metagenomic analysis may be required in the future to be able to detect these 
changes. There was a trend that fecal microbiota diversity increased in patients that had 
improved small intestinal permeability, but it was not statistically significant (Figure 5.5). 
Contrary to the literature14, HOMA-IR non-responders had a significant increase in fecal 
microbiota diversity following FMT (Figure 5.4).  
Based on the improvement in small intestinal permeability that was observed in the 
NAFLD patients, a subsequent clinical trial was designed and implemented for another 
condition, MS, with suspected gut microbiome differences and abnormal gut barrier 
function. Ten patients with MS were recruited to this study and randomized to either an 
early or late intervention group. Patients in the early intervention group received one FMT 
per month for the first six months of the study and were observed once per month for the 
final six months of the study. Patients in the late intervention group served as a control 
group and were observed once per month for the first six months of the study and then 
received one FMT per month for the last six months of the study. Due to the premature 
death of the principal investigator, this study was stopped, and only six of the ten patients 
received all six FMTs. As there have been no prior publications of FMT in MS patients in 
peer-reviewed journals, the primary outcomes of this study were safety, including: EDSS, 
MRI activity, and blood, urine, and stool biochemical tests.  
There were no significant changes in EDSS following FMT (Figure 6.1) nor new MRI 
activity developed following FMT (data not shown). Based on these findings, it was 
concluded that FMT was well tolerated and safe in MS patients. The fecal microbiota 
composition of patients was followed before and after FMTs, and similar to the NAFLD 
study, there were no differentially abundant bacteria identified using statistical 
measurements between baseline fecal microbiota compositions and subsequent timepoints. 
Each individual experienced different changes to the composition of their fecal microbiota. 
Donor 2 in this study was characterized by their high relative abundance of Prevotella, and 
three out of five MS patients who received this donor’s stool had an increase in the relative 






it was concluded that FMT could to alter the fecal microbiota of MS patients. Five patients 
completed the lactulose:mannitol urine test to assess small intestinal permeability before 
and after all six FMTs. Two patients had abnormal small intestinal permeability (>0.025 
lactulose:mannitol) and both improved following the full course of FMTs.  
7.3 Implications of Findings 
It has yet to be determined what is the full importance of bacterial cell viability in FMT 
treatments, but it is likely that the establishment of the donor microbiota in the recipients 
would be more challenging with reduced bacterial cell numbers. Both studies of the 
stability of FMT material identified the need to collect and process fecal samples in an 
anaerobic environment to try and prevent the initial loss and change in composition of 
viable bacteria that occurs during sample collection and processing before storage. The use 
of anaerobic jars to collect samples has recently been implemented by one research group 
to try and mitigate the effects of oxygen exposure during sample collection8. While there 
are practical limitations of using an anaerobic chamber to manufacture the material, as 
discussed in Chapter 3, the preservation of viable bacteria is critical as the necessary 
components of a successful FMT have yet to be identified.  
Direct application of this research is already occurring in the London, ON, FMT clinic. At 
the start of this project, only fresh fecal material, collected within four hours, was being 
used for FMT. Now whole stool can be refrigerated for longer than 4 hours at 4 °C. This 
was the method used for the NAFLD-FMT study, as the study began before the long-term 
storage results had been collected. It was then shown that the viability of whole stool was 
stable for up to three months at -80°C and the clinic began using these methods of 
collecting stool, which were implemented in the MS-FMT study. Without this research, it 
would be incredibly difficult to schedule donors to drop off fresh samples within the four-
hour window before a patient’s appointment and prepare the FMT. These methods allow 
the clinic to bank FMT material to use at a later date that still contained a similar number 






When this project began, the use of FMT capsules for rCDI had just recently been 
published15. Until then, FMTs were predominantly administered using nasojejunal16, 
enema1,16, or colonoscopy3,17-19. As the project progressed, research became available that 
FMT capsules were efficient at resolving rCDI4,6,15,20, that they were more appealing to 
patients6, and more cost efficient6. Thus, the stability of FMT capsules was also 
investigated and the concentration of viable bacteria in capsules was found to be stable 
during storage. This allowed us to prepare FMT capsules ahead of time and they could be 
used at a moment’s notice. This is an advantage over delivery through enema, which is 
commonly done at the FMT clinic in London, ON, as the process to prepare a fresh FMT 
takes up to one and a half hours and must be completed within an hour of the patient’s 
scheduled visit. The administration of capsules is easier and more pleasant for delivery as 
patients are able to take the capsules themselves, avoiding an invasive procedure. The 
proven stability of the FMT capsules during storage has led to further FMT clinical trials 
being developed by our research group using capsules as the method of delivery of FMT.  
It was found that different donors have different changes in viable bacteria during storage, 
and this phenomenon was noted by other studies of FMT material stability7,8. Differing 
changes in viable bacteria are likely a result of the unique inter-individual variation in the 
composition of the gut microbiome. While there were changes in the composition of viable 
bacteria, the total number of viable bacteria was comparable between donors during 
storage. If feasible in the future, clinics or stool banks could test each individual donor to 
determine how long their stool is stable for. 
Seven of twenty-one NAFLD patients and two of five MS patients had abnormal intestinal 
permeability at baseline and all of these patients experienced improvement following FMT. 
This indicates that FMT may be beneficial for a subset of patients with NAFLD and MS. 
It also raises the question of whether increased intestinal permeability is responsible for 
causing and/or progressing disease in all patients? It is of interest that all three donors from 
the NAFLD-FMT clinical trial and both donors from the MS clinical trial were able to 






using the extended screening criteria that we developed21, it was noteworthy that these 
parameters also selected for donors that could pass along the phenotype of normal intestinal 
barrier function in recipients that had abnormal permeability. Given that the numbers of 
patients with abnormal intestinal permeability and the number of donors were low in these 
studies, this theory should be tested in a larger number of patients with more FMT donors.  
The liver is thought to be affected by increased intestinal permeability because it is the first 
organ, after the intestine, to encounter the blood supply, making it most vulnerable to 
antigens that have passed through the intestinal lumen as a result of impaired intestinal 
barrier function22. The innate immune system in the liver can be activated by these antigens 
and cause inflammation23 leading to the development and progression of NAFLD24. If this 
clinical trial were to be repeated, a longer follow-up would be preferred to determine if 
PDFF improves after restoration of intestinal barrier function.  
The progression of MS is slow and approximately half of patients with RRMS will progress 
to SPMS within ten years of diagnosis25. Thus, the benefits of normal small intestinal 
permeability on disease progression require longer time frames to properly assess. This 
study followed patients for a maximum of twelve months, and a meta-analysis of the 
average number of relapses per year in RRMS has shown that it can range from 0.27 to 
1.66 26, therefore it was unlikely for a patient in this study to experience a relapse during 
follow-up. A future study with longer follow-up that could potentially assess if the rate of 
progression of MS can be slowed with FMT is required to determine if improved intestinal 
barrier function is beneficial to MS patients.  
Importantly, the results presented here represent the first study to show that intestinal 
permeability can be modulated with FMT. This has implications beyond the treatment of 
NAFLD and MS as a variety of conditions have been hypothesized to be caused or 
progressed by abnormal intestinal permeability, including rheumatoid arthritis27, type 1 






This therapy would be ideal for diseases that have slow progression, like MS, as damage 
sustained from autoimmune diseases would not likely be repaired through FMT but could 
potentially be halted from progressing further. Therefore, FMT for MS would ideally be 
given shortly after diagnosis to retain gut barrier function and to alter the microbiota that 
may have caused disease onset. Another autoimmune disease that has slower progression 
is type 1 diabetes mellitus. This condition has a ‘honeymoon’ period, where the pancreas 
is still able to produce some insulin, and less than the predicted amount of administered 
insulin is required to control blood glucose levels31. Ideally, FMT could be given to type 1 
diabetic patients at this stage to prolong the honeymoon period and slow the progression 
of the disease, but since ß islet cells cannot regenerate once they are lost32, FMT would not 
restore full function of the pancreas. A rat model supports this hypothesis by showing that 
the increase in intestinal permeability occurs before the onset of type 1 diabetes33. Latent 
autoimmune diabetes in adults (LADA), which is a slower progressing form of 
autoimmune related diabetes34, could be another potential application of FMT. At present 
it would be very difficult to predict who would go on to develop these diseases in humans 
and therefore it would not be practical to administer FMT prophylactically. 
7.4 Strengths 
7.4.1 Strengths of Model Organism Chosen 
One of the strengths of this research was that we were able to study the diseases NAFLD 
and MS in the model that naturally develops the disease, humans. While it is likely that the 
sample sizes for these studies could have been larger if an animal model, for example mice, 
were used, they may not accurately reflect how humans would respond to FMT therapy.  
Humans have distinct diets and gut physiology that differ from other animals that are 
commonly used as model organisms, and these differences can play a large role in the 
microorganisms that can survive and persist in the gut35. The gastrointestinal tract of 
different animal models can differ from humans in transit time, intestinal length, 
absorption, and pH35,36. Mice are most commonly used as the model organism for gut 






microorganisms that are markedly different from humans37. Eighty-five percent of bacteria 
found in the gut of mice are not found in humans38. To counteract this, some studies use 
gnotobiotic mice or administer antibiotics, and give FMTs from human participants to try 
to humanize the gut microbiome of mice39,40. Humans are not germ-free and studying the 
gut microbiome in this model may not be relevant. 
Obesity and the gut microbiome have been studied previously in mice as researchers found 
that an FMT from obese mice given to gnotobiotic mice caused significant weight gain and 
they believed that this was due to the increased energy harvesting potential of the obese 
gut microbiome41. A more recent study transplanted fecal matter from obese humans into 
gnotobiotic mice and there was significantly more weight gain observed than mice that 
received an FMT from the lean twins of the obese donor39. While the obese human donors 
had the same effect as the obese mice donors, these findings have never been replicated in 
human recipients. Studies have shown that the BMI of the FMT donor does not affect the 
BMI of a recipient post-transplant42,43. There has been one reported case of significant 
weight gain following FMT, but this weight gain was likely due to the recovery from rCDI, 
not FMT44. Mice do not normally develop NAFLD, but they can be induced to acquire the 
disease by a high-fat diet or genetic mutations that make mice resistant to leptin or produce 
non-functional leptin, so the sensation of satiety is suppressed45. Fibrosis can be developed 
in as early as six weeks when induced by diet46 or less than 3 months of age when 
genetically induced47. While the mice develop a NAFLD like disease, given that it is 
induced using different mechanisms than in humans, it is not truly reflective of NAFLD in 
humans.  
Similarly, mice do not naturally develop MS. There are two main models of MS-like 
disease in mice: experimental autoimmune encephalomyelitis (EAE) and Theiler’s Murine 
Encephalitis Virus-Induced Demyelinating Disease (TMEV-IDD). EAE can be induced by 
immunizing mice with myelin antigens or by administering myelin-specific T cells, both 
of which result in demyelination in the brain48. While these methods successfully result in 






demyelination through any mechanism in the gut, and therefore would not be relevant for 
an FMT study. Mouse models may not be appropriate for the study of NAFLD, MS and 
the gut microbiome, which is why a randomized control trial for humans was used instead. 
7.4.2 Strengths of Techniques Utilized 
One strength of this thesis was measuring changes in small intestinal permeability using 
the lactulose:mannitol urine test49. This test has been used as part of routine practice for 
over thirty years50. It is noninvasive, unlike assessing signs of increased intestinal 
permeability using histology on biopsies of the intestine51. The lactulose:mannitol test 
gives a quantitative output of intestinal permeability and is not subject to variation between 
histologists. Not all patients with increased intestinal permeability are detectable using 
histology52, and therefore lactulose:mannitol test can be more sensitive than biopsy. This 
test was well-tolerated in patients and compliance was high, as all patients completed this 
test at home.  
The use of PMA in combination with NGS was an additional strength of this study, as it 
limited the DNA from dead bacteria from being sequenced. PMA is able to bind to DNA 
from dead cells and free DNA, and therefore prevent its amplification during PCR and 
NGS53. Without PMA, this study would have been limited to identifying changes in viable 
bacteria in stool samples using culture-based techniques only. This would not have allowed 
the identification of what bacterial genera are most susceptible and resilient to the 
conditions that fecal samples are exposed to during preparation and storage before FMT. 
7.5 Limitations 
7.5.1 Limitations of FMT 
Beyond infection risk, one limitation of using FMT as a microbiome therapy is that the 
long-term safety surrounding FMT is unknown as this treatment is relatively new. There 
may be microbes present in fecal matter that are not presently being screened for in donors 
that could unknowingly be passed onto FMT recipients and cause complications in the 






bloating, low-grade fever, flatulence, constipation, diarrhea, nausea, and vomiting54. More 
serious adverse events have been reported that include the transmission of infectious 
agents, such as drug-resistant Escherichia coli55, bowel perforation56, and aspiration during 
sedation for FMT delivered by colonoscopy57. The latter two serious adverse events were 
related to the method of delivery of FMT, not the FMT material itself. It is incumbent upon 
FMT clinics and stool banks to expand the list of exclusion criteria for potential donors to 
improve the safety surrounding FMT. Overall, there have been very few serious adverse 
events reported for FMT, but long-term follow-up has yet to occur58. 
One potential limitation of our clinical trials was that we were unable to match FMT 
recipients to donors by sex, as this has been shown to cause differences in the composition 
the gut microbiome59. During the NAFLD-FMT clinical trial, the only female donor moved 
out of London, ON and was no longer available to donate. We were unable to find a female 
replacement throughout the course of the study so only a male donor was used. A similar 
problem was encountered in the MS-FMT clinical trial where the only two donors who met 
the strict donor screening criteria were male. Females are more likely to have both 
metabolic syndrome60 and MS61 than males. Differences in the gut microbiota of humans 
have been found between females and males that have metabolic syndrome. There have 
been higher relative abundances in the genera of Collinsella, Alistipes, Anaerotruncus, and 
Phascolarctobacterium in females with metabolic syndrome compared to males with 
metabolic syndrome62. Differences in the gut microbiota composition between females and 
males has not been reported in MS. It is possible that an FMT that causes beneficial effects 
in one sex, may not have the same effect in another sex if a different composition of bacteria 
may be driving the disease in females versus males. Individuals with low, medium, or high 
serum concentrations of testosterone in males or low, medium or high serum concentrations 
of estradiol in females had differences in the relative abundance of several genera in the 
fecal bacterial composition63. There are some concerns that FMTs from a differing sex may 
result in hormonal changes in the recipient. It was always our intention to match donors 






active donors would be needed to do this and samples from different sexes could be banked 
in the freezer to use at a later time.  
At present, it is difficult to predict what FMT donors will go on to result in successful 
FMTs, and like organ transplants, compatibility between recipients and donors may be 
required. The lack of improvement in insulin resistance and PDFF in the NAFLD-FMT 
study may been due to incompatible donors, and in the future this may be overcome as 
compatibility factors are elucidated. On the other hand, some studies have identified what 
they call “super-donors” who have higher rates of success than their other FMT donors64-
66. The reason for their high success rate has yet to be determined.  
7.5.2 Limitations of Microbiome Analysis 
A limitation of the toilet paper sampling method that was used to assess the fecal 
microbiota of patients that received FMT was that it did not assess changes in the 
microbiota composition of other areas of the gastrointestinal tract. The bacteria present on 
the toilet paper sample were likely more representative of the bacteria present on the 
mucosa in the distal colon, though this method is adequate to determine if there are major 
changes to the gut microbiota composition following FMT. There might have been changes 
in the composition of the gut microbiota in other regions of the GI tract as a result of FMT 
that were missed since they were not measured. However, taking samples of other sections 
of the GI tract would be costly and significantly more invasive for patients, like using an 
endoscopic brush to sample the small intestine67, which could have negatively affected 
patient recruitment and retention for theses clinical trials.  
We believe that the improvement in small intestinal permeability was in part due to 
increased production of butyrate by bacteria in the gut. One limitation of the two FMT 
clinical trials was that we did not measure of the concentration of SCFAs, such as butyrate, 
in the intestine of patients following FMT to determine if the improvement in small 
intestinal permeability was indeed correlated to its production by the gut microorganisms. 






procedure for patients to sample the intestinal lumen in the small intestine. Previous studies 
on the concentrations of SCFAs in the intestine have been performed on patients during 
surgery or post-mortem during autopsy68,69. We did not measure SCFAs in stool samples 
because the concentration of SCFAs in stool differs from those found in different regions 
of the intestine68 and the concentrations of SCFAs in stool do not necessarily relate to those 
at the sites of interest in the intestine. For example, butyrate can be overestimated if patients 
have shorter transit time, as there is less time butyrate to be absorbed by colonocytes before 
it exists the body70.  
If it were feasible to collect samples within the intestine, qPCR could also be used to 
determine the percentage of bacteria that possess the genes for butyrate production71. The 
proportion of butyrate producers could be examined to ascertain if the proportion of 
butyrate producers increased following FMT in patients that had improved small intestinal 
permeability. This technique could also be used on the stool samples that were collected 
from patients in both studies, however it is known that there are differences in the 
composition of bacteria in the small intestine versus stool72. The proportion of butyrate 
producers found in stool may not correlate with the proportion found in the small intestine.  
In order to conduct 16S rRNA gene sequencing analysis, extracted DNA needs to be 
amplified with barcoded primers using PCR. Subsequently, a library is prepared for 
Illumina NGS, it is sequenced, and the data analyzed using bioinformatic tools. There is 
inherent bias in all steps of 16S rRNA gene sequencing73. The largest source of bias is the 
initial PCR step to amplify DNA before sequencing73, as this occurs in the first step of 
library preparation and is carried on throughout the sequencing process. Universal primers 
for variable regions of the 16S rRNA gene can have primer bias and the 16S rRNA gene 
of different bacterial species can vary in amplification efficiencies74. This can lead to 
unequal amplification of different bacterial species and it can result in inaccurate relative 
abundances of bacteria being estimated during downstream analysis74. One way to 
overcome this would be to construct PCR-free Illumina libraries73, but this was not feasible 






Illumina sequencing run and the quantity of DNA in our samples was not large enough to 
bypass PCR. Using different thermocyclers and temperature ramp rates can also cause 
differences in library preparation for Illumina sequencing73. DNA sequences that have a 
G+C- and A+T-rich regions are amplified with lower efficiency and result in poorer quality 
library preparation for Illumina sequencing75. The same thermocycler and amplification 
protocol were used for all studies to eliminate variation. All of these sources of variation 
then contribute to bias when analyzing the 16S rRNA gene sequencing data using 
bioinformatics, as certain bacteria may be over or underrepresented in relative abundance.  
Another limitation of the microbiota analysis conducted for the NALFD and MS clinical 
trials was that metagenomic sequencing and analysis was not performed due to cost and 
infrastructure required to handle the large data sets that would be produced. The microbiota 
analysis that was performed only resolved bacteria to the genus level, and not species or 
strain which can be done with whole genome shot-gun sequencing76-77. If the bacterial 
strain of each OTU was resolved, the identity of bacterial strains that belonged to the donor 
and if those specific strains were transferred to FMT recipients could be determined. The 
percentage of bacteria originating from the donor could be calculated following the FMT 
and the change in percentage of engraftment could be measured quantitatively post-FMT 
to help to establish how long an FMT is retained in recipients. Metagenomics could also 
be used to identify major biochemical pathways employed by the microbiota population 
and give insight into what metabolites are being produced. The price of whole genome 
shot-gun sequencing is continuing to decrease, and this technique will be utilized for future 
FMT clinical trials performed by our research group.  
7.5.3 Limitations of Measuring Efficacy of FMT beyond rCDI 
For a condition such as rCDI, the measurement of efficacy of FMT is binary: either there 
is prevention of further relapse or there is not. There is no consensus for measuring efficacy 
of FMT for conditions beyond rCDI. This becomes challenging for complex diseases that 
have a variety of causes, unlike rCDI which is caused by a single pathogen, and can be 






patients over time. What if the FMT only improves one symptom of many that comprise a 
disease, should the FMT be considered effective? For the NAFLD-FMT clinical trial, there 
was improvement in small intestinal permeability, but not PDFF or insulin resistance. We 
believe that efficacy of FMT can be defined as an improvement in at least one disease 
outcome, as the possibility of seeing improvements in all indicators of a disease through 
FMT is unlikely. Engraftment of the donor may also need to be considered, however one 
study has shown that donor microbiota engraftment was not necessary for treating rCDI78. 
The same may not be true when FMT is used in other conditions.  
7.6 The Future of FMT 
The future of FMT therapy will likely include refinements to deliver the microorganisms 
or metabolites necessary for success without any unnecessary components of fecal matter. 
Until these components are identified, the way to best improve FMT may be to alleviate 
the burden of screening FMT donors. Being able to culture FMT material in the laboratory 
would be a benefit to FMT research, as one of the major limitations of establishing and 
running a stool bank is findings suitable donors9-12,21,79. In order to alleviate the need for 
human donors, a number of different methods could be used.  
If the microbes necessary for success of FMT are limited, then a probiotic containing these 
microorganisms could be developed to supplement the missing microbes from the gut 
microbiome. Probiotics comprised of Lactobacillus plantarum, Lactobacillus delbruekii, 
Lactobacillus acidophilus, Lactobacillus rhamnosus, and Bifidobacterium bifidum have 
been used in patients with NASH and they resulted in a decrease in PDFF80. This provides 
justification that for the conditions of NAFLD and MS, which are complex and 
multifaceted, a mixture or consortia of bacteria may be required.  
A product like SER-109, made by SERES Therapeutics that contains only bacterial spores 
has been reported to successfully treat rCDI81, however this product is still donor derived 
and is not cultured in vitro. An example of a consortia that is grown in the lab is MET-1, 






feces of a healthy human donor that can be grown in vitro in a chemostat model82. Growing 
up a fecal sample in a chemostat, an artificial gut model that can mimic the environment 
of different sections of the gastrointestinal tract, may prove beneficial since there would be 
no concern for transmission of disease since the bacteria are not grown in a human body. 
After the bacteria were isolated from a healthy donor, there would be no more need to 
recruit or screen healthy donors. This product would be defined and reproducible, unlike 
human feces, as the human gut microbiome composition is relatively stable, but it varies 
over time83. There are still limitations of culturing anaerobic bacteria in vitro and others 
have postulated that human derived FMT material could be cultured in the gut of an animal 
model, such as pigs, as they have been successfully colonized with human gut 
microbiomes84. Using an animal model could eliminate the need to screen for common 
human pathogens, as the model organisms are not hosts for these microbes. There are 
reservoirs of disease-free pigs that can be found in the sub-Antarctic Auckland Islands, 
isolated from human contact, that have been postulated to be suitable for in vivo cultivation 
of the human microbiome for FMT35 as they have already been successfully used for islet 
transplantation in patients with type 1 diabetes85.  
7.7 Conclusions and Future Directions 
There are a variety of methods currently in use to store and prepare fecal material for FMT, 
and this thesis has shown that there can be significant losses of bacteria as a result of these 
methods. While there does not appear to be an impact on the effectiveness of FMT for 
treating rCDI using FMT material prepared in a variety of ways, the expanded use of FMT 
for other conditions may be impacted by losses of vital microorganisms. Guidelines should 
be set in place for the storage and preparation of fecal material for FMT. Fecal samples 
should be stored at -80°C as whole stool or suspended in 10 % glycerol to result in the least 
amount of change in the composition and concentration of viable bacteria for stool samples 
prepared for delivery by enema, nasojejunal, endoscopy, or colonoscopy. FMT capsules 
are stable at -80 °C and can safely be stored long-term without significant decreases in 






likely benefit from anaerobic sample collection and processing and future work should be 
done to see if these methods improve bacterial viability. The optimized methods of storing 
and preparing fecal matter were used in both the NAFLD and MS clinical trials. FMT 
capsules are now being used for FMT clinical trials at the London, ON centre as they are 
able to be stored safely for long-term, they save time on the day of patients’ appointments, 
they are easily administered, are lower in cost, and have increased appeal for recipients.  
The donors selected using these expanded screening criteria were able to improve abnormal 
small intestinal permeability in both NAFLD and MS patients. It is widely hypothesized 
that improvements in abnormal intestinal permeability are a result of increased production 
of SCFAs, such as butyrate, by bacteria in the gut, which leads to an increase in tight 












Figure 7.1 FMT restores normal intestinal permeability by providing butyrate-
producing bacteria and increasing the prevalence of tight junction to limit 
paracellular transportation. The left side of the figure depicts abnormal intestinal 
permeability pre-FMT, where there is a decrease in butyrate producing microorganisms 
and a decrease in the number of tight junctions between intestinal epithelial cells. This 
leads to paracellular transport of microbial and dietary antigens across the intestinal 
epithelium into the lamina propria, which may contribute to the development and 
progression of MS and NAFLD through inflammation or activation of the immune system. 
Post-FMT there is an alteration in the microbial composition of the intestine, with an 
increase in the prevalence of butyrate producing bacteria leading to improved intestinal 
integrity, and microbial and dietary antigens are no longer able to pass paracellularly 
through the intestinal epithelium. 
Further work is needed to determine how FMT is able alter intestinal permeability and what 
components of FMT are necessary for this effect. The fecal microbiota was shown to 






responsible for the improvement or cause of abnormal small intestinal permeability. Future 
work should be conducted using metagenomics to be able to assign taxonomy down to the 
species and/or strain level to determine what bacteria originated from the donor and the 
extent and duration of donor fecal engraftment in recipients and changes in genes encoding 
major metabolic pathways. While FMT was not shown to improve NAFLD or metabolic 
syndrome, the benefits of normal small intestinal permeability may take longer to manifest 
than the 6 months of follow-up performed in this study. It was also concluded that FMT in 
MS patients was safe and tolerable. Both NAFLD and MS are important diseases 
worldwide due their significant burden on the health care system and progression of 
symptoms that can significantly impact quality of life. While there are a number of 
therapies available for both diseases that seek to reduce the symptoms or treat disease, none 
are particularly efficient, and the prevalence of both of these diseases are still increasing. 
Future studies with larger sample sizes and longer durations of follow-up will be required 
to assess the efficacy of this intervention in the treatment of NAFLD and MS. Overall, this 
work provided evidence that the use of FMT can be expanded to other conditions that have 
been shown to have abnormal intestinal permeability, including both autoimmune and 
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Glycerol **p=0.0036 p=0.4115 p=0.9151 p=0.5240 p=0.1292 p=0.1636 p=0.9102 
Whole 
Stool ****p<0.0001 p<0.9999 p=0.9955 p=0.9997 ***p=0.0002 **p=0.0013 *p=0.0121 
Saline ***p=0.0002 p=0.9974 p=0.1328 p=0.3391 *p=0.0131 **p=0.0044 ***p=0.0002 
Water **p=0.0027 *p=0.0187 p=0.1666 p=0.0881 p=0.9076 p=0.0532 p=0.1452 
 





























Blended ****p<0.0001 p=0.3955 p=0.6321 p=0.2596 p=0.9863 **p=0.0056 *p=0.0200 
4 Hours **p=0.0025 p=0.3629 p=0.3918 p=0.1130 *p=0.0231 **p=0.0028 p=0.9683 
24 
hours *p=0.0315 p=0.6526 p=0.1943 *p=0.0230 p=0.8311 p=0.2949 p=0.7915 
3 days ****p<0.0001 p=0.1143 p=0.9783 *p=0.0128 p=0.2475 ****p<0.0001 **p=0.0045 
5 days p=0.8215       
7 days p=0.0850       
 












1d Fresh vs 3d Fresh vs 5d Fresh vs 7d 
10 % 
Glycerol ****p<0.0001 p=0.2496 p=0.9425 p=0.3941 ****p<0.0001 ***p=0.0006 p=0.2410 
Whole 
Stool ****p<0.0001 p<0.9999 p=0.9998 p=0.1863 ****p<0.0001 *p=0.0257 ****p<0.0001 
Saline **p=0.0013 p=0.6919 p=0.1867 p=0.9996 **p=0.0033 **p=0.0059 p=0.0891 















































Blended ***p=0.0001 p=0.2403 p=0.9436 *p=0.0271 p=0.5447 ****p<0.0001 **p=0.0055 
4 Hours **p=0.0010 p=0.8611 **p=0.0018 *p=0.0487 *p=0.0141 p=0.2168 p=0.7046 
24 
hours **p=0.0018 p=0.9868 p=0.7019 **p=0.0065 p=0.5024 **p=0.0027 p=0.1084 
3 days p=0.6730       
5 days p=0.7733       
7 days p=0.1132       
 
 









 4 h 
Fresh vs 
1d 








l *p=0.0481 p=0.9627 p=0.9936 
p=0.166




1 p>0.9999 p=0.8981 
p=0.245
















































d **p=0.0024 p=0.8453 
**p=0.002
































































Fresh vs  
7d 
10 % 
Glycerol p=0.1383       
Whole 
Stool **p=0.0022 p>0.9999 p=0.9738 p=0.8261 p=0.1189 p=0.6040 p=0.0924 
Saline ****p<0.0001 p=0.1934 p=0.8057 p=0.2508 ***p=0.0010 p=0.0609 **p=0.0042 
Water p=0.3703       
 





























Blended ****p<0.0001 *p=0.0448 ***p=0.0003 ****p<0.0001 p=0.3800 p=0.1647 p=0.9618 
4 Hours p=0.3809       
24 
hours p=0.4177       
3 days **p=0.0081 p=0.2013 p=0.2281 p=0.6177 p=0.9999 *p=0.0197 *p=0.0232 
5 days p=0.1607       
7 days **p=0.0090 *p=0.0101 *p=0.0275 p=0.2097 p=0.9837 p=0.5914 p=0.8058 
 





Dunnett's Multiple Comparisons Test 
Fresh vs 
Blended 











Glycerol ****p<0.0001 **p=0.0086 ****p<0.0001 p=0.1939 p=0.9347 p=0.8993 p=0.9997 
Whole 
Stool *p=0.0204 p<0.9999 p=0.2277 p=0.8267 p=0.2774 p=0.9464 p=0.5957 
Saline ****p<0.0001 *p=0.0124 *p=0.0311 p=0.7478 p=0.0578 p=0.0822 p=0.2070 
Water ****p<0.0001 *p=0.0498 ****p<0.0001 p=0.5914 p=0.9999 p=0.9998 p=0.8671 
 





























Blended ***p=0.0001 ***p=0.0004 p=0.8791 p=0.9998 **p=0.0044 ***p=0.0005 p=0.9123 
4 Hours ***p=0.006 *p=0.0366 p=0.1046 p=0.7168 p=0.9987 **p=0.0017 **p=0.0094 
24 
hours p=0.1269       
3 days p=0.1612       
5 days p=0.2192       
















Dunnett's Multiple Comparisons Test 
Fresh vs 
Blended 




Fresh vs  
3d 





Glycerol ****p<0.0001 *p=0.0403 p=0.8170 
* 




Stool **p=0.0077 p>0.9999 p=0.4381 p=0.9997 p=0.7546 p=0.0736 p=0.9570 







Water *p=0.0311 p=0.6828 
** 





















































p<0.0001 *p=0.0253 **p=0.0024 
****p<0.000







































Fresh vs  
8 weeks 









p<0.0001 p=0.8996 p=0.0072 p=0.9298 p=0.4985 ****p<0.0001 
Saline 
**** 
p<0.0001 ****p<0.0001 ****p<0.0001 ****p<0.0001 ****p<0.0001 ****p<0.0001 
Water 
**** 














































p<0.0001 p=0.0760 *p=0.0211 p=0.0545 
***p=0.000

























p=0.0006 p=0.3227 p=0.5554 p=0.7672 p=0.0615 
 






Dunnett's Multiple Comparisons Test 
Fresh vs  
1 week 
Fresh vs  
2 weeks 
Fresh vs  
4 weeks 
Fresh vs  
8 weeks 
Fresh vs 
 12 weeks 
10 % 
Glycerol ****p<0.0001 p=0.3011 p=0.4812 p=0.8039 ****p<0.0001 ****p<0.0001 
Whole 
Stool ****p<0.0001 p=0.8794 p>0.9999 p=0.9989 p=0.4609 ****p<0.0001 
Saline ****p<0.0001 ****p<0.0001 ****p<0.0001 ****p<0.0001 ****p<0.0001 ****p<0.0001 
Water ****p<0.0001 p=0.9684 p=0.6447 **p=0.0089 **p=0.0032 ****p<0.0001 
 
Supplementary Table 2.16: Summary of statistics comparing Gram-positive anaerobes at -20 °C at 



























p=0.0034 p=0.8030 **p=0.0013 p=0.9994 ***p=0.0002 














p<0.0001 ****p<0.0001 p=0.9532 p=0.6607 
**** 
p<0.0001 **p=0.0032 p=0.2320 


















Fresh vs  
4 weeks 
Fresh vs 
 8 weeks 
Fresh vs 
 12 weeks 
10 % 
Glycerol p=0.5214      
Whole 
Stool ****p<0.0001 p=0.1010 **p=0.0031 *p=0.0371 ***p=0.0006 ****p<0.0001 
Saline ****p<0.0001 p=0.4973 **p=0.0015 ***p=0.0001 ****p<0.0001 ****p<0.0001 
Water p=0.3037      
 






















1wk *p=0.0388 *p=0.0466 p=0.2120 p=0.0781 p=0.8972 p=0.9964 p=0.9627 
2wk **p=0.0011 **p=0.0023 *p=0.0115 p=0.3781 p=0.9458 p=0.3005 p=0.2682 
4wk ***p=0.0008 p=0.0628 ***p=0.0003 p=0.0944 p=0.5594 p=0.9734 p=0.2203 
8wk ****p<0.0001 p=0.0685 ****p<0.0001 p=0.5176 
**** 
p<0.0001 p=0.8343 ***p=0.0001 
12wk ****p<0.0001 ****p<0.0001 ***p=0.0002 p=0.1272 p=0.6413 **p=0.0050 p=0.1103 
 




Dunnett's Multiple Comparisons Test 
Fresh vs  
1 week 
Fresh vs  
2 weeks 
Fresh vs 4 
weeks 
Fresh vs  
8 weeks 
Fresh vs  
12 weeks 
10 % 
Glycerol ****p<0.0001 p=0.8399 *p=0.0357 p=0.2767 ****p<0.0001 ****p<0.0001 
Whole 
Stool p=0.0624      
Saline **p=0.0082 p=0.5843 p=0.5974 p=0.1364 **p=0.0057 **p=0.0044 
Water **p=0.0028 *p=0.0457 p=0.2696 p=0.0716 ***p=0.0007 **p=0.0094 
 
























1wk p=0.1249       
2wk p=0.9620       
4wk p=0.3413       
8wk **p=0.0049 *p=0.0464 p=0.6405 p=0.9663 p=0.1542 *p=0.0108 p=0.3097 














Dunnett's Multiple Comparisons Test 
Fresh vs 
 1 week 
Fresh vs  
2 weeks 
Fresh vs  
4 weeks 
Fresh vs  
8 weeks 
Fresh vs  
12 weeks 
10 % 
Glycerol **p=0.0044 p=0.2029 *p=0.0143 p=0.0715 *p=0.0276 p=0.9997 
Whole 
Stool ****p<0.0001 p=0.8482 ***p=0.0001 *p=0.0101 **p=0.0034 ****p<0.0001 
Saline ****p<0.0001 ***p=0.0001 ****p<0.0001 ****p<0.0001 ****p<0.0001 ****p<0.0001 
Water **p=0.0016 *p=0.0199 p=0.7788 *p=0.0106 **p=0.0030 *p=0.0396 
 
Supplementary Table 2.22: Summary of statistics comparing Gram-negative aerobes at -20 °C at 
































































































Dunnett's Multiple Comparisons Test 
Fresh vs  
1 week 
Fresh vs  
2 weeks 
Fresh vs  
4 weeks 
Fresh vs  
8 weeks 
Fresh vs  
12 weeks 
10 % 
Glycerol *p=0.0301 p=0.7903 p=0.9259 p=0.1500 p=0.9960 **p=0.0086 
Whole 
Stool  **p=0.0074 p=0.9593 p=0.9844 p=0.0637 p=0.9839 p=0.1702 
Saline ****p<0.0001 ****p<0.0001 ****p<0.0001 ****p<0.0001 ****p<0.0001 ****p<0.0001 
Water ****p<0.0001 ****p<0.0001 ****p<0.0001 ****p<0.0001 p=0.7748 ****p<0.0001 
 

















































5 *p=0.0167 p=0.2947 
**p=0.007
































Dunnett's Multiple Comparisons Test 
Fresh vs 1 
week 
Fresh vs 
 2 weeks 
Fresh vs 
 4 weeks 
Fresh vs  
8 weeks 
Fresh vs  
12 weeks 
10 % 
Glycerol p=0.0570      
Whole 
































































p<0.0001 p=0.6893 p=0.7612 ****p<0.0001 ****p<0.0001 p=0.9993 
8wk 
**** 





p<0.0001 p=0.9430 p=0.7774 ****p<0.0001 ***p=0.0002 p=0.4721 
 


















Glycerol ****p<0.0001 *p=0.0137 ****p<0.0001 **p=0.0011 p=0.1241 ****p<0.0001 
Whole 
Stool **p=0.0067 p=0.3311 p=0.7432 p=0.8421 p=0.9910 p=0.1458 
Saline ****p<0.0001 p=0.2388 ****p<0.0001 ****p<0.0001 ****p<0.0001 ****p<0.0001 
Water **p=0.0042 p=0.9999 p=0.4677 *p=0.0321 p=0.9006 **p=0.0050 
 
Supplementary Table 2.28: Summary of statistics comparing Gram-positive anaerobes at -80 °C at 






















1wk *p=0.0131 **p=0.0099 p=0.8113 p=0.4718 p=0.0747 p=0.2487 p=0.9340 
2wk ***p=0.0003 ***p=0.0007 p=0.9190 p=0.4752 *p=0.0041 *p=0.0460 p=0.3527 
4wk 
**** 
p<0.0001 **p=0.0025 p=0.9112 p=0.9704 ***p=0.0003 **p=0.0021 p=0.9989 
8wk 
**** 
p<0.0001 p=0.6538 *p=0.0222 p=0.9292 
**** 
p<0.0001 p=0.9752 **p=0.0028 
12w













Dunnett's Multiple Comparisons Test 
Fresh vs 
 1 weeks 
Fresh vs  
2 weeks 
Fresh vs 
 4 weeks 
Fresh vs 
 8 weeks 
Fresh vs  
12 weeks 
10 % 
Glycerol p=0.4776     
 
Whole 
Stool ****p<0.0001 p=0.2458 p=0.1902 ***p=0.0009 ****p<0.0001 ****p<0.0001 
Saline ****p<0.0001 p=0.9958 p=0.1927 p=0.9493 ****p<0.0001 p=0.0018 
Water p=0.0622      
 























1wk *p=0.0490 *p=0.0380 p=0.5299 p=0.9398 p=0.4229 p=0.1244 p=0.8608 
2wk *p=0.0247 p=0.0536 p=0.1003 p=0.9432 p=0.9605 p=0.2900 p=0.2863 
4wk ***p=0.0001 ****p<0.0001 *p=0.0369 *p=0.0169 p=0.1928 p=0.2240 p=0.9982 
8wk **p=0.0029 p=0.1044 p=0.0736 p=0.9204 p=0.9958 *p=0.0163 *p=0.0106 
12wk ***p=0.0001 ***p=0.0001 *p=0.0237 p=0.9787 p=0.1084 ***p=0.0004 p=0.1274 
 

















Glycerol ****p<0.0001 p=0.9671 p=0.1295 p=0.1951 p=0.8080 ****p<0.0001 
Whole 
Stool ****p<0.0001 ****p<0.0001 ****p<0.0001 p=0.9068 *p=0.0233 p=0.2439 
Saline ****p<0.0001 p=0.9755 p=0.2283 **p=0.0017 ****p<0.0001 ****p<0.0001 
Water *p=0.0276 p=0.9997 p=0.4919 p=0.09911 p=0.2020 p=0.1081 
 
































p<0.0001 p=0.9540 p<0.9999 ****p<0.0001 ****p<0.0001 p=0.9616 





p<0.0001 p=0.3252 ****p<0.0001 ****p<0.0001 **p=0.0072 


























Glycerol ****p<0.0001 ****p<0.0001 ****p<0.0001 ****p<0.0001 p=0.7133 ***p=0.0008 
Whole 
Stool p=0.1095      
Saline ****p<0.0001 ****p<0.0001 ****p<0.0001 ****p<0.0001 ****p<0.0001 ****p<0.0001 
Water **p=0.0100 p=0.9998 p=0.6263 p=0.5838 *p=0.0158 p=0.9794 
 
Supplementary Table 2.34: Summary of statistics comparing Gram-negative aerobes at -80 °C at 






































p<0.0001 ****p<0.0001 ****p<0.0001 **p=0.0027 p=0.9813 **p=0.0024 
8wk 
**** 





p<0.0001 ****p<0.0001 **p=0.0013 *p=0.0180 *p=0.0315 ****p<0.0001 
 


















Glycerol p=0.0570      
Whole 
Stool *p=0.0158 p=0.2302 p=0.9864 p=0.7144 p=0.9421 p=0.4508 
Saline ****p<0.0001 ****p<0.0001 ****p<0.0001 ****p<0.0001 ****p<0.0001 ****p<0.0001 





















































2wk ***p=0.0006 p=0.3156 p=0.0748 p=0.0999 **p=0.0033 **p=0.0047 p=0.9995 


























Appendix B – Chapter 3 Supplementary Material 
 
Supplementary Table 3.1: Summary of statistics for viable total anaerobes throughout preparation 















































































































Supplementary Table 3.2: Summary of statistics comparing viable total anaerobes at each time point 




Tukey’s Multiple Comparison Test 
Donor 1 vs Donor 2 
 
Donor 1 vs Donor 3 
 
Donor 2 vs Donor 3 
 
Fresh p=0.9778    
Capsule p=0.1943    
1 d ****p<0.0001 p=0.9055 ***p=0.0001 ***p=0.0002 
3 d ****p<0.0001 ****p<0.0001 p=0.2234 ****p<0.0001 
5 d p=0.6399    
1 wk ***p=0.0007 ***p=0.0006 **p=0.0053 p=0.0834 
2 wk p=0.1862    
1 m p=0.1774    
2 m ***p=0.0010 **p=0.0068 ***p=0.0009 p=0.1167 
 
 
Supplementary Table 3.3: Summary of statistics for viable Gram-positive anaerobes throughout 






















Fresh vs  
1 m 
 

























































































Supplementary Table 3.4: Summary of statistics comparing viable Gram-positive anaerobes at each 




Tukey’s Multiple Comparison Test 
Donor 1 vs Donor 2 
 
Donor 1 vs Donor 3 
 
Donor 2 vs Donor 3 
 
Fresh p=0.3125    
Capsule p=0.3973    
1 d *p=0.0141 p=0.9882 *p=0.0203 *p=0.0240 
3 d ****p<0.0001 ****p<0.0001 *p=0.0465 ****p<0.0001 
5 d **p=0.0030 p=0.0654 **p=0.0024 *p=0.0484 
1 wk ***p=0.0004 ***p=0.0003 **p=0.0037 *p=0.0368 
2 wk ***p=0.0005 ***p=0.0008 p=0.9987 ***p=0.0008 
1 m p=0.0514    
2 m p=0.1145    
 
























Fresh vs  
1 m 
 















































































Tukey’s Multiple Comparison Test 
Donor 1 vs Donor 2 
 
Donor 1 vs Donor 3 
 
Donor 2 vs Donor 3 
 
Fresh *p=0.0127 *p=0.0170 p=0.9518 *p=0.0239 
Capsule *p=0.0369 *p=0.0310 p=0.2328 p=0.3110 
1 d ****p<0.0001 ****p<0.0001 p=0.4649 ****p<0.0001 
3 d ***p=0.0001 ***p=0.0002 p=0.8493 ***p=0.0002 
5 d ****p<0.0001 ****p<0.0001 ****p<0.0001 **p=0.0043 
1 wk **p=0.0013 **p=0.0033 **p=0.0017 p=0.7300 
2 wk ****p<0.0001 ****p<0.0001 ***p=0.0008 ****p<0.0001 
1 m ***p=0.0001 ***p=0.0002 ***p=0.0003 p=0.7188 












Supplementary Table 3.7: Summary of statistics for viable bifidobacteria throughout preparation 























Fresh vs  
1 m 
 
Fresh vs  
2 m 




























































Supplementary Table 3.8: Summary of statistics comparing viable bifidobacteria at each time point 




Tukey’s Multiple Comparison Test 
Donor 1 vs Donor 2 
 
Donor 1 vs Donor 3 
 
Donor 2 vs Donor 3 
 
Fresh *p=0.0147 *p=0.0127 p=0.3367 p=0.0788 
Capsule **p=0.0079 **p=0.0084 *p=0.0230 p=0.6446 
1 d ****p<0.0001 ***p=0.0001 ***p=0.0001 p=0.8792 
3 d ****p<0.0001 ***p=0.0002 ***p=0.0001 p=0.8411 
5 d ****p<0.0001 ****p<0.0001 ****p<0.0001 p=0.6634 
1 wk ***p=0.0006 ***p=0.0006 **p=0.0037 p=0.5205 
2 wk ****p<0.0001 ****p<0.0001 ****p<0.0001 p=0.1321 
1 m **p=0.0010 ****p<0.0001 ***p=0.0006 p=0.1635 
2 m ****p<0.0001 ****p<0.0001 ****p<0.0001 p=0.3993 
 
 
Supplementary Table 3.9: Summary of statistics for viable Gram-negative aerobes throughout 























Fresh vs  
1 m 
 






























































Supplementary Table 3.10: Summary of statistics comparing viable Gram-negative aerobes at each 




Tukey’s Multiple Comparison Test 
Donor 1 vs Donor 2 
 
Donor 1 vs Donor 3 
 
Donor 2 vs Donor 3 
 
Fresh **p=0.0030 p=0.6642 **p=0.0083 **p=0.0035 
Capsule ****p<0.0001 ***p=0.0002 ****p<0.0001 ****p<0.0001 
1 d **p=0.0014 **p=0.0038 p=0.6478 **p=0.0017 
3 d ****p<0.0001 p=0.1842 ***p=0.0003 ****p<0.0001 
5 d **p=0.0017 *p=0.0483 *p=0.0289 **p=0.0014 
1 wk ***p=0.0005 **p=0.0068 *p=0.0278 ***p=0.0004 
2 wk **p=0.0014 **p=0.0011 p=0.0576 *p=0.0182 
1 m **p=0.0043 *p=0.0191 p=0.3519 **p=0.0040 
2 m ****p<0.0001 **p=0.0055 **p=0.0012 ****p<0.0001 
 
Supplementary Table 3.11: Summary of statistics for viable Gram-positive aerobes throughout 























Fresh vs  
1 m 
 










































































Supplementary Table 3.12: Summary of statistics comparing viable Gram-positive aerobes at each 




Tukey’s Multiple Comparison Test 
Donor 1 vs Donor 2 
 
Donor 1 vs Donor 3 
 
Donor 2 vs Donor 3 
 
Fresh *p=0.0275 *p=0.0369 p=0.9800 *p=0.0465 
Capsule ****p<0.0001 ****p<0.0001 p=0.9877 ****p<0.0001 
1 d **p=0.0028 **p=0.0031 p=0.5569 **p=0.0087 
3 d *p=0.0212 *p=0.0191 p=0.4609 p=0.0883 
5 d **p=0.0040 **p=0.0039 p=0.4041 *p=0.0160 
1 wk **p=0.0011 **p=0.0015 p=0.7545 **p=0.0027 
2 wk **p=0.0010 **p=0.0017 p=0.9871 **p=0.0019 
1 m ***p=0.0004 ***p=0.0005 p=0.6428 **p=0.0011 












Supplementary Table 3.13: Summary of statistics for Shannon Diversity Index of viable bacteria 






















Fresh vs  
1 m 
 






































3 p=0.1603      NA   
 
Supplementary Table 3.14: Summary of statistics comparing Shannon Diversity Index at each time 




Tukey’s Multiple Comparison Test 
Donor 1 vs Donor 2 
 
Donor 1 vs Donor 3 
 
Donor 2 vs Donor 3 
 
Fresh *p=0.0185 p=0.8765 *p=0.0220 *p=0.0394 
Capsule ****p<0.0001 ***p=0.0002 **p=0.0018 ****p<0.0001 
1 d ***p=0.0002 *p=0.0417 **p=0.0012 ***p=0.0001 
3 d ***p=0.0006 p=0.4390 **p=0.0020 ***p=0.0007 
5 d ****p<0.0001 p=0.8380 ****p<0.0001 ****p<0.0001 
1 wk ***p=0.0006 p=0.5138 **p=0.0017 ***p=0.0007 
2 wk NA p=0.0772 NA NA 
1 m ****p<0.0001 p=0.0505 ****p<0.0001 ****p<0.0001 
2 m NA NA NA ***p=0.0001 







Appendix C – Chapter 5 Supplementary Material 
Supplementary Table 5.1 Summary of appointments and sample collection. 
 Baseline 2 days 7 days 2 weeks 6 weeks 3 months 6 months 
FMT X       
Fecal 
Specimen 
X       
MRI X      X 
Urine X    X   
Diet History 
Questionnaire  
X    X   
Blood X   X X  X 
Toilet Paper X X X X X X X 
Supplementary Table 5.2 Summary of FMT donor characteristics. 
 Donor 1 Donor 2 Donor 3 
Age (years) 28 22 23 
Sex M F M 
BMI 23.9 19.18 21.6 
Hgb A1c (%) 5.2 5.2 4.8 
Total Cholesterol 
(mmol/L) 
4.71 4.22 4.25 
HDL (mmol/L) 1.48 1.13 1.31 
LDL (mmol/L) 2.98 2.14 3.2 
Triglycerides 
(mmol/L) 
0.54 2.09 1.62 
ALT (U/L) 16 8 20 
ALK phos (U/L) 27 111 80 
Total bilirubin 
(µmol/L) 
30.4 5 10 




















1 Allogenic F4  31.457% 
2 Allogenic F0/1  32.908% 
3 Allogenic F1 4 (steatosis 2, lobular 
inflammation 1, ballooning 1) 
21.287% 
4 Allogenic F3 2 (steatosis 1, lobular 
inflammation 1) 
19.253% 
5 Allogenic F2  17.524% 
6 Allogenic F2  19.253% 
7 Allogenic F4  18.485% 
8 Allogenic F2 2 (steatosis 1, lobular 
inflammation 1) 
15.008% 
9 Allogenic F3  11.971% 
10 Allogenic F1  11.509% 
11 Allogenic F4 3 (steatosis 1, lobular 
inflammation 1, ballooning 1) 
15.941% 
12 Allogenic F0 1 (steatosis 1) 12.097% 
13 Allogenic F0/1  9.244% 
14 Allogenic F0/1  15.456% 
15 Allogenic F0/1  31.165% 







2 (steatosis 1, inflammation 1)  
32.378% 
18 Autologous F4 2 (steatosis 2) 2.219% 
 
19 
Autologous F1 4 (steatosis 2, lobular 
inflammation 1, ballooning 1) 
 
20 Autologous F0/1  28.379% 
21 Autologous F0/1  32.512% 
Nine patients had fibrosis staged by biopsy, seven patients were staged with fibroscan, 
and five patients were staged with MR elastography. All had steatosis documented by 
ultrasound. 
NAFLD Activity Scores (NAS) are provided for those patients who underwent liver 
biopsy (25). 







Supplementary Figure 5.1 Small intestinal permeability was not related to fibrosis 
score at baseline. Small intestinal permeability was determined using the 
lactulose:mannitol urine test. A ratio above 0.025 was considered to be abnormal. Fibrosis 
score (F0-F4) was determined by biopsy, fibroscan, or MR elastrography. Kruskal-Wallis 
test was used to compare the mean small intestinal permeability for each fibrosis score to 









Supplementary Figure 5.2 Fecal microbiome comparison at baseline between 
allogenic FMT recipients with abnormally high small intestinal permeability versus 
patients with normal permeability. Fecal samples were collected by patients one day 
before their scheduled appointments, the DNA was extracted and the V4 region of the 16S 
rRNA gene was amplified and sent for Illumina MiSeq next-generation sequencing. The 
resulting reads were analyzed using ALDEx2 (version 3.9) in R (version 3.5.3) to identify 
differentially abundant genera. There were no significant changes in the composition of 
fecal bacteria of NAFLD patients with abnormally high small intestinal permeability 
compared to NAFLD patients with normal small intestinal permeability at baseline. Non-
significant genera that are rare are shown in black and non-significant genera that are 
abundant are shown in grey. Significant genera would be shown in red (effect size >|3|).  






















































































































































































Supplementary Figure 5.3 Fecal microbiome comparison between baseline and 6 
weeks in allogenic FMT recipients with abnormally high small intestinal 
permeability. Fecal samples were collected by patients one day before their scheduled 
appointments, the DNA was extracted and the V4 region of the 16S rRNA gene was 
amplified and sent for Illumina MiSeq next-generation sequencing. The resulting reads 
were analyzed using ALDEx2 (version 3.9) in R (version 3.5.3) to identify differentially 
abundant genera. There were no significant changes in the composition of fecal bacteria of 
NAFLD patients with abnormally high permeability at baseline compared to 6 weeks 
following the FMT. Non-significant genera that are rare are shown in black and non-
significant genera that are abundant are shown in grey. Significant genera would be shown 
in red (effect size >|3|). 





















































































































































































Supplementary Figure 5.4 Fecal microbiome comparison between baseline and 6 
weeks in allogenic FMT recipients. Fecal samples were collected by patients one day 
before their scheduled appointments, the DNA was extracted and the V4 region of the 16S 
rRNA gene was amplified and sent for Illumina MiSeq next-generation sequencing. The 
resulting reads were analyzed using ALDEx2 (version 3.9) in R (version 3.5.3) to identify 
differentially abundant genera. There were no significant changes in the composition of 
fecal bacteria of NAFLD patients with abnormally high permeability at baseline compared 
to 6 weeks following the FMT. Non-significant genera that are rare are shown in black and 
non-significant genera that are abundant are shown in grey. Significant genera would be 
shown in red (effect size >|3|). 


































































































































































































































Supplementary Figure 5.5 Fecal microbiota composition of Donor 1 throughout the 
clinical trial. Toilet paper samples were collected from the donor every three months 
throughout the study. The DNA was extracted and the V4 region of the 16S rRNA gene 
was amplified and sent for Illumina MiSeq next-generation sequencing. The resulting reads 
were used to generate bar plots in base R (version 3.5.3). Each column represents the fecal 








Supplementary Figure 5.6 Fecal microbiota composition of Patient 1 following an 
allogenic FMT. Patient 1 received an allogenic FMT from Donor 1. Toilet paper samples 
were collected from patients at baseline, 2 days, 7 days, 2 weeks, 6 weeks, 3 months, and 
6 months post-FMT. The DNA was extracted and the V4 region of the 16S rRNA gene 
was amplified and sent for Illumina MiSeq next-generation sequencing. The resulting reads 
were used to generate bar plots in base R (version 3.5.3). Each column represents the fecal 








Supplementary Figure 5.7 Fecal microbiota composition of Patient 2 following an 
allogenic FMT. Patient 2 received an allogenic FMT from Donor 3. Toilet paper samples 
were collected from patients at baseline, 2 days, 7 days, 2 weeks, 6 weeks, 3 months, and 
6 months post-FMT. The DNA was extracted and the V4 region of the 16S rRNA gene 
was amplified and sent for Illumina MiSeq next-generation sequencing. The resulting reads 
were used to generate bar plots in base R (version 3.5.3). Each column represents the fecal 








Supplementary Figure 5.8 Fecal microbiota composition of Patient 3 following an 
allogenic FMT. Patient 3 received an allogenic FMT from Donor 1. Toilet paper samples 
were collected from patients at baseline, 2 days, 7 days, 2 weeks, 6 weeks, 3 months, and 
6 months post-FMT. The DNA was extracted and the V4 region of the 16S rRNA gene 
was amplified and sent for Illumina MiSeq next-generation sequencing. The resulting reads 
were used to generate bar plots in base R (version 3.5.3). Each column represents the fecal 










Supplementary Figure 5.9 Fecal microbiota composition of Patient 4 following 
allogenic FMT. Patient 4 received an allogenic FMT from Donor 1. Toilet paper samples 
were collected from patients at baseline, 2 days, 7 days, 2 weeks, 6 weeks, 3 months, and 
6 months post-FMT. The DNA was extracted and the V4 region of the 16S rRNA gene 
was amplified and sent for Illumina MiSeq next-generation sequencing. The resulting reads 
were used to generate bar plots in base R (version 3.5.3). Each column represents the fecal 








Supplementary Figure 5.10 Fecal microbiota composition of Patient 5 following 
allogenic FMT. Patient 5 received an allogenic FMT from Donor 1. Toilet paper samples 
were collected from patients at baseline, 2 days, 7 days, 2 weeks, 6 weeks, 3 months, and 
6 months post-FMT. The DNA was extracted and the V4 region of the 16S rRNA gene 
was amplified and sent for Illumina MiSeq next-generation sequencing. The resulting reads 
were used to generate bar plots in base R (version 3.5.3). Each column represents the fecal 







Supplementary Figure 5.11 Fecal microbiota composition of Patient 6 following an 
allogenic FMT. Patient 6 received an allogenic FMT from Donor 1. Toilet paper samples 
were collected from patients at baseline, 2 days, 7 days, 2 weeks, 6 weeks, 3 months, and 
6 months post-FMT. The DNA was extracted and the V4 region of the 16S rRNA gene 
was amplified and sent for Illumina MiSeq next-generation sequencing. The resulting reads 
were used to generate bar plots in base R (version 3.5.3). Each column represents the fecal 








Supplementary Figure 5.12 Fecal microbiota composition of Patient 7 following an 
allogenic FMT. Patient 7 received an allogenic FMT from Donor 1. Toilet paper samples 
were collected from patients at baseline, 2 days, 7 days, 2 weeks, 6 weeks, 3 months, and 
6 months post-FMT. The DNA was extracted and the V4 region of the 16S rRNA gene 
was amplified and sent for Illumina MiSeq next-generation sequencing. The resulting reads 
were used to generate bar plots in base R (version 3.5.3). Each column represents the fecal 








Supplementary Figure 5.13 Fecal microbiota composition of Patient 8 following an 
allogenic FMT. Patient 8 received an allogenic FMT from Donor 1. Toilet paper samples 
were collected from patients at baseline, 2 days, 7 days, 2 weeks, 6 weeks, 3 months, and 
6 months post-FMT. The DNA was extracted and the V4 region of the 16S rRNA gene 
was amplified and sent for Illumina MiSeq next-generation sequencing. The resulting reads 
were used to generate bar plots in base R (version 3.5.3). Each column represents the fecal 








Supplementary Figure 5.14 Fecal microbiota composition of Patient 9 following an 
allogenic FMT. Patient 9 received an allogenic FMT from Donor 1. Toilet paper samples 
were collected from the patient at baseline, 2 days, 7 days, 2 weeks, 6 weeks, 3 months, 
and 6 months post-FMT. The DNA was extracted and the V4 region of the 16S rRNA gene 
was amplified and sent for Illumina MiSeq next-generation sequencing. The resulting reads 
were used to generate bar plots in base R (version 3.5.3). Each column represents the fecal 








Supplementary Figure 5.15 Fecal microbiota composition of Patient 10 following an 
allogenic FMT. Patient 10 received an allogenic FMT from Donor 2. Toilet paper samples 
were collected from patients at baseline, 2 days, 7 days, 2 weeks, 6 weeks, 3 months, and 
6 months post-FMT. The DNA was extracted and the V4 region of the 16S rRNA gene 
was amplified and sent for Illumina MiSeq next-generation sequencing. The resulting reads 
were used to generate bar plots in base R (version 3.5.3). Each column represents the fecal 







Supplementary Figure 5.16 Fecal microbiota composition of Patient 11 following an 
allogenic FMT. Patient 11 received an allogenic FMT from Donor 2. Toilet paper samples 
were collected from patients at baseline, 2 days, 7 days, 2 weeks, 6 weeks, 3 months, and 
6 months post-FMT. The DNA was extracted and the V4 region of the 16S rRNA gene 
was amplified and sent for Illumina MiSeq next-generation sequencing. The resulting reads 
were used to generate bar plots in base R (version 3.5.3). Each column represents the fecal 







Supplementary Figure 5.17 Fecal microbiota composition of Patient 12 following an 
allogenic FMT. Patient 12 received an allogenic FMT from Donor 1. Toilet paper samples 
were collected from patients at baseline, 2 days, 7 days, 2 weeks, 6 weeks, 3 months, and 
6 months post-FMT. The DNA was extracted and the V4 region of the 16S rRNA gene 
was amplified and sent for Illumina MiSeq next-generation sequencing. The resulting reads 
were used to generate bar plots in base R (version 3.5.3). Each column represents the fecal 







Supplementary Figure 5.18 Fecal microbiota composition of Patient 14 following an 
allogenic FMT. Patient 14 received an allogenic FMT from Donor 1. Toilet paper samples 
were collected from patients at baseline, 2 days, 7 days, 2 weeks, 6 weeks, 3 months, and 
6 months post-FMT. The DNA was extracted and the V4 region of the 16S rRNA gene 
was amplified and sent for Illumina MiSeq next-generation sequencing. The resulting reads 
were used to generate bar plots in base R (version 3.5.3). Each column represents the fecal 









Supplementary Figure 5.19 Fecal microbiota composition of Patient 15 following an 
allogenic FMT. Patient 15 received an allogenic FMT from Donor 1. Toilet paper samples 
were collected from patients at baseline, 2 days, 7 days, 2 weeks, 6 weeks, 3 months, and 
6 months post-FMT. The DNA was extracted and the V4 region of the 16S rRNA gene 
was amplified and sent for Illumina MiSeq next-generation sequencing. The resulting reads 
were used to generate bar plots in base R (version 3.5.3). Each column represents the fecal 







Supplementary Figure 5.20 Fecal microbiota composition of Patient 16 following an 
autologous FMT. Patient 16 received an autologous FMT. Toilet paper samples were 
collected from patients at baseline, 2 days, 7 days, 2 weeks, 6 weeks, 3 months, and 6 
months post-FMT. The DNA was extracted and the V4 region of the 16S rRNA gene was 
amplified and sent for Illumina MiSeq next-generation sequencing. The resulting reads 
were used to generate bar plots in base R (version 3.5.3). Each column represents the fecal 








Supplementary Figure 5.21 Fecal microbiota composition of Patient 17 following an 
autologous FMT. Patient 17 received an autologous FMT. Toilet paper samples were 
collected from patients at baseline, 2 days, 7 days, 2 weeks, 6 weeks, 3 months, and 6 
months post-FMT. The DNA was extracted and the V4 region of the 16S rRNA gene was 
amplified and sent for Illumina MiSeq next-generation sequencing. The resulting reads 
were used to generate bar plots in base R (version 3.5.3). Each column represents the fecal 








Supplementary Figure 5.22 Fecal microbiota composition of Patient 18 following an 
autologous. Patient 18 received an autologous FMT. Toilet paper samples were collected 
from patients at baseline, 2 days, 7 days, 2 weeks, 6 weeks, 3 months, and 6 months post-
FMT. The DNA was extracted and the V4 region of the 16S rRNA gene was amplified and 
sent for Illumina MiSeq next-generation sequencing. The resulting reads were used to 
generate bar plots in base R (version 3.5.3). Each column represents the fecal microbiota 








Supplementary Figure 5.23 Fecal microbiota composition of Patient 19 following an 
autologous FMT. Patient 19 received an autologous FMT. Toilet paper samples were 
collected from patients at baseline, 2 days, 7 days, 2 weeks, 6 weeks, 3 months, and 6 
months post-FMT. The DNA was extracted and the V4 region of the 16S rRNA gene was 
amplified and sent for Illumina MiSeq next-generation sequencing. The resulting reads 
were used to generate bar plots in base R (version 3.5.3). Each column represents the fecal 







Supplementary Figure 5.24 Fecal microbiota composition of Patient 21 following an 
autologous FMT. Patient 21 received an autologous FMT. Toilet paper samples were 
collected from patients at baseline, 2 days, 7 days, 2 weeks, 6 weeks, 3 months, and 6 
months post-FMT. The DNA was extracted and the V4 region of the 16S rRNA gene was 
amplified and sent for Illumina MiSeq next-generation sequencing. The resulting reads 
were used to generate bar plots in base R (version 3.5.3). Each column represents the fecal 









Supplementary Figure 5.25 Non-esterified fatty acids decrease at 6 weeks’ post-
transplant in patients who received an allogenic FMT. Non-esterified fatty acids were 
measured from blood samples taken at baseline, 2 weeks, 6 weeks, and 6 months. Wilcoxon 
matched-pairs signed rank test was performed to compare the NEFA concentrations at 
baseline and 6 weeks’ post-FMT in both the allogenic and autologous groups (p=0.0084 
and p=0.1562, respectively). A) The concentrations of non-esterified fatty acids of patients 
over time who received an allogenic FMT (n=15). Median (IQR); baseline: 631 µmol/L 
(332-675 µmol/L), 2 weeks: 557 µmol/L (407-633 µmol/L), 6 weeks: 423 µmol/L (192-
591 µmol/L), and 6 months: 621 µmol/L (362.5-842 µmol/L). (B) The concentrations of 
non-esterified fatty acids of patients over time who received an autologous FMT (n=6). 
Median (IQR); baseline: 485 µmol/L (415-955.3 µmol/L), 2 weeks: 603.5 µmol/L (445.3-
722.5 µmol/L), 6 weeks: 453 µmol/L (401.3-758 µmol/L), and 6 months: 644 (557.5-706 









Supplementary Figure 5.26 Cholesterol:HDL ratio decreases over 6 months in 
patients who received an allogenic FMT. Cholesterol and HDL cholesterol were 
measured from blood samples taken at baseline, 2 weeks, 6 weeks, and 6 months. Wilcoxon 
matched-pairs signed rank test was performed to compare the Cholesterol:HDL ratio at 
baseline and 6 months’ post-FMT in both the allogenic and autologous groups (p=0.0034 
and p=0.0625, respectively). A) The ratios of Cholsterol:HDL of patients over time who 
received an allogenic FMT. Median (IQR); baseline: 4.8 (3.1-6), 2 weeks: 4.8 (3.05-5.325), 
6 weeks: 4.4 (3-5), and 6 months 4.1 (2.7-5.4). B) The ratios of Cholesterol:HDL of patients 
over time who received an autologous FMT. Median (IQR); baseline: 3.1 (2.75-3.425), 2 
weeks: 3 (2.25-3.4), 6 weeks: 3.1 (2.425-3.5), and 6 months: 2.55 (2.225-3.225). The red 












Supplementary Figure 5.27 The concentration of cholesterol does not change over 
time after FMT. Cholesterol was measured from blood samples taken at baseline, 2 weeks, 
6 weeks, and 6 months. Wilcoxon matched-pairs signed rank test was performed to 
compare the cholesterol at baseline and 6 weeks’ post-FMT in both the allogenic and 
autologous groups (p=0.0637 and p=0.844, respectively. A) The concentration of 
cholesterol over time in patients who received an allogenic FMT (n=15). B) The 
concentration of cholesterol over time in patients who received an autologous FMT (n=6). 

















































Supplementary Figure 5.28 The concentration of HDL cholesterol does not change 
over time after FMT. HDL cholesterol was measured from blood samples taken at 
baseline, 2 weeks, 6 weeks, and 6 months. Wilcoxon matched-pairs signed rank test was 
performed to compare the HDL cholesterol at baseline and 6 weeks’ post-FMT in both the 
allogenic and autologous groups (p= 0.634 and p=0.688, respectively. A) The 
concentration of HDL cholesterol over time in patients who received an allogenic FMT 
(n=15). B) The concentration of HDL cholesterol over time in patients who received an 
autologous FMT (n=6). The black dotted line represents the cutoff for the normal 



















































Supplementary Figure 5.29 The concentration of LDL cholesterol does not change 
over time after FMT. LDL cholesterol was measured from blood samples taken at 
baseline, 2 weeks, 6 weeks, and 6 months. Wilcoxon matched-pairs signed rank test was 
performed to compare the LDL cholesterol at baseline and 6 weeks’ post-FMT in both the 
allogenic and autologous groups (p=0.153 and p=0.313, respectively. A) The concentration 
of LDL cholesterol over time in patients who received an allogenic FMT (n=15). B) The 
concentration of LDL cholesterol over time in patients who received an autologous FMT 
(n=6). The black dotted line represents the cutoff for the normal concentration of LDL 





















































Supplementary Figure 5.30 The concentration of triglycerides is decreased at 6 
weeks’ post-FMT in after an allogenic FMT. Triglycerides was measured from blood 
samples taken at baseline, 2 weeks, 6 weeks, and 6 months. Wilcoxon matched-pairs signed 
rank test was performed to compare the triglycerides at baseline and 6 weeks’ post-FMT 
in both the allogenic and autologous groups (p=0.027 and p=0.781, respectively). A) The 
concentration of triglycerides over time in patients who received an allogenic FMT (n=15). 
B) The concentration of triglycerides over time in patients who received an autologous 
FMT (n=6). The black dotted line represents the cutoff for the normal concentration of 










Supplementary Figure 5.31 The concentration of fasting glucose does not change over 
time after FMT. Fasting glucose was measured from blood samples taken at baseline, 2 
weeks, 6 weeks, and 6 months. Wilcoxon matched-pairs signed rank test was performed to 
compare the fasting glucose at baseline and 6 weeks’ post-FMT in both the allogenic and 
autologous groups (p=0.827 and p=0.844, respectively. A) The concentration of fasting 
glucose over time in patients who received an allogenic FMT (n=15). B) The concentration 
of fasting glucose over time in patients who received an autologous FMT (n=6). The black 















































Supplementary Figure 5.32 Change in ApoB:ApoA1 over time. Concentrations of 
ApoB:ApoA1 were determined from fasting blood sample at baseline and 6 weeks’ post-
transplant. Wilcoxon matched-pairs signed rank test was performed to compare the ratio 
of ApoB:ApoA1 at baseline and 6 weeks’ post-FMT in both the allogenic and autologous 
groups (p=0.330 and p=0.688, respectively). A) Ratio of ApoB:ApoA1 in patients who 
received an allogenic FMT over time (n=15). B) Ratio of ApoB:ApoA1 in patients who 













































Supplementary Figure 5.33 Patients’ weights do not change after receiving an FMT. 
Weight was measured at baseline, 2 weeks, 6 weeks and 6 months. A) The weights of 
patients over time who received an allogenic FMT (n=15). Median (IQR); baseline: 104.7 
kg (86.8-119.1 kg), 2 weeks 102.8 kg (85.4-117.6 kg), 6 weeks: 104.5 kg (87.6-117.7 kg), 
and 6 months: 105.6 kg (82.6-121.8 kg). B) The weights of patients over time who received 
an autologous FMT (n=6). Median (IQR); baseline: 94.3 kg (84.75-144.3 kg), 2 weeks: 









































Supplementary Figure 5.34 Waist-to-hip ratio remains constant after an FMT. Waist 
and hip measurements were taken at baseline, 2 weeks, 6 weeks, and 6 months. A) The 
waist-to-hip ratios of patients over time who received an allogenic FMT (n=15). Median 
(IQR); baseline: 0.9673 (0.9274-0.9884), 2 weeks: 0.9537 (0.9337-0.9553), 6 weeks: 0.954 
(0.9232-0.9929), and 6 months: 0.9613 (0.915-1.0070). B) The waist-to-hip ratios of 
patients who received an autologous FMT (n=6). Median (IQR); baseline: 0.9706 (0.9274-
0.9912), 2 weeks: 0.9717 (0.9424-0.9877), 6 weeks: 0.9664 (0.9448-0.9986), and 6 









































Supplementary Figure 5.35 BMI remains constant after FMT. Weight and height were 
measured at baseline, 2 weeks, 6 weeks, and 6 months. A) The BMI of patients who 
received an allogenic FMT (n=15). Median (IQR); baseline: 36.6 (32.5-40.4), 2 weeks: 
35.8 (32.1-38.5), 6 weeks: 35.9 (32.2-39.7), and 6 months: 36.7 (31.9-39.8). B) The BMI 
of patients who received an autologous FMT (n=6). Median (IQR); baseline: 34.9 (29.1-













Supplementary Figure 5.36 Nutrient and caloric intake do not change following 
allogenic and autologous FMT. Patients completed DHQII at baseline and 6 weeks 
post-FMT. Students’ t-tests were used to compare the differences in changes in 
intakes at baseline and 6 weeks post-FMT in both the allogenic and autologous 
groups. There were 7 participants at baseline with energy intakes <1500; 4 in the allogenic 
group and 3 in the autologous group this is likely to represent underreporting of energy 
intakes. At follow up there were 8 under reporters; 5 allogenic and 3 autologous. Under 
reporters were included. There was no statistically significant between group difference in 
































































Appendix D – Chapter 6 Supplementary Material 




 6 FMTs (n=6) 
Albumin Baseline mean ± SD 
Change in mean after treatment 
P-value 
45.0 ± 1.0 
0.17 
0.750 
AlkPhos Baseline mean ± SD 
Change in mean after treatment 
P-value 
42.3 ± 7.4 
-5.5 
0.500 
ALT Baseline mean ± SD 
Change in mean after treatment 
P-value 
20.4 ± 12.5 
1.6 
0.625 
AST Baseline mean ± SD 
Change in mean after treatment 
P-value 
20.0 ± 3.3 
-1.2 
0.625 
Anion Gap Baseline mean ± SD 
Change in mean after treatment 
P-value 
12.2 ± 1.9 
0.13 
>0.999 
Bicarbonate Baseline mean ± SD 
Change in mean after treatment 
P-value 





Baseline mean ± SD 
Change in mean after treatment 
P-value 
11.8 ± 8.0 
0.4 
0.563 
Calcium Baseline mean ± SD 
Change in mean after treatment 
P-value 
2.25 ± 0.06 
0.025 
0.188 
Chloride Baseline mean ± SD 





Creatinine Baseline mean ± SD 
Change in mean after treatment 
P-value 





Baseline mean ± SD 
Change in mean after treatment 
P-value 
4.4 ± 0.7 
0.5 
0.250 
Magnesium Baseline mean ± SD 
Change in mean after treatment 
P-value 
0.88 ± 0.07 
-0.008 
0.250 








Wilcoxon matched-pairs signed rank test used for statistical analysis.  
  




Sodium Baseline mean ± SD 
Change in mean after treatment 
P-value 
139.6 ± 2.7 
0.8 
0.750 
Urea Baseline mean ± SD 
Change in mean after treatment 
P-value 









Supplementary Table 6.2 Baseline and change in baseline in hematology data 
 
 
Wilcoxon matched-pairs signed rank test used for statistical analysis.  
Laboratory 
Test 
 6 FMTs (n=6) 
LKC Baseline mean ± SD 
Change in mean after treatment 
P-value 
6.1 ± 1.5 
-0.7 
>0.999 
ERC Baseline mean ± SD 
Change in mean after treatment 
P-value 
4.55 ± 0.40 
-0.025 
0.500 
Hemoglobin Baseline mean ± SD 
Change in mean after treatment 
P-value 
140 ± 8 
-1 
0.125 
HCT Baseline mean ± SD 
Change in mean after treatment 
P-value 
0.42 ± 0.02 
0.00 
>0.999 
MCV Baseline mean ± SD 
Change in mean after treatment 
P-value 
92.1 ± 5.6 
0.9 
0.188 
RDW CV Baseline mean ± SD 
Change in mean after treatment 
P-value 
12.8 ± 0.4 
-0.3 
0.375 
MPV Baseline mean ± SD 
Change in mean after treatment 
P-value 





Baseline mean ± SD 
Change in mean after treatment 
P-value 
206 ± 60 
2 
0.813 
Neutrophils Baseline mean ± SD 
Change in mean after treatment 
P-value 
3.9 ± 1.5 
-0.5 
>0.999 
Lymphocyte Baseline mean ± SD 
Change in mean after treatment 
P-value 
1.5 ± 0.4 
-0.1 
>0.999 
Monocyte Baseline mean ± SD 
Change in mean after treatment 
P-value 
0.5 ± 0.2 
0.0 
>0.999 
Eosinophil Baseline mean ± SD 
Change in mean after treatment 
P-value 
0.1 ± 0.1 
0.0 
>0.999 
Basophil Baseline mean ± SD 






























Wilcoxon matched-pairs signed rank test used for statistical analysis. 
  
Assessment  6 FMTs (n=6) 
Heart rate (bpm) Baseline mean ± SD 
Change in mean after treatment 
P-value 





Baseline mean ± SD 
Change in mean after treatment 
P-value 





Baseline mean ± SD 
Change in mean after treatment 
P-value 




(breaths per min) 
Baseline mean ± SD 
Change in mean after treatment 
P-value 





Baseline mean ± SD 
Change in mean after treatment 
P-value 









Supplementary Figure 6.1. ALDEx plot of MS patients at baseline compared to 1 
month (1 FMT). Fecal samples were collected from patients one to two days before their 
scheduled appointments, the DNA was extracted and the V4 region of the 16S rRNA gene 
was amplified and sent for Illumina MiSeq next-generation sequencing. The resulting reads 
were analyzed using ALDEx2 (version 3.9) in R (version 3.5.3) to identify differentially 
abundant genera. There were no significant changes in the composition of fecal bacteria of 
MS patients at baseline compared to receiving one FMT. Non-significant genera that are 
rare are shown in black and non-significant genera that are abundant are shown in grey. 
Significant genera would be shown in red.  





































































































































































































































































































































































































































































































































































































































































































































































Supplementary Figure 6.2 ALDEx plot of MS patients at baseline compared to 2 
months (2 FMTs). Fecal samples were collected from patients one to two days before their 
scheduled appointments, the DNA was extracted and the V4 region of the 16S rRNA gene 
was amplified and sent for Illumina MiSeq next-generation sequencing. The resulting reads 
were analyzed using ALDEx2 (version 3.9) in R (version 3.5.3) to identify differentially 
abundant genera. There were no significant changes in the composition of fecal bacteria of 
MS patients at baseline compared to receiving two FMTs. Non-significant genera that are 
rare are shown in black and non-significant genera that are abundant are shown in grey. 
Significant genera would be shown in red.  




















































































































































































































































































































































































































































































































































































































































































































Supplementary Figure 6.3 ALDEx plot of MS patients at baseline compared to 3 
months (3 FMTs). Fecal samples were collected from patients one to two days before their 
scheduled appointments, the DNA was extracted and the V4 region of the 16S rRNA gene 
was amplified and sent for Illumina MiSeq next-generation sequencing. The resulting reads 
were analyzed using ALDEx2 (version 3.9) in R (version 3.5.3) to identify differentially 
abundant genera. There were no significant changes in the composition of fecal bacteria in 
MS at baseline compared to receiving 3 FMTs. Non-significant genera that are rare are 
shown in black and non-significant genera that are abundant are shown in grey. Significant 
genera would be shown in red.  






























































































































































































































































































































































































































































































































































































































































































































Supplementary Figure 6.4 ALDEx plot of MS patients at baseline compared to 4 
months (4 FMTs). Fecal samples were collected from patients one to two days before their 
scheduled appointments, the DNA was extracted and the V4 region of the 16S rRNA gene 
was amplified and sent for Illumina MiSeq next-generation sequencing. The resulting reads 
were analyzed using ALDEx2 (version 3.9) in R (version 3.5.3) to identify differentially 
abundant genera. There were no significant changes in the composition of fecal bacteria of 
MS patients at baseline compared to receiving four FMTs. Non-significant genera that are 
rare are shown in black and non-significant genera that are abundant are shown in grey. 
Significant genera would be shown in red.  






























































































































































































































































































































































































































































































































































































































































































Supplementary Figure 6.5 ALDEx plot of MS patients at baseline compared to 5 
months (5 FMTs). Fecal samples were collected from patients one to two days before their 
scheduled appointments, the DNA was extracted and the V4 region of the 16S rRNA gene 
was amplified and sent for Illumina MiSeq next-generation sequencing. The resulting reads 
were analyzed using ALDEx2 (version 3.9) in R (version 3.5.3) to identify differentially 
abundant genera. There were no significant changes in the composition of fecal bacteria of 
MS patients at baseline compared to receiving five FMTs. Non-significant genera that are 
rare are shown in black and non-significant genera that are abundant are shown in grey. 
Significant genera would be shown in red.  






























































































































































































































































































































































































































































































































































































































































Supplementary Figure 6.6 ALDEx plot of MS patients at baseline compared to 6 
months (6 FMTs). Fecal samples were collected from patients one to two days before their 
scheduled appointments, the DNA was extracted and the V4 region of the 16S rRNA gene 
was amplified and sent for Illumina MiSeq next-generation sequencing. The resulting reads 
were analyzed using ALDEx2 (version 3.9) in R (version 3.5.3) to identify differentially 
abundant genera. There were no significant changes in the composition of fecal bacteria of 
MS patients at baseline compared to receiving six FMTs. Non-significant genera that are 
rare are shown in black and non-significant genera that are abundant are shown in grey. 
Significant genera would be shown in red.  

















































































































































































































































































































































































































































































































































































































































Supplementary Figure 6.7 Fecal microbiota composition of patient MK-FMT-001. 
Fecal samples were collected from patients one to two days before their scheduled 
appointments, the DNA was extracted and the V4 region of the 16S rRNA gene was 
amplified and sent for Illumina MiSeq next-generation sequencing. The resulting reads 
were used to generate bar plots in base R (version 3.5.3). Each column represents the fecal 
microbiota composition at one time point. This patient was in the study for 11 months in 
the early intervention group; they received six FMTs from donor 1 and were followed for 
six months following the last FMT. Black arrows indicate the appointments that the patient 
received an FMT. * indicates the baseline microbiota, taken 2-3 days before the first FMT 








Supplementary Figure 6.8 Fecal microbiota composition of patient MK-FMT-002. 
Fecal samples were collected from patients one to two days before their scheduled 
appointments, the DNA was extracted and the V4 region of the 16S rRNA gene was 
amplified and sent for Illumina MiSeq next-generation sequencing. The resulting reads 
were used to generate bar plots in base R (version 3.5.3). Each column represents the fecal 
microbiota composition at one time point. This patient was in the study for 12 months in 
the late intervention group; they received six FMTs from donor 2. Black arrows indicate 
the appointments that the patient received an FMT. * indicates the baseline microbiota, 







Supplementary Figure 6.9 Fecal microbiota composition of patient MK-FMT-003. 
Fecal samples were collected from patients one to two days before their scheduled 
appointments, the DNA was extracted and the V4 region of the 16S rRNA gene was 
amplified and sent for Illumina MiSeq next-generation sequencing. The resulting reads 
were used to generate bar plots in base R (version 3.5.3). Each column represents the fecal 
microbiota composition at one time point. This patient was in the study for 12 months in 
the late intervention group; they received six FMTs from donor 2. Black arrows indicate 
the appointments that the patient received an FMT. * indicate the baseline microbiota, 








Supplementary Figure 6.10 Fecal microbiota composition of patient MK-FMT-004. 
Fecal samples were collected from patients one to two days before their scheduled 
appointments, the DNA was extracted and the V4 region of the 16S rRNA gene was 
amplified and sent for Illumina MiSeq next-generation sequencing. The resulting reads 
were used to generate bar plots in base R (version 3.5.3). Each column represents the fecal 
microbiota composition at one time point. This patient was in the study for 10 months in 
the early intervention group; they received six FMTs from donor 1. Black arrows indicate 
the appointments that the patient received an FMT. This patient forgot to bring in a fecal 
sample at the 1 month time point. * indicate the baseline microbiota, taken 2-3 days before 








Supplementary Figure 6.11 Fecal microbiota composition of patient MK-FMT-007. 
Fecal samples were collected from patients one to two days before their scheduled 
appointments, the DNA was extracted and the V4 region of the 16S rRNA gene was 
amplified and sent for Illumina MiSeq next-generation sequencing. The resulting reads 
were used to generate bar plots in base R (version 3.5.3). Each column represents the fecal 
microbiota composition at one time point. This patient was in the study for 12 months in 
the late intervention group; they received six FMTs from donor 1. Black arrows indicate 
the appointments that the patient received an FMT. * indicate the baseline microbiota, 








Supplementary Figure 6.12 Fecal microbiota composition of patient MK-FMT-008. 
Fecal samples were collected from patients one to two days before their scheduled 
appointments, the DNA was extracted and the V4 region of the 16S rRNA gene was 
amplified and sent for Illumina MiSeq next-generation sequencing. The resulting reads 
were used to generate bar plots in base R (version 3.5.3). Each column represents the fecal 
microbiota composition at one time point. This patient was in the study for 7 months in the 
late intervention group; they received two FMTs from donor 2. Black arrows indicate the 
appointments that the patient received an FMT. * indicate the baseline microbiota, taken 








Supplementary Figure 6.13 Fecal microbiota composition of patient MK-FMT-009. 
Fecal samples were collected from patients one to two days before their scheduled 
appointments, the DNA was extracted and the V4 region of the 16S rRNA gene was 
amplified and sent for Illumina MiSeq next-generation sequencing. The resulting reads 
were used to generate bar plots in base R (version 3.5.3). Each column represents the fecal 
microbiota composition at one time point. This patient was in the study for 9 months in the 
late intervention group; they received four FMTs from donor 2. Black arrows indicate the 
appointments that the patient received an FMT. * indicate the baseline microbiota, taken 







Supplementary Figure 6.14 Fecal microbiota composition of patient MK-FMT-010. 
Fecal samples were collected from patients one to two days before their scheduled 
appointments, the DNA was extracted and the V4 region of the 16S rRNA gene was 
amplified and sent for Illumina MiSeq next-generation sequencing. The resulting reads 
were used to generate bar plots in base R (version 3.5.3). Each column represents the fecal 
microbiota composition at one time point. This patient was in the study for 7 months in the 
early intervention group; they received six FMTs from donor 1. Black arrows indicate the 
appointments that the patient received an FMT. * indicate the baseline microbiota, taken 







Supplementary Figure 6.15 Fecal microbiota composition of patient MK-FMT-011. 
Fecal samples were collected from patients one to two days before their scheduled 
appointments, the DNA was extracted and the V4 region of the 16S rRNA gene was 
amplified and sent for Illumina MiSeq next-generation sequencing. The resulting reads 
were used to generate bar plots in base R (version 3.5.3). Each column represents the fecal 
microbiota composition at one time point. This patient was in the study for 6 months in the 
early intervention group; they received six FMTs from donor 2. Black arrows indicate the 
appointments that the patient received an FMT. * indicate the baseline microbiota, taken 








Supplementary Figure 6.16 Fecal microbiota composition of patient MK-FMT-012. 
Fecal samples were collected from patients one to two days before their scheduled 
appointments, the DNA was extracted and the V4 region of the 16S rRNA gene was 
amplified and sent for Illumina MiSeq next-generation sequencing. The resulting reads 
were used to generate bar plots in base R (version 3.5.3). Each column represents the fecal 
microbiota composition at one time point. This patient was in the study for 8 months in the 
late intervention group; they received three FMTs from donor 2. Black arrows indicate the 
appointments that the patient received an FMT. * indicate the baseline microbiota, taken 
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